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Abstract
A common feature of numerous neurodegenerative disorders is the abnormal
accumulation of aggregated protein in distinct regions of the brain, such as
alpha-Synuclein (Syn) aggregates in the substantia nigra and hypothalamus
in Parkinson’s disease (PD), and Huntingtin (Htt) aggregates in the striatum
and cerebral cortex in Huntington’s disease (HD).
In this study, a library of approximately 5000 natural compounds was
screened for inhibitors of Htt aggregation in vitro using an automated filter
retardation assay. One of the hits was (-)- Epigallocatechin gallate (EGCG),
a compound present in green and black tea. The antioxidant properties of
this substance have been linked to neuroprotection in model systems for PD
and Alzheimer’s disease (AD) before, making it a promising candidate for
the development of a treatment for neurodegenerative diseases. Inhibition of
protein aggregation by EGCG, however, has not been demonstrated so far.
This study shows that EGCG inhibits the aggregation not only of Htt,
but also of Syn by stabilizing an oligomeric conformation of the respective
proteins in a dose-dependent manner. These oligomers do not seed the ag-
gregation of Htt and Syn. Also, EGCG modifies the exposure of different
epitopes recognized by conformation-specific antibodies during the aggrega-
tion process. The compound might therefore lead aggregation-prone proteins
on an alternative folding pathway in the misfolding cascade. The results fur-
thermore suggest that direct interaction occurs between EGCG and proteins
in an unfolded, ’open’ conformation. EGCG also reduces toxicity caused
by misfolded Htt or Syn in cell culture model systems, suggesting that the
oligomeric protein species formed in the presence of EGCG are not toxic to
living cells. EGCG might therefore represent a chemical chaperone that can
modulate misfolding and toxicity of proteins associated with neurodegener-
ative diseases and could provide the basis for the development of a novel
pharmacotherapy for these fatal disorders.
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Zusammenfassung
Eine Gemeinsamkeit vieler verschiedener neurodegenerativer Erkrankungen
ist die abnormale Ansammlung von aggregierten Proteinen in bestimmten
Hirnregionen, wie z. B. von alpha-Synuclein (Syn)-Aggregaten in der Sub-
stantia Nigra und im Hypothalamus bei der Parkinson’schen Krankheit (PD)
oder von Huntingtin (Htt)-Aggregaten im Striatum und Cortex bei Chorea
Huntington (HD).
Mit einer automatisierten Filtrationsmethode wurde am Anfang dieser
Studie eine Bibliothek von ca. 5000 natürlichen Substanzen nach Inhibito-
ren der Htt-Aggregation in vitro durchsucht. Eine der wirksamen Substanzen
war (-)-Epigallocatechingallat (EGCG), eine Verbindung, die in grünem und
schwarzem Tee vorkommt. Die antioxidativen Eigenschaften von EGCG wur-
den bereits früher mit einer neuroprotektiven Wirkung in Modellsystemen für
PD und für die Alzheimer’sche Krankheit (AD) in Verbindung gebracht, was
EGCG zu einem vielversprechenden Kandidaten für die Entwicklung einer
neuen Behandlungsmethode macht. Eine inhibierende Wirkung auf Protein-
aggregation wurde jedoch bis jetzt noch nicht nachgewiesen.
Diese Studie zeigt, dass EGCG nicht nur die Aggregation von Htt hemmt,
sondern auch die von Syn, indem es dosisabhängig eine oligomere Protein-
konformation stabilisiert. Diese Oligomere wirken jedoch nicht als Keime in
Aggregationsreaktionen von Htt oder Syn. Zusätzlich verändert EGCG die
Exposition bestimmter Epitope, die von konformationsspezifischen Antikör-
pern im Laufe der Aggregation erkannt werden. Daher könnte die Substanz
Proteine, die zur Aggregation neigen, auf einen alternativen Faltungspfad in
der Missfaltungskaskade führen. Weiterhin legen die Ergebnisse nahe, dass
eine direkte Wechselwirkung zwischen EGCG und Proteinen in einer un-
gefalteten, ’offenen’ Konformation stattfindet. In verschiedenen Zellkultur-
Modellsystemen verringerte EGCG die Toxizität, die von missgefalteten Pro-
teinen ausgeht, was nahelegt, dass die neu geformten oligomeren Spezies nicht
toxisch für lebende Zellen sind. EGCG könnte daher ein chemisches Chaperon
darstellen, das die Missfaltung und Toxizität von Proteinen, die mit neuro-
degenerativen Krankheiten assoziiert sind, verringert. Die Substanz könnte
daher die Basis zur Entwicklung einer neuen Therapie für diese unheilbaren
Krankheiten darstellen.
Schlagwörter:
neurodegenerative Erkrankung, Aggregationsinhibitor, Antioxidans, grüner
Tee, Amyloid
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Chapter 1
Introduction
1.1 Neurodegenerative disorders
Neurodegenerative diseases are conditions, which are characterized by a pro-
found reduction in the size and volume of the human brain due to the death
of neurons in specific brain areas typical for each disease. Neurodegenerative
disorders evolve gradually and the symptomatic expression occurs only when
the nerve cell loss exceeds a certain threshold, so that the actual onset of
brain degeneration may precede the clinical expression by many years. The
clinical symptoms of neurodegenerative diseases such as movement disorders
or memory dysfunction have been recognized for a long time, however deeper
understanding of the biochemical background is quite recent.
Parkinson’s disease (PD) was described by James Parkinson in the early
19th century to include an ’involuntary tremulus motion, with lessened mus-
cular power in parts not in action and even when supported with a propen-
sity to bend the trunk forward, and to pass from a walking to a running
pace’ [Parkinson, 1817]. In 1872 George Huntington described another disor-
der later named Huntington’s disease (HD) as hereditary chorea with three
marked peculiarities: The hereditary nature, a tendency to insanity and
suicide, and the manifestation as a disease only in adult life [Huntington,
1872]. Similarly, Alzheimer’s disease (AD) was described in 1906 by Alois
Alzheimer, however, due to the short life expectancy (app. 50 years) at that
time the disorder was extremely rare [Alzheimer, 1906]. Today, overall life
expectancy has risen considerably leading to an increased number of cases in
all neurodegenerative diseases.
The diverse group of neurodegenerative disorders includes diseases such
as PD, AD, polyglutamine (polyQ) disorders like HD and several forms of
spinocerebellar ataxia (SCA), transmissible spongiform encelopathies (TSE’s,
1
2comprising several human and animal diseases) and amyotrophic lateral scle-
rosis (ALS). Despite their obvious differences in clinical symptoms and dis-
ease progression they share many common properties [Martin, 1999]: Most
of the diseases (except HD and SCA) are not exclusively hereditary. They all
normally appear late in life, and their pathology is characterized by neuronal
loss and synaptic abnormalities. Their hallmark feature is that a particular
protein can assume a misfolded conformation, which leads in most cases to
aggregation and accumulation in tissues as fibrillar or amorphous deposits
(Table 1.1) [Carrell and Lomas, 1997; Dobson, 1999; Soto, 2001].
1.1.1 Amyloid protein aggregates in the brain
The term amyloid describes various types of protein aggregates that share
specific traits when examined microscopically. The name is derived from the
early mistaken identification of the substance as starch (amylum in Latin),
based on crude iodine-staining techniques. In pathological examinations
amyloid was originally used to describe the extracellular protein deposits
found in AD and systemic amyloid disorders. Recently, it has been extended
to describe intracellular aggregates as well. Amyloid refers to protein aggre-
gates which are organized in a β-sheet structure, bind specifically to dyes
such as Congo red and Thioflavin S, exhibit a high resistance to proteolytic
degradation and heat denaturation, and have a fibrillar morphology observed
by electron microscopy [Soto, 2003].
Disease Protein
deposits
Toxic protein Affected brain
region
Alzheimer’s
disease (AD)
extracellular
plaques
β-Amyloid (Aβ) hippocampus,
cerebral cortex
intracellular
tangles
Tau
Parkinson’s
disease (PD)
intracellular
Lewy bodies
α-Synuclein
(Syn)
substantia
nigra,
hypothalamus
Transmissible
spongiform en-
cephalopathies
(TSE’s)
extracellular
prion plaques
PrPSc various regions,
mostly cortex
and cerebellum
3Disease Protein
deposits
Toxic protein Affected brain
region
Huntington’s
disease (HD)
intracellular
nuclear
inclusions
Huntingtin
(Htt)
striatum,
cerebral cortex
Spinocerebellar
ataxias (SCA’s)
intracellular
nuclear and
cytoplasmic
inclusions
SCA1-3,
SCA7-8, SCA17
cerebellar
cortex, dentate
nuclei, olivary
nuclei
Spinal and
bulbar muscular
atrophy
(SMBA)
intracellular
nuclear
inclusions
Androgen
receptor
motor neurons
in the
brainstem,
anterior horn of
the spinal cord,
dorsal root
ganglia
Dentatorubral
and
pallidolysian
atrophy
(DRPLA)
intracellular
nuclear
inclusions
Atrophin dentatorubral
and
pallidolysian
systems
Familial
amyotrophic
lateral sclerosis
(ALS)
intracellular
Bunina bodies
Superoxide
dismutase 1
(SOD1)
motor cortex,
brainstem
Table 1.1: Proteins involved in neurodegenerative disorders
Although the presence of proteinaceous aggregates in the brains of pa-
tients suffering from a neurodegenerative disease has been known for many
years, it is still under discussion whether they are the direct cause and the
primary toxic species leading to neurodegeneration or rather innocent by-
standers and a secondary effect. The neuropathological link between protein
aggregation and disease is confused by a sometimes poor correlation between
the load of amyloid deposits in the brain and the severity of disease [Forno,
1996; Gutekunst et al., 1999]. Furthermore, protein aggregates in the brain
can also result from generally decreased protein turnover in normal aging
and can be found in tissues from healthy people [Keller et al., 2004].
However, specific domains, which are responsible for the self-aggregation
4of the proteins listed in Table 1.1 can be introduced into conformationally
stable, non-toxic proteins and can cause them to form fibrils in vitro or
toxic aggregates in animal models [Ordway et al., 1997; Tanaka et al., 2002].
This argues for a special role for protein aggregates associated with neurode-
generative disease as compared to aggregates resulting from normal aging
processes.
The aggregation process
Based on biophysical studies, native amyloidogenic proteins are thought to
be unfolded with a random coil structure in aqueous solution [Masino et al.,
2002; Li et al., 2002]. Thus, they expose hydrophobic surfaces which are oth-
erwise hidden within the protein structure and can potentially interact with
each other or with other proteins in the surroundings. In vitro studies sug-
gest that aggregation depends on specific intermolecular interactions between
folding intermediates [Wetzel, 1996] that lead to the formation of microag-
gregates, which can further seed the aggregation reaction. Kinetic analyses
of aggregation processes have shown that an initial lag-phase depends on the
protein concentration and can be skipped by the addition of exogenous seeds
[Scherzinger et al., 1999]. Furthermore, point mutations associated with fa-
milial variants of the disease, such as the A53T and A30P Syn mutants in
PD, can destabilize the native conformation of the protein and increase the
likelihood for self-association and aggregation [Bertoncini et al., 2005]. The
formation of amyloid fibrils has been shown to be a complex process, in-
volving one or more discrete intermediates: First oligomers, then so-called
protofibrils and finally mature fibres are formed (Figure 1.1) [Harper et al.,
1999; Conway et al., 2000b; Poirier et al., 2002]. Recent studies indicate
that different proteins involved in neurodegenerative diseases do not only
exhibit structural similarities when aggregated into mature amyloid fibres
[O’Nuallain and Wetzel, 2002], but the oligomeric forms already share com-
mon features. They can be recognized by an antibody specifically directed
against the oligomeric form of amyloidogenic proteins [Kayed et al., 2003] and
show permeabilization of lipid bilayers as a conformation-dependent activity
only in their oligomeric state [Kayed et al., 2004].
However, it has been proposed lately that the mature amyloid fibre might
not be the main toxic species, but rather protein oligomers formed early in
the aggregation process, since proteins which are not associated with amyloid
disease but able to aggregate into fibrils in vitro are toxic to cells in culture
while they still possess a non-fibrillar, oligomeric morphology [Bucciantini
et al., 2002, 2004]. Although Bucciantini et al. [2004] suggest that only the
oligomeric species are toxic to cells, there is also contradictory evidence: A
5Figure 1.1: Schematic representation of the protein aggregation pathway [Soto,
2003].
study conducted by Yang et al. [2002] shows that aggregated polyglutamine
species cause severe damage to mammalian cells when delivered to the nu-
cleus [Yang et al., 2002]. In addition, observing amyloid plaques in a trans-
genic mouse model Tsai et al. [2004] found that fibrillar amyloid deposits lead
to synaptic abnormalities and breakage of neuronal branches. For the prion
protein a recent study has shown that 17 to 27 nm particles of 300 to 600
kDa show the highest infectivity and might be the most toxic species of this
particular protein [Silveira et al., 2005]. However, the toxicity of oligomeric
and fibrillar species might differ for various amyloidogenic proteins, and for
most of them the most dangerous particles have not been defined so far.
In cells many factors can influence protein aggregation, such as protein
synthesis and degradation, protein concentration, molecular chaperones and
proteases as well as post-translational modifications such as glycosylation
and phosphorylation [Hatters et al., 2002; Munishkina et al., 2004]. Interac-
tions with all kinds of exposed hydrophobic surfaces also enable the forming
amyloid fibrils to recruit other proteins, a process that might significantly
influence the toxicity of the forming aggregate [Perutz et al., 1994; Charles
et al., 2000; Trojanowski and Lee, 2000; Busch et al., 2003]. Studies in cell
culture models have shown that inclusion bodies in these systems have a very
complex structure and include different proteins such as chaperones, parts of
the ubiquitin-proteasome-system, proteins of the centrosome and cytoskele-
ton [Rajan et al., 2001; Waelter et al., 2001], as well as different transcription
factors such as TCERG1 (also known as CA150) [Holbert et al., 2001], CTBP
6[Kegel et al., 2002] and p53 [Steffan et al., 2000]. The coaggregation of mis-
folded proteins with normal proteins could therefore be responsible for the
toxicity of protein aggregates [Nucifora et al., 2001]. It remains unclear,
however, how these complex inclusions are formed and to which extent fib-
rillar aggregates and oligomers contribute to the cytotoxicity observed in the
disease state.
1.1.2 Huntington’s disease
Huntington’s disease (HD) is a progressive neurodegenerative disorder with
autosomal dominant inheritance affecting around one in 10 000 individuals.
The age of onset of the disease is typically around 40-50 years, although rare
juvenile cases have also been reported.
Clinical symptoms
Usually, the first symptoms observed include mild personality changes, mi-
nor motor abnormalities and a slow deterioration of intellectual functions,
preceding the obvious signs of chorea, hypokinesia, rigidity or dystonia by
at least three years. The latter symptoms gradually worsen during the pro-
gression of the disease and are accompanied by impaired speech, swallowing
difficulties and weight loss; alterations in behaviour and personality changes,
such as irritability, social withdrawal, loss of motivation, depressed moods,
anxiety and even aggression are also noted. HD ultimately leads to death
after approximately 15 to 20 years by causes associated with the disease such
as pneumonia, choking, and nutritional deficiencies [Beighton and Hayden,
1981].
Neuropathology
Characteristic neuropathological features of the disease include weight loss
of the total brain by approximately 10-20 per cent. The reduction in size
occurs in the cerebral hemispheres, the diencephalon, the cerebellum, and
also in the brainstem and the spinal cord. The most striking feature is a
shrunken appearance of the neostriatum with gross atrophy of the caudate
nucleus and putamen, accompanied by enlargement of the lateral ventricles
(Figure 1.2); [Vonsattel et al., 1985].
Treatment options
The only therapies available to date are symptomatic, for example trying to
medicamentously fight chorea or treat the psychological changes with antide-
7Figure 1.2: Image of an HD brain. Top: Brain section from an HD patient, bot-
tom: Normal control brain. From: Harvard Center for Neurodegen-
eration and Repair, http://www.hcnr.med.harvard.edu/visitorInfo/-
huntingtons.php.
pressant drugs. Several drugs have also been tested for a potential neuro-
protective treatment, however no major breakthrough has been achieved yet.
The only studies so far that lead to improvement of cognitive function and
performance in electrophysiological tests have been attempts to transplant
foetal tissue into the caudate and putamen of HD patients [Bachoud-Levi
et al., 2000]. Although the outcome of these studies appears promising, their
dependence on foetal neuronal tissue will always restrict the widespread avail-
ability of this form of treatment, and stem cell research is not yet advanced
enough to be able to provide surrogate tissue.
Cause of the disease
The huntingtin protein and its properties. In 1993 an expansion of
the CAG repeat in the first exon of the IT15 gene was discovered to be
the mutation causing HD [HDCRG, 1993], and the protein encoded by this
gene was termed huntingtin (Htt). It can be found in almost all tissues of the
human body, although it is mainly expressed in the brain in cortex and stria-
tum, with neuronal expression predominating over glial expression [Strong
et al., 1993; Trottier et al., 1995a]. Intracellularly Htt is present in nuclei,
cell bodies, dendrites and nerve terminals [Trottier et al., 1995b; DiFiglia
et al., 1995]. Subcellular fractionations and immunohistochemical studies
show that it is enriched in membrane-containing fractions and associated
with microtubules [Gutekunst et al., 1995].
Htt consists of 3144 amino acids and harbors several important domains:
Next to the N-terminal polyQ domain, which contains the mutation respon-
sible for HD, lies a proline-rich domain, followed by several HEAT-domains.
837 putative HEAT repeats which are arranged in three main clusters have
been identified within the Htt sequence with bioinformatical methods [An-
drade and Bork, 1995]. HEAT repeats are sequences of around 40 amino
acids that have been found in a variety of large eucaryotic proteins involved
in cytoplasmic and nuclear transport processes, microtubule dynamics and
chromosome segregation [Andrade and Bork, 1995; Andrade et al., 2001].
Htt contains a functionally active C-terminal nuclear export signal (NES)
and a less active nuclear localization signal (NLS), which might hint to a
transport function through the nuclear pore [Xia et al., 2003]. This hypoth-
esis is further supported by the finding that Htt interacts with the nuclear
pore protein TPR, which exports proteins from the nucleus [Cornett et al.,
2005].
Three putative cleavage sites for caspases at aspartates D513, D530 and
D586 have been described for Htt [Wellington et al., 2002], and function-
ally active calpain cleavage sites have been found in mouse and human Htt
[Gafni and Ellerby, 2002; Gafni et al., 2004]. Furthermore, two different
Htt fragments have been identified that build up either cytoplasmic or nu-
clear inclusions in a cell model for HD [Lunkes et al., 2002]. The authors of
the study suggest that these fragments are intermediate breakdown products
with high aggregation potential that are generated by aspartic proteases and
the proteasome during the normal clearance of Htt.
Four types of post-translational modification have been described for the
Htt protein: Lysines K6, K9 and K15 compete for sumoylation and ubiquiti-
nation [Steffan et al., 2004; Kalchman et al., 1996], and phosphorylation can
take place at serines S421 and S434 [Humbert et al., 2002; Luo et al., 2005].
Furthermore, Htt is palmitoylated by HIP-14 (huntingtin-interacting protein
14, a palmitoyl transferase), but the precise position of the modification is
unknown [Huang et al., 2004]. For an overview of the Htt domain structure
and post-translational modifications, see Fig. 1.3.
Putative normal functions of Htt. The normal function of the protein
is not known at present, although different studies offer a variety of possi-
bilities. The large size of Htt suggests more than one function in different
cell compartments. Characteristic for essential proteins, Htt is conserved
throughout many species. It is necessary in embryonic development, which
has been shown in experiments with ’knock-out’ mice [Duyao et al., 1995;
Nasir et al., 1995; Zeitlin et al., 1995].
A role of Htt as an anti-apoptotic protein has been proposed and is sup-
ported by several studies: Htt is not only a substrate for Akt, a serine/threo-
nine kinase which activates cellular survival pathways and blocks cell death
9Figure 1.3: The domain structure of the Htt protein [Cattaneo et al., 2005]. Q(n):
polyglutamine tract, P(n): polyproline sequence, red squares: three
main HEAT repeat clusters. Arrows: caspase cleavage sites, blue ar-
rowheads: calpain cleavage sites, green and orange arrowheads: ap-
proximate amino acid regions for protease cleavage in the cerebral cor-
tex (B), in the striatum (C) and in both brain regions (A), yellow
arrowhead: cleavage site for aspartic endopeptidases [Lunkes et al.,
2002]. Red circles: ubiquitination (UBI) and sumoylation (SUMO).
Blue circles: phosphorylation at S421 and S434. Glutamic acid-,
serine- and proline-rich regions are indicated (serine-rich regions en-
circled in green). NES: nuclear export signal.
[Humbert et al., 2002], but synthesis of Htt also protects from a variety of
apoptotic stimuli in a neuronal cell culture model, possibly by inhibition of
procaspase-9 processing [Rigamonti et al., 2000, 2001]. Furthermore, over-
expression of wild-type Htt upregulates the transcription of brain-derived
neurotrophic factor (BDNF), a survival gene, in striatal neurons [Zuccato
et al., 2001].
Further possible functions can also be deduced from the analysis of in-
teracting proteins, a large number of which has been identified in the past
years (Table 1.2).
Binding partner Properties Reference
AP2A2 (Adaptor-related
protein complex 2, α 2
subunit)
AP-2 adaptor complex Faber et al.
[1998]
CBS (Cystathionine-β-
synthase)
anabolism of cysteine Boutell et al.
[1998]
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Binding partner Properties Reference
CREB1 (cAMP
responsive element
binding protein 1)
transcription activator Bao et al. [1996]
CBP (CREB binding
protein)
acetyltransferase enzyme Steffan et al.
[2000]
CTBP1 (C-terminal
binding protein 1)
transcription repressor Kegel et al.
[2002]
DLG4 (Discs, large
homolog 4)
synaptic scaffolding Sun et al. [2001]
FNBP3 (Formin binding
protein 3)
RNA splicing factor Faber et al.
[1998]
GAPD (Glyceraldehyde-
3-phosphate
dehydrogenase)
glycolytic enzyme Burke et al.
[1996]
GIT (G-protein
coupled-receptor kinase
interacting protein 1)
integrator of signalling
pathways controlling
vesicle trafficking,
adhesion, cytoskeletal
organization
Goehler et al.
[2004]
GRAP (GRB2-related
adaptor protein)
RAS protein signaling Burke et al.
[1996]
GRB2 (Growth factor
receptor-bound protein
2)
growth factor signaling Liu et al. [1997]
HAP1 (Htt-associated
protein 1)
endocytosis and cellular
trafficking
Li et al.
[1998a,b]
HIP1 (Htt interacting
protein 1)
endocytosis,
pro-apoptotic factor
Wanker et al.
[1997]
HIP14 (Htt interacting
protein 14)
endocytosis and cellular
trafficking
Faber et al.
[1998]; Singaraja
et al. [2002]
HIP2 (Htt interacting
protein 2)
ubiquitin-conjugated
enzyme
Kalchman et al.
[1996]; Faber
et al. [1998]
HYPB (Htt interacting
protein B)
RNA splicing factor Faber et al.
[1998]
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Binding partner Properties Reference
HYPC (Htt interacting
protein C)
transcription activator Faber et al.
[1998]
HYPE (Htt interacting
protein E)
unknown Faber et al.
[1998]
HYPK (Htt interacting
protein K)
unknown Faber et al.
[1998]
HYPM (Htt interacting
protein M)
unknown Faber et al.
[1998]
ITPR1 (Inositol
1,4,5-triphosphate
receptor, type 1)
calcium release channel Tang et al.
[2003]
MAGEA3 (Melanoma
antigen, family A, 3)
unknown Faber et al.
[1998]
MAP3K10
(Mitogen-activated
protein kinase kinase
kinase 10)
JNK signaling pathway
and neuronal apoptosis
Liu et al. [2000]
NCOR1 (Nuclear
receptor co-repressor 1)
transcription repressor Boutell et al.
[1999]
NFKB1 (Nuclear factor
of kappa light
polypeptide gene
enhancer in B-cells 1)
transcription activator Takano and
Gusella [2002]
OPTN (Optineurin
(FIP2))
GTPase Rab8 interactor Faber et al.
[1998]
PACSIN1 (Protein
kinase C and casein
kinase substrate in
neurons 1)
endocytosis Modregger et al.
[2002]
PDE1A
(Phosphodiesterase 1A,
calmodulin-dependent)
calcium binding
regulatory protein
Bao et al. [1996]
PQBP1 (Polyglutamine
binding protein 1)
transcription coactivator Waragai et al.
[1999]
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Binding partner Properties Reference
RASA1 (RAS p21
protein activator
(GTPase activating
protein) 1)
Ras GTPase-activating
protein
Burke et al.
[1996]; Liu et al.
[1997]
REST (RE1-silencing
transcription factor)
transcription supressor Zuccato et al.
[2003]
SAP30 (Sin3-associated
polypeptide, 30kDa)
histone deacetylase
complex
Boutell et al.
[1999]; Steffan
et al. [2000]
SH3GL3 (SH3-domain
GRB2-like 3)
endocytosis, vesicle
trafficking
Sittler et al.
[1998]
Sp1 transcription activator Dunah et al.
[2002]
SYMPK (Symplekin) tight junction plaque
protein
Faber et al.
[1998]
TAFII130 (TATA box
binding protein
(TBP)-associated factor,
135kDa)
transcription activator Dunah et al.
[2002]
TBP (TATA box
binding protein)
basal transcription
activator
Huang et al.
[1998]
TCERG1 (Transcription
elongation regulator 1
(CA150))
transcription activator Holbert et al.
[2001]
TGM2
(Transglutaminase 2)
crosslinking of proteins
by isopeptide bonds,
role in apoptosis
Chun et al.
[2001]
TP53 (Tumor protein
p53)
transcription factor Steffan et al.
[2000]
TPH1 (Tryptophan
hydroxylase 1)
catalyzes the
monooxygenation of
tryptophan
Yohrling et al.
[2002]
TRIP10 (Thyroid
hormone receptor
interactor 10)
Cdc421 interacting
protein-4, signaling
Holbert et al.
[2003]
1cell division cycle 42
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Binding partner Properties Reference
TUBG1 (Tubulin,
gamma 1)
microtubule cytoskeleton
organization
Hoffner et al.
[2002]
Table 1.2: Binding partners of Htt
This list of interacting proteins can at least partially be summarized from
a functional point of view, yielding information about Htt’s possible normal
cellular activities:
The interaction of HAP1, a protein involved in membrane trafficking,
with Htt suggests a role as a linker protein between vesicles, endosomes and
motor proteins for the trafficking in axons. This interaction might play a role
in cargo transport along microtubules in axons [Block-Galarza et al., 1997;
Engelender et al., 1997].
A function in the synapse for Htt could be deduced from its interaction
with HAP1 and FIP-2, both of which have been linked to subcellular pro-
cesses modifying the shape of dendritic spines [Li et al., 2000b; Hattula and
Peranen, 2000]. Another protein influencing spine morphology and synapse
formation in neuronal cells is GIT1 [Zhang et al., 2003], which was recently
demonstrated to interact with Htt [Goehler et al., 2004]. Htt might there-
fore influence synaptic transmission, learning and memory by enhancing the
growth of dendritic spines together with its interaction partners. Further-
more, a large number of interaction partners involved in clathrin-mediated
endocytosis such as HIP1, PACSIN1, SH3GL3 and HIP14 have been iden-
tified [Kalchman et al., 1997; Sittler et al., 1998; Modregger et al., 2002;
Singaraja et al., 2002].
Other interacting proteins, such as the transcription factors and activators
CREB1 [Bao et al., 1996], TP53 [Steffan et al., 2000], TCERG1 [Holbert
et al., 2001], CTBP1 [Kegel et al., 2002], Sp1 and TAFII130 [Dunah et al.,
2002], suggest a role for Htt in transcriptional regulation.
The large number of Htt interacting proteins and Htt’s activities in differ-
ent subcellular compartments led to the hypothesis that Htt acts a scaffolding
protein modulating the binding activities of single factors in multi-protein
signalling complexes [Harjes and Wanker, 2003].
Htt in the disease state. In healthy people, the polyQ repeat sequence
in the Htt protein contains 8-37 glutamine residues, whereas this number
ranges from 38 up to 182 in HD patients [Rubinsztein et al., 1996; Sathasivam
et al., 1997]. Thus, the pathological threshold for the length of the glutamine
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stretch in Htt lies around 37 residues; shorter stretches appear to be well
tolerated by neurons. There is also a strong correlation between the length
of the polyQ sequence and the age of onset of the disease as well as the
severity of symptoms: Longer polyQ repeats lead to an earlier onset and more
severe symptoms [Rubinsztein et al., 1993]. Another characteristic feature
of HD is the so-called ’anticipation’, which describes the phenomenon where
symptoms often worsen in successive generations [Ranen et al., 1995]. The
instability of the elongated CAG repeat is the cause for this. However, the
molecular mechanisms causing the expansion of polyQ repeats in HD remain
unclear to date.
In the disease state, several normal functions of Htt in the cell might
be disturbed. Additionally or in combination new, pathological functions
could arise through disturbed protein-protein interactions. One model for
the possible impact of mutant Htt on several cellular processes is shown in
Figure 1.4:
Figure 1.4: Model for the cellular pathogenesis in Huntington’s disease [Landles
and Bates, 2004].
According to this model, the molecular chaperones Hsp70 and Hsp40 (see
also Chapter 1.2.1) promote the folding of newly synthesized Htt into a na-
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tive structure. Wild-type Htt is predominantly cytoplasmic, but may also
be transported into the nucleus (1). Chaperones can facilitate the recogni-
tion of abnormal proteins, promoting either their refolding, or ubiquitina-
tion and subsequent degradation by the 26S proteasome (see also Chapter
1.2.1). The HD mutation induces conformational changes and is likely to
cause the abnormal folding of Htt, which, if not corrected by chaperones,
leads to the accumulation of misfolded Htt in the cytoplasm (2). Alter-
natively, mutant Htt might also be proteolytically cleaved, giving rise to
amino-terminal fragments, which form β-sheet structures (3). Ultimately,
toxicity might be elicited by mutant full-length Htt or by cleaved N-terminal
fragments, which may form soluble monomers, oligomers or large insoluble
aggregates. In the cytoplasm, mutant forms of Htt may impair the ubiquitin-
proteasome system (UPS), leading to the accumulation of more misfolded
proteins (4). These toxic proteins might also impair normal vesicle transport
and clathrin-mediated endocytosis and, thereby, putative normal functions
of wild-type Htt (see Chapter 1.1.2). Also, the presence of mutant Htt could
activate proapoptotic proteins directly or indirectly by mitochondrial dam-
age, leading to greater cellular toxicity and other deleterious effects (5). In
an effort to protect itself, the cell accumulates toxic fragments into ubiq-
uitinated cytoplasmic perinuclear aggregates (6). In addition, mutant Htt
can be translocated into the nucleus to form nuclear inclusions, which may
disrupt transcription and the UPS (7).
Model systems reproducing HD features As mentioned earlier, an
important property of mutant Htt is its ability to form extremely stable,
protease- and SDS-resistant fibrillar aggregates in vitro and in vivo [Scher/-
zin/ ger et al., 1997]. These protein aggregates are also found in nerve ter-
minals and as intranuclear inclusion bodies in patient brains, containing N-
terminal fragments of Htt [DiFiglia et al., 1997; Sieradzan et al., 1999]. The
fragments are thought to be generated through cleavage by caspases or other
proteases (Figure 1.3). Similar inclusions have also been found in diverse
model systems of the disease, listed in Table 1.3.
Model
system
Protein
fragment used
Reproduced
features of disease
Reference
in vitro,
purified
protein
human Htt exon 1 SDS-resistant,
fibrillar aggregates
Scher/-zin/
ger et al.
[1997]
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Model
system
Protein
fragment used
Reproduced
features of disease
Reference
S.
cerevisiae
human Htt,
N-terminal
fragment
cytoplasmic
aggregates
Krobitsch
and
Lindquist
[2000]
S.
cerevisiae
human Htt exon 1 SDS-resistant,
peri-nuclear
aggregates
Muchowski
et al. [2000]
neuroblas-
toma
cells
N-terminal
fragments of
human Htt
cytoplasmic and
nuclear inclusions,
ubiquitinated;
cytotoxicity
Cooper et al.
[1998]
neuroblas-
toma
cells
truncated and
full-length human
Htt constructs
cytoplasmic and
nuclear aggregates,
ubiquitinated
Lunkes and
Mandel
[1998]
2-2
(monkey
kidney)
cells
truncated and
full-length human
Htt constructs
subcellular
localization of
aggregates dependent
on protein length,
truncated Htt causes
elevated apoptosis
levels
Martindale
et al. [1998]
COS
(monkey
kidney)
cells
first 17 amino
acids of Htt fused
to PolyQ stretch
cytoplasmic
aggregates,
co-aggregation of
CBP
Kazantsev
et al. [1999]
293
(human
embryonic
kidney)
Tet-Off
cells
human Htt exon 1 peri-nuclear
inclusions,
ubiquitinated;
co-localization of
chaperones;
cytotoxicity
Waelter et al.
[2001]
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Model
system
Protein
fragment used
Reproduced
features of disease
Reference
D. mela-
nogaster
N-terminal
fragment (144
amino acids) of
human Htt
expressed in
photoreceptor
neurons
nuclear localization
and
neurodegeneration
Jackson et al.
[1998]
D. mela-
nogaster
polyQ-tract fused
to HA-epitope,
expressed in retinal
cells
aggregates,
degeneration of the
eyes
Kazemi-
Esfarjani and
Benzer [2000]
D. mela-
nogaster
polyQ-peptides
expressed in
different cell types
depending on the
promoter
severe cytotoxicity,
behavioral phenotype
Marsh et al.
[2000]
C. elegans 171 amino acids
N-terminal
fragment of human
Htt, expression in
sensory neurons
aggregation,
progressive
neurodegeneration
and cell death
Faber et al.
[1999]
C. elegans polyQ-tract fused
to GFP, expression
in body wall
muscle cells
cytoplasmic
aggregates,
constitutive
activation of heat
shock response
Satyal et al.
[2000]
transgenic
mice
human Htt exon 1 neuronal intranuclear
inclusions,
ubiquitinated;
progressive
neuropathology
Mangiarini
et al. [1996]
transgenic
mice
polyQ tract
introduced in
mouse hdh gene
production and
aggregation of
N-terminal fragments
in striatal neurons
Shelbourne
et al. [1999];
Li et al.
[2000a]
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Model
system
Protein
fragment used
Reproduced
features of disease
Reference
transgenic
mice
N-terminal
fragment of human
Htt (171 amino
acids)
behavioural
abnormalities,
intranuclear and
neuritic aggregates
Schilling
et al. [1999]
transgenic
mice
human full-length
Htt Q46 and Q72
selective degeneration
of medium spiny
neurons in the
striatum,
translocation of
N-terminal Htt
fragments to the
nucleus, aggregation
independent of
neurodegeneration
Hodgson
et al. [1999]
transgenic
mice
N-terminal human
Htt fragment Q120
frequent and
widespread Htt
inclusions, no
neuronal dysfunction
or degeneration
Slow et al.
[2005]
Table 1.3: Model systems for Htt aggregation
In all model systems listed above, the appearance of aggregates is de-
pendent on the length of the polyQ stretch. Interestingly, the pathological
threshold of 38 glutamines could also be reproduced in these models. How-
ever, the formation of Htt aggregates and neuronal death are correlated to
different degrees in the diverse model systems, adding to the ongoing debate
whether aggregates are cause or consequence of the disease, as discussed in
Chapter 1.1.1.
1.1.3 Parkinson’s disease
Parkinson’s disease (PD) is one of the most common neurodegenerative dis-
orders with a prevalence of 1.8% in persons 65 years of age and older in
Europe [de Rĳk et al., 2000]. The mean age of onset is estimated as the
early-to-mid 60s. Initial symptoms, however, can arise between age 21 and
40 in young-onset cases (affecting 5-10 % of PD patients) and even before
the age of 20 in juvenile-onset cases.
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Clinical symptoms
The clinical manifestations include resting tremor, muscular rigidity and
bradykinesia, accompanied by various non-motor features such as autonomic
dysfunction, cognitive and psychiatric changes, sensory symptoms, depres-
sion and sleep disturbances. Dementia also develops in about 40 percent of
affected individuals [Samii et al., 2004].
Neuropathology
Figure 1.5: Degeneration of nigral neurons in PD. The pars compacta region of the
substantia nigra in the normal brain (left) appears dark because the
dopamine-producing neurons are highly pigmented with melanin; as
neurons die from PD, their color fades (right). From: The University
of Texas Southwestern Medical Center, STARS2 program resources,
http://www.swmed.edu/stars/resources/neurodisslides.html.
For a definite diagnosis of PD an autopsy is needed; the typical patho-
logical findings are a greatly diminished number of nigral dopamine neurons
(Figure 1.5) and the presence of proteinaceous inclusions, so-called Lewy
bodies in the remaining neurons [Fearnley and Lees, 1991]. Clinical signs
of PD become evident when about 80 percent of striatal dopamine and 50
percent of nigral neurons are lost [Samii et al., 2004].
Lewy bodies and Lewy neurites are considered to be the two pathological
hallmarks of both PD and dementia with Lewy bodies (DLB). They contain
partially truncated and full-length α-Synuclein protein, which show either a
straight or twisted filament morphology [Arima et al., 1998]. Further com-
ponents include Ubiquitin, lipids [Gai et al., 2000] and cytoskeletal proteins
such as neurofilaments, microtubules and Tau [Pollanen et al., 1992; Gal-
loway et al., 1992]. Lewy bodies are not confined to the substantia nigra but
can be seen in the cortex, amygdala, locus coeruleus, vagal nucleus and the
peripheral autonomic nervous system, where they could account for many of
the non-motor symptoms.
2Science Teacher Access to Resources at Southwestern
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Treatment options
Effective neuroprotective agents as treatment options have not been identi-
fied so far and slowing down the disease on a cellular level is not possible to
date. As in HD the treatment is mostly symptomatic and starts when the
symptoms become bothersome or cause disability. The major focus of treat-
ment lies on the replacement of dopamine, which is lost due to the death of
dopaminergic neurons. Early PD is mostly treated with either dopamine ag-
onists, which can stimulate dopamine receptors in the brain and thus mimic
the action of dopamine, or levodopa, which directly replaces dopamine [Foley
et al., 2004]. Levodopa remains the most potent antiparkinson drug and is
the backbone of treatment throughout most of the disease course.
Surgical options for treatment were far more common before the intro-
duction of levodopa in the 1960s [Samii et al., 2004]. Fetal nigral tissue
transplantation has been shown to result in the survival of dopamine neu-
rons, however, either no relevant motor improvement was noted [Olanow
et al., 2003] or severe side-effects occurred [Freed et al., 1992], which ex-
cludes transplantation from the list of treatment options for PD at present.
What causes Parkinson’s disease?
Most cases of PD occur sporadically without a previous family history of
the disease. Therefore, the cause of the disorder remains unknown for the
majority of PD patients. It is supposedly the result of many factors acting
together including aging, genetic susceptibility, and environmental factors.
There are, however, also inherited forms with abnormalities in five genes. In
addition, six other gene loci for PD have been identified (Table 1.4). Even
though they affect only few patients, the study of mutations can increase the
general knowledge of the disease mechanism; the affected genes (and their
protein products) have therefore been studied extensively.
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Gene
locus,
protein
Known
muta-
tions
Properties Clinical
features Reference
PARK1,
α-
Synuclein
A53T,
A30P,
E46K
major
component of
Lewy bodies;
fibrillar
aggregates;
expression in
animal models
can mimic PD
dementia,
hypoventilation,
abnormal eye
movements
Polymeropoulos
et al.
[1997];
Kruger
et al.
[1998];
Baba et al.
[1998];
Zarranz
et al.
[2004]
PARK2,
Parkin
several,
including
point
mutations,
deletions,
duplica-
tions
mutations cause
PD without
Lewy bodies;
normal function:
ubiquitin-
protein
ligase
early onset,
dystonia at
onset, brisk
reflexes, very
good response
to levodopa
Abbas
et al.
[1999]
PARK3,
protein
unknown
dementia
associated with
neurofibrillary
tangles and
senile plaques
Gasser
et al.
[1998]
PARK4,
protein
unknown
dementia,
postural tremor,
early weight loss
Farrer
et al.
[1999]
PARK5,
Ubiquitin
C-terminal
hydrolase
L1
(UCHL1)
I93M supports the
implication of
the ubiquitin-
proteasome
system in PD
typical PD Wintermeyer
et al.
[2000]
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Gene
locus,
protein
Known
muta-
tions
Properties Clinical
features Reference
PARK6,
PTEN3-
induced
kinase 1
(PINK)
several Ser/Thr protein
kinase targeted
to mitochondria,
might exert a
protective effect
on the cell
early onset,
tremor
dominant
Beilina
et al.
[2005]
PARK7,
DJ1
protein
deletion,
point
mutations
L166P,
E46D
hydroperoxide-
responsive
protein; linked
to oxidative
stress in PD
early onset,
dystonia,
psychic
disturbances
Hering
et al.
[2004]
PARK8,
protein
unknown
L-DOPA
responsive
Parkinsonism
Funayama
et al.
[2002]
PARK9,
protein
unknown
Kufor-Rakeb
syndrome,
juvenile onset,
paralysis,
dementia
Hampshire
et al.
[2001]
PARK10,
protein
unknown
late onset Hicks et al.
[2002]
PARK11,
protein
unknown
early onset Pankratz
et al.
[2003]
Table 1.4: Proteins associated with familiar Parkinson’s disease
From all proteins listed in Table 1.4, α-Synuclein has been studied most
extensively. It is the major component of Lewy bodies found in PD patient
brain tissue and its aggregation process has been studied in in vitro, cell
culture and animal models (Table 1.6).
3Protein Tyrosine phosphatase and Tensin homolog
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The α-Synuclein protein
α-Synuclein (Syn) is encoded by a gene on chromosome 4 that can be tran-
scribed and translated into full-length Syn with 140 amino acids as well as a
rare, shorter splice variant with 112 amino acids that has not been character-
ized in detail so far [Ueda et al., 1994]. The name Synuclein was first given to
a 143 amino acid neuronal protein which was found by expression screening
of the electric organ of the fish Torpedo californica. The name of the protein
derives from its localization in the nucleus and presynaptic nerve terminals,
and its expression is specific for the nervous system [Maroteaux et al., 1988].
Orthologues in human, namely the 140 amino acid NACP (non-amyloid β
compound of Alzheimer’s disease amyloid precursor) and Synelfin in zebra
finch were cloned independently [Ueda et al., 1993; George et al., 1995].
Figure 1.6: The domain structure of α-Synuclein and sites of interaction with its
binding partners [Lucking and Brice, 2000].
The schematic representation of Syn in Fig. 1.6 shows seven repeats of a
KTKEGV motif in the N-terminus, a feature reminiscent of the lipid-binding
domain of apolipoproteins [Segrest et al., 1994]. The so-called NAC (non-
amyloid component) domain, which corresponds to amino acids 61-95, has
been reported to be present in extracellular amyloid plaques in Alzheimer’s
disease, although recently this localization of Syn fragments to plaques was
questioned [Culvenor et al., 1999]. From the structural point of view, Syn
has an ’open’ random coil conformation in aqueous solution, with only the
N-terminal portion being able to form an α-helical structure upon binding
to phospholipid membranes [Davidson et al., 1998].
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Other members of the Synuclein family include β-Synuclein, which is
also predominantly expressed in the brain, and gamma-Synuclein (BCSG1,
persyn), which is not only expressed in the adult brain but also found in
ovarian tumors [Jakes et al., 1994; Lavedan et al., 1998].
Putative normal functions of α-Synuclein. The finding of a structural
change from random coil to an α-helical fold upon lipid binding and the
presynaptic localization of the protein led to the hypothesis that Syn might
have a function in the regulation of synaptic plasticity and neuronal differ-
entiation. Indeed, Syn has also been found to bind rat brain vesicles via the
first four 11-mer N-terminal repeats [Jensen et al., 1998] (Fig. 1.6). Fur-
thermore, Synelfin, the bird ortholog of Syn, is upregulated in vivo during
the period of song learning, which requires maximal neuronal plasticity in
zebra finch [George et al., 1995], and treatment of rat phaeochromocytoma
cells (PC12) with nerve growth factor which induces a neuronal phenotype
increases Syn levels [Steffan et al., 2000]. The interaction of Syn with Syn-
philin was found in a two-hybrid screen [Engelender et al., 1999]. Synphilin
shows strong association with synaptic vesicles, so it might be a synaptic
partner of Syn mediating its function at the synapse [Ribeiro et al., 2002]. A
recent study proposes a role for Syn as a molecular chaperone assisting in the
folding and refolding of synaptic proteins called SNAREs4 which are crucial
for the release of neurotransmitters, vesicle recycling and synaptic integrity
[Chandra et al., 2005].
A role for Syn in the regulation of cell viability or as a chaperone can
be deduced from its binding partners, such as extracellular regulated kinase
(ERK), dephospho-BAD and PKC (proteins involved in the regulation of cell
viability) as well as the 14-3-3 proteins, which all are chaperones particularly
abundant in the brain [Ostrerova et al., 1999].
Furthermore, Syn binds to the microtubule-binding domain of Tau and
may thereby mediate Tau’s function in the formation of microtubules [Jensen
et al., 1999].
An overview of possible functions for Syn deduced from its binding part-
ners is presented in Table 1.5.
4soluble NSF attachment receptors
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Binding
partner
Properties Reference
Brain vesicles neurotransmitter release,
regulation of synaptic plasticity
Jensen et al.
[1998]
Phospholipase
D (PLD)
lipid metabolism, vesicle
trafficking, inhibited by Syn
Jenco et al.
[1998]
Synphilin associated with synaptic vesicles,
regulation of synaptic plasticity
Engelender
et al. [1999]
14-3-3 proteins chaperoning function Ostrerova et al.
[1999]
Protein kinase
A (PKA)
Tau phosphorylation, stimulated
by Syn
Jensen et al.
[1999]
Tau component of the cytosceleton,
Syn possibly regulates Tau’s
interaction with microtubules
Jensen et al.
[1999]
Bad regulation of cell viability Ostrerova et al.
[1999]
Protein kinase
C (PKC)
regulation of cell viability Ostrerova et al.
[1999]
Extracellular
regulated kinase
(ERK)
regulation of cell viability Ostrerova et al.
[1999]
Table 1.5: Binding partners of α-Synuclein
α-synuclein in the disease state and PD model systems. Recent
research suggests that Syn contributes to the pathophysiology of many neu-
rodegenerative illnesses. Syn accumulates in Lewy bodies in PD and DLB,
and in dystrophic neurites in PD and ALS. Furthermore, glia cells show Syn
accumulation in multiple systems atrophy [Spillantini et al., 1998a,b; Takeda
et al., 1998]. A number of studies show that Syn can be toxic. Incubation
of Syn with neuronal cells induces apoptosis [El-Agnaf et al., 1998] and mice
expressing human Syn with the initially reported Ala53Thr mutation (Table
1.4) exhibit late-onset neurodegeneration, motor dysfunction and Syn aggre-
gation in the brain [Lee et al., 2002]. In Drosophila models, expression of
normal and mutated Syn has also resulted in many phenotypes resembling
PD symptoms including motor deficits, specific neurodegeneration and intra-
neuronal inclusions [Feany and Bender, 2000]. For an overview of PD model
systems with Syn overexpression see Table 1.6. The accumulation of Syn has
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been shown to render endogenous dopamine toxic [Xu et al., 2002; Junn and
Mouradian, 2002] and PARK1 double knock-out mice (lacking both alleles
coding for Syn) display functional deficits in the nigrostriatal dopamine sys-
tem [Abeliovich et al., 2000]. These findings could explain why dopaminergic
neurons are especially vulnerable in PD.
Model
system
Expressed
Protein
Reproduced features
of disease Reference
in vitro,
purified
protein
wt, A53T, A30P
Syn
amyloid fibrils, bind
Congo red and
Thioflavin T, resistant
to proteases
Conway
et al.
[2000a]
S. cerevisiae wt, A53T, A30P
Syn
expression of high
amounts of Syn leads to
aggregation and toxicity
Outeiro
and
Lindquist
[2003]
S. cerevisiae wt Syn aggregation triggered by
oxidative stress,
expression of Syn is toxic
Zabrocki
et al.
[2005]
BE-M17 neu-
roblastoma
cells
wt, A53T, A30P
Syn
iron and free radical
generators stimulate the
formation of
ubiquitinated inclusions
Ostrerova-
Golts et al.
[2000]
human
embryonic
kidney HEK
293 cells,
human
dopaminergic
SK-N-SH
cells
wt, A53T, A30P
Syn
protein dose-dependent
toxicity, higher toxicity
with A53T and A30P
expression
Ostrerova
et al.
[1999]
murine neu-
roblastoma
cells
wt Syn decreased viability,
increased sensitivity to
H2O2
Prasad
et al.
[2004]
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Model
system
Expressed
Protein
Reproduced features
of disease Reference
rat primary
neurons, rat
mesen-
cephalic
cells
A53T Syn death of dopamine
neurons
Zhou et al.
[2000]
rat neuro-
blastoma
PC12 cells
wt and A53T
Syn
only with A53T:
ubiquitinated
aggregates, cell death,
proteasome impairment,
absence of dopamine
release
Stefanis
et al.
[2001]
U373
astrocytoma
cells
C-terminally
truncated wt
Syn
apoptotic cell death
through caspase
activation
Stefanova
et al.
[2003]
Mesc2.10
human mes-
encephalic
cells
lentiviral
overexpression
of A53T Syn
decreased dopamine
release, increased
intracellular levels of
superoxide
Lotharius
et al.
[2002]
murine
primary
neurons
GFP-tagged wt,
A53T and A30P
Syn
wt and A53T: formation
of proteasome-sensitive
inclusions
McLean
et al.
[2001]
D.
melanogaster
wt, A53T and
A30P Syn
dopaminergic cell loss,
intraneuronal inclusions,
locomotor dysfunction
Feany and
Bender
[2000]
C. elegans wt and A53T
Synculein
loss of dopaminergic
neurons
Lakso
et al.
[2003]
mouse model lentiviral
expression of wt
and A30P Syn
ubiquitinated inclusions
of Syn, progressive loss
of Syn expressing
neurons
Lauwers
et al.
[2003]
transgenic
mice
wt Syn loss of dopaminergic
neurons, inclusion body
formation
Masliah
et al.
[2000]
28
Model
system
Expressed
Protein
Reproduced features
of disease Reference
transgenic
mice
human A53T
Syn, in
combination
with
knocked-out
mouse syn
movement disorder,
motor neuron damage
Cabin
et al.
[2002]
transgenic
mice
A53T and wt
Syn
A53T: abnormal protein
distribution, no
aggregation; wt +
A53T: reduction of
motor activity
Gispert
et al.
[2003]
transgenic
mice
wt and A30P
Syn
A30P: ubiquitinated and
proteinase-K resistant
inclusion bodies,
progressive locomotor
dysfunction
Neumann
et al.
[2002]
transgenic
mice
wt, A53T and
A30P Syn
only A53T: progressive
motor dysfunction, Syn
accumulation
Lee et al.
[2002]
transgenic
mice
wt and A53T
Syn
neuronal Syn
accumulations, neuronal
degeneration, motor
deficits
van der
Putten
et al.
[2000]
transgenic
mice
wt, A53T and
A30P Syn
A30P: no inclusions, but
progressive motor
impairment, no specific
loss of dopaminergic
neurons
Gomez-
Isla et al.
[2003]
marmoset
(monkey)
model
viral expression
of wt Syn in the
substantia nigra
Syn-positive inclusions,
loss of dopaminergic
neurons, progressive
motor impairment
Kirik et al.
[2003]
Table 1.6: PD model systems with α-Synuclein overexpression
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1.2 Molecular mechanisms of neurodegener-
ative disease
1.2.1 Cellular defense against misfolded proteins
Protein folding in the complex environment of a living cell is typically a
process which does not occur spontaneously but requires the help of a class
of proteins which are highly conserved among species, the molecular chaper-
ones. They prevent inappropriate interactions within and between non-native
polypeptides, enhance the efficacy of de novo protein folding and promote
the refolding of proteins which have become misfolded as a result of cellu-
lar stress [Hartl and Hayer-Hartl, 2002]. Chaperones have essential roles in
many cellular processes, not only in protein folding, but also in the target-
ing, transport and degradation of proteins as well as in signal transduction
[Muchowski and Wacker, 2005].
Families of molecular chaperones
Hsp100: Heat shock protein 100 (Hsp100) chaperones are members of the
AAA+ family (Adenosine Triphosphatases with diverse activities), which
share a common ATPase domain and form large ring-shaped structures. In
yeast Hsp104, the best-characterized Hsp100 protein, regulates protein ag-
gregation, disaggregation and thermotolerance [Sanchez and Lindquist, 1990;
Shorter and Lindquist, 2004]. Valosin-containing protein (VCP), also known
as p97, is the only protein so far characterized which might represent a mam-
malian member of the Hsp100 family. It has been linked to quality control
in the endoplasmatic reticulum and there is evidence that it might be in-
activated in neurodegenerative diseases [Kobayashi et al., 2002]. A recent
study furthermore showed that VCP modulates the aggregation behavior of
Ataxin-3, a protein linked to spinocerebellar ataxia type 3 [Boeddrich et al.,
2006].
Hsp90: Hsp90 chaperones are essential components of the eukaryotic cy-
tosol, where they stabilize misfolded proteins and regulate the activity of
various signalling proteins, including steroid hormone receptors, tyrosine ki-
nases, nitric oxide synthase and calcineurin [Young and Hartl, 2002].
Hsp60: Hsp60 chaperones are heptameric complexes of identical subunits
stacked back to back in a double-ring structure containing a large central
cavity, in which protein folding is thought to occur [Bukau and Horwich,
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1998]. In eukaryotes Hsp60 family members, also called Group I chaperonins,
are found in the mitochondria and cooperate with a cofactor of the Hsp10
family. A second class of chaperonins (Group II chaperonins) is found in the
eukaryotic cytosol but has no Hsp10 cofactor.
Hsp70: Hsp70 chaperones together with Hsp40s, their co-chaperones, as-
sist in the stabilization and folding of many substrates and are found in most
cellular compartments [Bukau and Horwich, 1998]. In humans 11 genes that
encode Hsp70 family members have been identified so far [Tavaria et al.,
1996]. All Hsp70 proteins have a conserved amino-terminal ATPase domain,
which binds and hydrolyses ATP, and a carboxy-terminal substrate-binding
domain.
Hsp40: Hsp40 co-chaperones bind Hsp70 through a conserved J-domain
and stimulate ATP hydrolysis, resulting in a conformational switch which
closes the substrate-binding pocket of Hsp70 and facilitates the capture of
non-native protein substrates [Hartl, 1996]. Hsp20 proteins also bind pro-
tein substrates and target them to Hsp70, enhancing the efficiency of the
Hsp70/ Hsp40 refolding cycle. Higher eukaryotes have many Hsp40 family
members, whose differential expression or localization might regulate the sub-
strate specificity of conserved Hsp70 family members [Cheetham and Caplan,
1998].
Small heat shock proteins (sHsps): sHsps have a molecular mass of
less than 40kDa and assemble into large, oligomeric structures that resem-
ble a hollow ball. All sHsps contain a conserved, C-terminal α-crystallin
domain of about 100 residues that mediates oligomeric assembly. Similar
to Hsp90 chaperones, sHsps transiently interact with and stabilize misfolded
substrates, conceivably until the Hsp70/Hsp40 system can actively refold
them [Clark and Muchowski, 2000; Horwitz, 1992].
Cellular protein degradation
The ubiquitin-proteasome system: Chaperones bind to exposed hy-
drophobic regions in proteins, thus preventing aggregation and providing
more time for folding. However, if a given protein does not acquire a properly
folded conformation in a reasonable timeframe it becomes eligible for degra-
dation. The ubiquitin-proteasome pathway described below is the principal
mechanism for proteolysis in the mammalian cytosol and nucleus (Figure
1.7).
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Figure 1.7: The ubiquitin-proteasome pathway [Taylor et al., 2002]. (A) Proteins
targeted for degradation are tagged by covalent linkage to ubiquitin.
Selective ubiquitination is accomplished by a series of enzymes (E1,
E2 and E3) that constitute the ubiquitin ligase system. (B) Ubiquiti-
nated substrates are recognized, unfolded and degraded in an energy-
dependent manner by the proteasome.
Multiple molecules of ubiquitin, a conserved 8.5 kDa polypeptide, con-
stitute the signal for a proteasome attack. The first ubiquitin is covalently
joined to the substrate through an isopeptide bond between the C-terminus
of ubiquitin and a lysine residue of the target protein. Due to this mode of
attachment ubiquitin, which is always synthesized with a C-terminal exten-
sion, must be proteolytically processed before it can acquire activity. Pro-
teases called ubiquitin C-terminal hydrolases (UCHs) assist in this process.
Ubiquitin-substrate ligation is accomplished through three enzymatic steps,
with the key steps of substrate selection and ubiquitin transfer being del-
egated to a ligase (E3). There are many E3s; they recognize their cognate
substrates by binding to specific substrate-specific signals in a manner that is
frequently regulated by covalent modification. Additional ubiquitins are then
linked to the first one to form a polyubiquitin chain, which is a potent at-
tractive signal for the regulatory complex of the proteasome [Scheffner et al.,
1995].
The 26S proteasome consists of more than 60 subunits. A central, barrel-
shaped catalytic (20S) complex carries multiple active sites which are se-
questered in an interior chamber and only accessible through a narrow ax-
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ial pore [Tanaka et al., 1988; Yoshimura et al., 1993]. Two distally posi-
tioned regulatory (19S) complexes unfold the substrate polypeptide chain
and translocate it through this pore into the active-site chamber, using inte-
gral chaperone subunits placed immediately adjacent to the axial pore of the
20S complex [Braun et al., 1999]. During proteasomal proteolysis ubiquitin
is removed and recycled and the target protein is broken down into small
peptides. These molecules can then be further hydrolyzed by other cellular
peptidases and the resulting amino acids are recycled during the synthesis of
new proteins.
Autophagy: Autophagy constitutes the second important pathway for the
degradation of cellular constituents, and the only known way to degrade en-
tire organelles. The three types of autophagy are microautophagy, which has
not been characterized well in mammalian cells so far, macroautophagy and
chaperone-mediated autophagy. The process of macroautophagy is composed
of four main steps: Induction, formation of the autophagosome, autophago-
some docking and fusion with the lysosome, and autophagic body breakdown.
Macroautophagy is regulated both developmentally and nutritionally. Non-
specific autophagy is induced by starvation, whereas specific autophagy can
function in the selective sorting and turnover of certain cytoplasmic proteins
or entire organelles.
After induction of autophagy, cytoplasmic components are sequestered
into a double-membrane vesicle that is thought to derive from the endoplas-
matic reticulum [Dunn, 1990]. Then the resulting autophagosome is delivered
to and fuses with the lysosome, a process which in yeast depends on com-
ponents of the SNARE machinery and Rab GTPases [Ishihara et al., 2001].
Finally, the cytoplasmic components are degraded within the lysosome, which
contains a range of hydrolases that are able to degrade essentially any sub-
cellular constituent (proteins, lipids, nucleic acids, carbohydrates) [Klionsky
and Emr, 2000].
Substrates for chaperone-mediated autophagy contain a motif that is bio-
chemically related to the pentapeptide KFERQ and are selectively recognized
by a cytosolic chaperone, the heat shock cognate protein of 73 kDa (hsc73)
[Dice, 1990; Chiang et al., 1989]. This complex binds to the lysosome asso-
ciated membrane protein type 2a (lamp2a), and is completely translocated
into the lysosomal matrix by a second chaperone, namely the lysosomal hsc73
[Agarraberes et al., 1997].
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Chaperones in neurodegenerative disease
Despite the existence of the chaperone machinery, which is specialized in the
recognition of misfolded proteins, amyloidogenic proteins are able to assume
a ’toxic fold’ and form insoluble aggregates within the cell. Therefore, many
studies have tried to find out why misfolded proteins in neurodegenerative
disorders are not dealt with by the chaperone machinery and whether it is
possible to alter cellular folding and degradation pathways so that the level
of toxic aggregates in the cell would be reduced.
One reason why the chaperone system cannot prevent neurodegenerative
diseases could be the recruitment of molecular chaperones and of components
of the ubiquitin-proteasome system into protein aggregates; this phenomenon
has been reported to happen in patient brain tissue as well as in disease model
systems [Muchowski and Wacker, 2005]. The co-localization of the protein
quality control machinery with inclusion bodies might reflect an irreversible
sequestration and subsequent loss of function of chaperones and/or a failed
attempt to refold or degrade aggregated proteins.
Another explanation for the accumulation of misfolded proteins is that
the chaperone system may get overloaded due to an enormous amount of
amyloids. The normal cellular levels of chaperones might be sufficient to
control the damaging effects of aggregation-prone proteins for decades, but
aging processes have been reported to slow down the protein degradation
machinery in general [Szweda et al., 2002]. Therefore, a shift in the balance
between chaperone capacity and production of misfolded protein may be
crucial for triggering the onset of disease [Sakahira et al., 2002].
Autophagy in neurodegenerative disease
In contrast to the proteasome, autophagy does not require the tagging and
unfolding of its substrates and the proteins do not have to enter the system
via a narrow pore for degradation, but are simply surrounded by membrane
structures. These features make autophagy interesting for neurodegenerative
disorders, since large assemblies and aggregates of misfolded proteins are
unlikely to be unfolded and inserted into the proteasomal pore. In fact, it
has been shown that polyQ containing peptides cannot be degraded by the
proteasome [Venkatraman et al., 2004], but proteins such as Htt and Syn are
degraded by autophagy [Ravikumar et al., 2002; Webb et al., 2003].
Nevertheless also the autophagic system is not able to prevent the ulti-
mate formation of inclusion bodies and neurodegeneration. In many neu-
rodegenerative diseases such as PD, HD, AD, ALS or in prion diseases the
accumulation of autophagic vesicles has been observed [Nagai et al., 2003;
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Shintani and Klionsky, 2004; Yu et al., 2005]. However, it is not known
whether this represents an increase in autophagy, and hence an effort of the
cell to degrade insoluble protein aggregates, or a block in the consumption
of autophagosomes. In the case of Syn it has been shown that the wild-type
protein is degraded by autophagy, but mutated Syn associated with famil-
ial PD is not [Cuervo et al., 2004]. Similarly, impaired autophagy has been
observed in a mouse model expressing mutant presenilin 1 and mutant amy-
loid precursor protein (APP), both associated with familial AD [Yu et al.,
2005]. These results suggest, that mutations connected to inherited forms of
neurodegenerative diseases might influence the degradation of the proteins
by autophagy and thereby facilitate the accumulation of aggregates.
1.2.2 Oxidative stress, antioxidants and neurodegen-
eration
Since the brain consumes a large percentage of the body’s oxygen supply,
is rich in polyunsaturated fatty acids, accumulates metal ions, is relatively
low in antioxidants and is composed largely of non-mitotic cells, this organ
is especially vulnerable to oxidative stress. When the brain ages, intrinsic
oxidative stress increases as a consequence of diminished antioxidant defense
capabilities [Poon et al., 2004]. Free radical damage to neurons caused by the
particular molecular alterations in neurodegenerative disorders could increase
these effects of normal brain aging considerably.
Biomarkers of oxidative stress in the brain such as protein oxidation or
oxidative damage to DNA have been connected to several neurodegenerative
disorders or animal models thereof [Ebadi et al., 1996; Browne et al., 1997;
Polidori et al., 1999; Bogdanov et al., 2001]. Oxidative stress in biological
systems results from an imbalance between the production of reactive oxygen
species (ROS) and their clearance by cellular antioxidant systems. Normally
cells scavenge deleterious ROS molecules using different types of enzymes
(Fig. 1.8).
Superoxide, produced from oxygen in mitochondria, is the principal source
of cellular ROS. It is normally degraded by mitochondrial superoxide dismu-
tase (SOD2), which converts superoxide to hydrogen peroxide. Catalase, in
turn, converts hydrogen peroxide to molecular oxygen and water [McCord
et al., 1971]. SOD2 has been linked to neurodegenerative diseases since mice
lacking this enzyme die prematurely, showing metabolic and tissue patholo-
gies that include a lethal spongiform neurodegenerative disorder [Melov et al.,
1998].
Hydrogen peroxide can also be detoxified by glutathione peroxidase using
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Figure 1.8: Reactive oxygen species in neurodegenerative disorders. An imbal-
ance between the production and elimination of reactive oxygen species
could contribute to the pathogenesis of PD and other neurodegenera-
tive disorders [Lotharius and Brundin, 2002]. Abbreviation: DOPAC,
3,4-dihydroxyphenyacetic acid; other abbreviations are described in
the text.
reduced glutathione (GSH). The hereby oxidized glutathione (GSSG) can be
reduced by GSSG reductase and reused [Hayes and McLellan, 1999]. During
normal aging many organisms show a decline in reduced glutathione [Sohal
and Weindruch, 1996], and a reduction of GSH levels in the substantia nigra
of PD patients is correlated to the degree of disease severity [Riederer et al.,
1989].
Another protective enzyme is GSH-S -transferase, which can convert elec-
trophilic centres of various potentially toxic compounds to thioether bonds.
Furthermore, enzymes such as DNA glycosylases are responsible for the re-
pair of the oxidatively damaged DNAs [Imai and Nakagawa, 2003; Barnes
and Lindahl, 2004].
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Huntington’s disease: Mitochondrial dysfunction is a known feature of
Huntington’s disease that may lead to increased oxidative damage, since mi-
tochondria are a major source of free radicals in the cell. Studies which
determined the levels of 8-hydroxy-2-deoxyguanosine as a marker for oxida-
tive damage to DNA have found increased levels in transgenic mouse models
of HD [Bogdanov et al., 2001] as well as in nuclear DNA from the caudate
nucleus and mitochondrial DNA from the parietal cortex of patients [Browne
et al., 1997; Polidori et al., 1999].
Parkinson’s disease: Basal levels of oxidative stress in the substantia ni-
gra pars compacta which are already high in non-affected individuals seem
to be further increased in PD, along with a high concentration of iron found
in the respective area of patient brains [Riederer et al., 1989]. A possi-
ble explanation for the specific death of dopaminergic neurons in PD could
be that the metabolism of dopamine itself may lead to the production of
reactive oxygen species including H2O2. As seen in Figure 1.8 (a), the
metabolism of dopamine (DA) leads to the formation of superoxide an-
ions (O2·−), dopamine-quinone species (SQ·) and hydroxyl radicals (OH·).
Dopamine breakdown can occur spontaneously in the presence of iron or can
be catalyzed by monoamine oxidase (MAO) in a reaction that generates hy-
drogen peroxide (H2O2). Even though hydrogen peroxide is not damaging to
cells, the formation of hydroxyl radicals by the Fenton reaction (Fig. 1.8 a,
last equation) with iron can lead to cytotoxicity. The symptomatic treatment
with L-DOPA may also add to the oxidative load [Shulman, 2000; Weinreb
et al., 2003]. Correspondingly, in vitro studies also link Syn aggregation to
oxidative stress, with the disease-associated mutants making cells even more
vulnerable [Hashimoto et al., 1999; Kanda et al., 2000]. These findings sug-
gest that in PD an abnormal increase in the production of ROS might tilt the
balance between production and elimination, leading to enhanced oxidative
stress as outlined in Figure 1.8 (b).
1.3 Strategies for the development of thera-
peutics
The current knowledge of neurodegenerative disorders identifies oxidative
stress and protein aggregation as two of the major culprits for the neurotoxi-
city observed in patient brains as well as in different model systems. Protein
aggregation could overload cellular protein degradation systems, and toxicity
could arise from the aggregation process itself, the final aggregates or inter-
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mediate structures. These disease mechanisms have been studied extensively
in the last few years, and many substances have been proposed to lower
toxicity and neuronal death in diverse model systems [Herbst and Wanker,
2006].
1.3.1 In vitro systems
Aggregation inhibitor screens with purified proteins have been performed
with model systems for different diseases such as HD [Heiser et al., 2002],
PD [Conway et al., 2001] or AD [Esler et al., 1997]. In vitro model systems
allow the exclusive detection of substances that interfere directly with the
protein aggregation process. The purified protein and the drug are present
in a buffered solution, a system which is extremely simplified compared to
the complex environment of a brain cell. However, limiting the number of
possible interaction partners for the molecules in solution often leads to more
reliable, reproducible results and can yield basic structures whose properties
can be refined in additional steps. Nevertheless, hits derived from such a
screen have to be validated in cell culture and animal models, since the
substances could be toxic to living cells, might not be able to penetrate cell
membranes and the blood-brain-barrier or could also be metabolized quickly
to inert or even noxious products. Within these limits in vitro screening
methods are well suited for the study of direct protein-drug interactions and
molecular mechanisms by which the aggregation process might be stopped
or altered.
1.3.2 Cell based systems
Compound screens based on mammalian or yeast cells can use several phe-
nomena as a readout, since either protein aggregation itself or cellular re-
sponses to eventually toxic protein aggregates can be monitored. Aggrega-
tion has been evaluated directly with the filter retardation assay adapted
to mammalian cells, yielding a high-throughput screening method for com-
pounds which inhibit prion aggregation [Winklhofer et al., 2001]. A more
tedious method has been developed by Apostol et al. [2003], relying on the
manual counting of aggregates visualized with fluorescence microscopy.
In yeast, the aggregation of Htt exon 1 protein with an elongated polyQ
stretch is toxic and prevents the cultures from growing. This has been used
for aggregation inhibitor screens in order to look for substances, which can
reverse the impaired growth phenotype [Zhang et al., 2005]. Furthermore,
Piccioni et al. [2004] have developed a screening method which measures
the activation of caspase-3 in a model system for SBMA. Another system
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employed by Westerheide et al. [2004] does not focus on a specific disorder,
but is designed to identify compounds which activate heat shock proteins in
mammalian cells using a luciferase reporter assay.
As can be seen from the literature the possibilities for screen develop-
ment in eukaryotic cells are manifold, however, all of them also have certain
drawbacks. For example, they would also detect compounds that activate
the cellular protein degradation machinery or cellular survival pathways and
that may not interfere directly with protein aggregation. Also, a wide range
of concentrations should be tested, since the therapeutic windows might be
small and could differ considerably between different compounds and cell
lines used in the screen. Therefore, secondary assays and appropriate con-
trols are crucial for the validation of hits derived from cell based compound
screens.
1.3.3 Genomic screens for aggregation modifiers
Another set of screening methods does not rely on compound libraries but
aims at the identification of normal cellular proteins that can modify the
toxicity or aggregation behaviour of amyloidogenic proteins. Mammalian
cells have highly developed interaction networks between different proteins,
DNA, RNA and lipids. There is evidence that these carefully balanced in-
teractions are disturbed in neurodegenerative disorders (see Figure 1.4 and
Chapter 1.2). The toxicity of Htt with an elongated polyQ stretch in yeast
has been exploited to identify yeast genes, which either worsen [Willingham
et al., 2003] or restore [Giorgini et al., 2005] the impaired growth phenotype.
Similarly, screens in C. elegans model systems have identified genes, which
modulate the neurotoxicity caused by the expression of Htt with an elon-
gated polyQ stretch [Faber et al., 2002] or cause the premature appearance
of protein aggregates [Nollen et al., 2004].
Such screening methods are useful for the elucidation of pathogenic mech-
anisms and the identification of new target proteins for therapeutic interven-
tions. Identification, however, is only the first of many steps towards the
development of a drug, since the complete knock-out of proteins which en-
hance amyloid toxicity would almost certainly lead to undesired and severe
side effects. Therefore, the follow-up of a genomic screen should focus on
specific modulation of toxicity pathways without influencing normal cellular
functions of the genes and proteins involved.
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1.3.4 Evidence for the protective effect of chaperones
in models of neurodegenerative disease
As mentioned in Chapter 1.2.1, chaperones play an important role in the
cell’s natural defense system against misfolded proteins. Overexpression of
chaperone proteins should therefore be able to protect cells against the tox-
icity caused by amyloidogenic proteins.
In vitro studies have shown that the Hsp70/Hsp40 chaperone system
inhibits the assembly of polyQ proteins into fibrils in an ATP-dependent
manner: Chaperones caused the formation of amorphous, detergent-soluble
aggregates and were most effective, when added in the lag-phase of the aggre-
gation reaction [Muchowski et al., 2000]. In accordance with these findings,
the overexpression of heat shock proteins in yeast and mammalian cell culture
systems inhibits the formation of large inclusion bodies, resulting instead in
detergent-soluble aggregates [Sittler et al., 2001; Cashikar et al., 2005]. The
synergistic effects of chaperones in increasing the solubility of amyloid pro-
teins have also been confirmed in Drosophila, where the expression of Hsp70
led to efficient suppression of the disease phenotype in transgenic flies carry-
ing the human HD- or PARK1-gene respectively [Bonini, 2002]. The reduced
toxicity seen in animal and cellular model systems after the upregulation of
chaperone levels might result from the more efficient degradation of small,
soluble aggregates, as has been shown for polyQ proteins by Bailey et al.
[2002]. Less conclusive results have been obtained with animal models over-
expressing chaperones, since studies on mouse models of HD, SCA7 and ALS
reported no improvement of the neurodegenerative phenotype [Hansson et al.,
2003; Helmlinger et al., 2004; Liu et al., 2005]. A study on PARK1 transgenic
mice, however, reports a reduction in aggregate load and neuronal survival
upon co-expression of Hsp70 [Klucken et al., 2004]. Nevertheless, chaperones
may protect against neurodegeneration by converting toxic conformations
of misfolded proteins into nontoxic forms, which are tolerable for cells and
might be turned over more easily by the proteolytic machinery.
1.3.5 Therapeutic strategies targeting protein aggre-
gation
Regarding the situation in vivo, the prevention of protein aggregation in
neurodegenerative diseases is an attractive therapeutic target. The cellular
protein degradation machinery might be able to cope with mono- or even
oligomers of the toxic proteins, eliminate them from the cell and prevent
the accumulation of larger species. However, the mechanism of action for
drugs identified as aggregation inhibitors in high-throughput screens has to
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be analyzed in detail to make sure that the species stabilized by the inhibitor
are not toxic for mammalian cells. There is increasing evidence that strategies
lowering the aggregate load in different model systems also reduce cellular
toxicity:
1. Stopping the expression of mutant Htt in a conditional mouse model
of HD leads to the improvement of motor function and the clearance
of neuronal aggregates [Yamamoto et al., 2000].
2. Peptides have been identified that bind mutant Htt and thereby inter-
fere with the process of aggregation. Expression of these peptides in
a Drosophila model of HD reduced lethality and neurodegeneration in
this model system [Kazantsev et al., 2002; Nagai et al., 2003].
3. A cellular high-throughput screen identified an inhibitor of polyQ ag-
gregation, which also ameliorates toxicity in a Drosophila model [Pol-
lanen et al., 1992].
4. Lead compounds identified in a yeast screen are able to inhibit polyg-
lutamine aggregation and also suppress neurodegeneration in a Droso-
phila model [Zhang et al., 2005].
5. A high-throughput screen for aggregation inhibitors of mutant Htt iden-
tified a class of benzothiazole compounds as effective inhibitors which
are also beneficial in cell culture models of HD [Heiser et al., 2002].
6. For Alzheimer’s disease, a strategy using immunization against the
Aβ-peptide (see Table 1.1) reduces the deposition of fibrillar Aβ in
the brain and ameliorates the behavioural impairment in a transgenic
mouse model [Janus et al., 2000].
7. Small molecules that inhibit the fibrillogenesis of synthetic Aβ-peptide
rescue long-term potentiation in brain slice culture models, which is
blocked by soluble Aβ oligomers [Walsh et al., 2005].
8. Small molecules designed to bind Aβ can increase their own steric bulk
by attracting chaperones and disrupt the interactions between single
Aβ molecules. These aggregation inhibitors have been shown to reduce
the toxicity of aggregated Aβ peptide in cultured hippocampal neurons
[Gestwicki et al., 2004].
9. Rapamycin, an inducer of autophagy, reduced the number of aggre-
gates and improved the phenotype in fly and mouse models of HD
[Ravikumar et al., 2004].
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1.3.6 Antioxidants as a treatment option for neurode-
generative disease
Since oxidative stress is also linked to neurodegenerative diseases (Chapter
1.2.2), the protective potential of antioxidants has not only been tested in
several models systems, but has also been addressed by clinical trials.
However, no improvement of motor or cognitive features was achieved
in HD patients with either coenzyme Q10, a cofactor in the mitochondrial
respiratory chain with anitoxidant properties, or idebenone, an analogue of
coenzyme Q10 [Feigin et al., 1996; Ranen et al., 1996]. Neither did the free-
radical scavenger OPC-14,117 (Oligomeric Proanthocyanidin 14,117), which
belongs to a family of flavonoids found in pine bark, grape seed and grape
skin, improve HD symptoms [HSG, 1998]. A trial of α-tocopherol (vitamin
E) did not yield clear-cut benefits either, although the disease progression in
early stages of HD might have been slowed down [Peyser et al., 1995].
In PD patients, however, a clinical trial with coenzyme Q10 showed pro-
mising results: The drug slowed the decline in mental and motor function
[Shults et al., 2002], although a total rescue from the PD pathology was not
possible.
1.4 Aim of the study
The laboratory of Prof. Dr. Erich Wanker performed several drug screens in
which inhibitors of Htt exon 1 protein aggregation were identified and several
of these inhibitors were published [Heiser et al., 2000; Sittler et al., 2001;
Heiser et al., 2002]. Another screen using a library of approximately 5000
natural substances led to an interesting hit, which has not been characterized
in HD model systems so far: The major polyphenol present in green tea, (-
)-Epigallocatechin gallate (EGCG) [Ehrnhoefer et al., 2006].
This substance is a promising drug for the treatment of neurodegenerative
diseases, since its antioxidant properties have already proven to be beneficial
in cell culture and mouse models for AD and PD [Levites et al., 2001; Choi
et al., 2001]. A recent study shows that EGCG is able to modulate Amy-
loid Precursor Protein (APP) cleavage in mouse brain and thereby reduces
cerebral amyloidosis [Rezai-Zadeh et al., 2005]. A study on autoimmune en-
cephalomyelitis furthermore shows neuroprotective effects of the compound
in a mouse model, suggesting that either EGCG itself or an active metabolite
is able to penetrate the blood-brain barrier [Aktas et al., 2004]. Pharma-
cological data is available from studies done on EGCG’s anti-carcinogenic
properties [Chow et al., 2003] and natural polyphenols occurring in tea, fruit
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and wine have previously been linked to neuroprotection [Commenges et al.,
2000]. Furthermore, epidemiologic studies suggest that Parkinson’s disease is
less prevalent among Asian cultures that traditionally ingest large amounts
of green tea [Zhang and Roman, 1993; Chan et al., 1998]. Studies on the
neuroprotective effects of EGCG have so far almost exclusively focused on
its antioxidant properties in AD and PD models [Choi et al., 2001; Nie et al.,
2002], an effect in HD model systems or a direct influence on protein aggrega-
tion has never been shown. Thus, the examination of the influence of EGCG
and related compounds on protein aggregation in diverse model systems of
neurodegenerative disease was the main focus of this study.
Chapter 2
Results
2.1 Green tea catechins inhibit Htt exon 1
protein aggregation
2.1.1 Discovery of catechins with an in vitro aggrega-
tion inhibitor screen
The catechin (-)-Epigallocatechin gallate (EGCG) was identified as an in-
hibitor of Htt exon 1 protein aggregation in vitro during a screen of ap-
proximately 5000 natural compounds [Ehrnhoefer et al., 2006], which was
performed using an automated filter retardation assay [Heiser et al., 2002].
Briefly, purified, GST-tagged Htt exon 1 protein containing 51 glutamine
repeats (GST-HDQ51, for the sequence, see Figure 2.1) was incubated at
a concentration of 0.62 µM in the presence of elastase and the respective
compound at different concentrations. Elastase is a protease that digests
Htt during incubation at 37℃, and the fragments containing the polyQ tract
immediately start forming fibrillar aggregates. After overnight incubation,
the protein solution was denatured and filtered as described in Materials and
Methods. Subsequently, aggregates retained on the filter membrane were
quantified by immunodetection with the CAG53b antibody. If the compound
present in the incubation reaction inhibits the formation of SDS-resistant Htt
fibrils, no aggregates are trapped on the filter and, as a consequence, no or
only a very weak signal is observed. Since the inhibitors were dissolved in
DMSO, the solvent alone was incubated with the protein in parallel control
reactions.
EGCG is the most abundant member of a family of compounds named
catechins that are present in green and black tea. In order to learn more
about the structural elements necessary for the inhibition of Htt aggrega-
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Figure 2.1: Schematic representation of the GST-Htt exon 1 fusion protein with
51 glutamines (GST-HDQ51). Cleavage with elastase occurs preferen-
tially at amino acids with small side-chains such as alanine.
tion, three related catechins were tested with the filter retardation assay, and
their inhibitory potentials were compared to that of EGCG (for the chemical
structures of all four catechins, see Figure 2.2). With the filter retardation
assay EGCG was found to be a very effective aggregation inhibitor with an
IC50 value (50% inhibition of aggregation) of 1 µM, which corresponds to a
1.6 fold molar excess of drug over protein (see Figure 2.3). (-)-Gallocatechin
gallate (GCG), which is a stereoisomer of EGCG, also possesses a good in-
hibitory potential with an IC50 of 2 µM, whereas (-)-Gallocatechin (GC) and
(-)-Epigallocatechin (EGC), which lack the gallate moiety, are not able to
inhibit Htt exon 1 protein aggregation in vitro (Figure 2.3).
Figure 2.2: Chemical structures of the green tea catechins tested.
2.1.2 Aggregate morphology
The morphology of protein aggregates can be observed with electron mi-
croscopy (EM). In order to determine, whether the different catechins visibly
modify the shape of Htt aggregates, 0.62 µM GST-HDQ51 protein was incu-
bated with elastase and a 10-fold molar excess of compound at 37 ℃ for 3 h.
Then, aliquots of the reactions were negatively stained with uranyl acetate
and observed on carbon coated copper grids under an electron microscope.
Figure 2.4 shows that HDQ51 fibres (indicated by arrows) are abundant
in the DMSO control sample and are similar to Htt aggregates described
in the literature [Scher/-zin/ ger et al., 1997; Heiser et al., 2002]. In the
presence of EGCG or GCG, however, the amount of fibrils is dramatically
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Figure 2.3: EGCG and GCG inhibit HDQ51 aggregation in vitro. 0.62 µM GST-
HDQ51 protein was incubated with elastase and different amounts of
catechins at 37 ℃ for 16 h. Samples were denatured, subjected to the
filter retardation assay and insoluble aggregates on the membrane were
visualized with the CAG53b antibody. (A): Representative filters. (B):
Quantification of the results shown in (A). The amount of aggregates
retained on the filter in the DMSO control was arbitrarily set at 100%.
reduced. Instead, small, amorphous protein assemblies (indicated by arrow-
heads) could be found, suggesting that the compounds block fibrillogenesis,
but do not prevent the formation of microaggregates, which are not detected
with the filter retardation assay. The compounds GC and EGC did not visi-
bly influence the formation of HDQ51 fibrils, consistent with the results from
the filter assay.
2.1.3 Inhibition of Htt aggregation is not a general fea-
ture of antioxidant substances
Since green tea catechins are known to be potent antioxidants [Frei and
Higdon, 2003], experiments were performed to find out whether antioxidants
in general have inhibitory potential in our Htt aggregation assay. 0.62 µM
GST-HDQ51 was incubated with elastase and the antioxidant compounds
to be tested at 37 ℃ for 16 h, the samples were then denatured by boiling
with SDS/DTT, subjected to the filter retardation assay and subsequent
immunodetection with the CAG53b antibody. Figure 2.5 shows that the
natural antioxidants ascorbic acid and α-tocopherol are not able to inhibit
Htt aggregation in our experimental setup. This indicates that the structure
rather than the antioxidant potential of EGCG is important for its inhibition
of HDQ51 aggregation.
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Figure 2.4: EGCG and GCG reduce the amount of HDQ51 fibrils observed by elec-
tron microscopy. 0.62 µM GST-HDQ51 protein was incubated with
elastase and a tenfold molar excess of compound at 37 ℃ for 3 h.
Aliquots were negatively stained with uranyl acetate and observed on
carbon coated copper grids with a Philips CM100 EM. The white bars
indicate a length of 500 nm, arrows indicate HDQ51 fibrils present in
the solvent control (DMSO) and in GC- and EGC-treated reactions.
Arrowheads point to small amorphous protein assemblies or microag-
gregates formed in the presence of EGCG or GCG.
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Figure 2.5: Ascorbic acid and tocopherol do not inhibit HDQ51 aggregation. (A):
0.625 µM GST-HDQ51 protein was incubated with elastase and 0.625,
3.125 or 6.25 µM of different antioxidant compounds at 37℃ for 16 h.
Samples were denatured and analyzed by the filter retardation assay
using the CAG53b antibody. Of the three antioxidants tested, only
EGCG reduced the amount of HDQ51 aggregates. (B): Quantification
of the results shown in (A). The amount of aggregates retained on the
filter in the DMSO control was arbitrarily set at 100%. (C): Ascorbic
acid and α-tocopherol are structurally different from EGCG (Fig. 2.2).
2.1.4 Oxidative or reducing conditions do not change
the inhibition of Htt aggregation by EGCG
Next, it was determined whether the inhibition of Htt aggregation by EGCG
can be modified by either oxidative or reducing conditions. 0.62 µM GST-
HDQ51 protein was incubated at 37 ℃ with elastase and 0.06, 0.6 or 3 µM
EGCG in the presence of different amounts of either H2O2 or DTT. After
16 h, the samples were denatured and insoluble HDQ51 aggregates were
detected with the filter retardation assay using the CAG53b antibody. As
determined before (Figs. 2.3 and 2.5), 0.06 and 0.6 µM EGCG did not inhibit
HDQ51 aggregation, whereas 3 µM EGCG effectively blocked the formation
of Htt aggregates. This inhibition pattern was not changed in the presence
of up to 10 µM of either H2O2 or DTT, indicating that oxidative or reducing
conditions did not significantly influence the potential of EGCG to inhibit
Htt aggregation (Fig. 2.6).
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Figure 2.6: Oxidative or reducing conditions do not modify the inhibition of
HDQ51 aggregation by EGCG. 0.6 µM GST-HDQ51 was incubated
at 37 ℃ with elastase and 0.06, 0.6 or 3 µM EGCG in the presence
of different amounts of either H2O2 or DTT. After 16 h, samples were
denatured by boiling in SDS/DTT. Protein aggregates were trapped
on a cellulose acetate filter and visualized by immunodetection using
the CAG53b antibody. Concentrations of up to 0.6 µM EGCG did
not inhibit Htt aggregation, whereas 3 µM EGCG completely blocked
the formation of insoluble protein aggregates. This pattern was not
changed by the addition of H2O2 or DTT. (A): Quantification of the
results obtained with H2O2. (B): Quantification of the results ob-
tained with DTT. The amount of aggregates retained on the filter in
the DMSO control was arbitrarily set at 100%.
2.2 The mechanism of EGCG-mediated inhi-
bition of Htt aggregation
In the next part of the study, the mechanism of EGCG-mediated inhibi-
tion of Htt aggregation was analyzed. Two GST-Htt exon 1 proteins with
53 glutamines and additional FLAG- or myc- tags (GST-FLAG-HDQ53 and
GST-myc-HDQ53) were used for this purpose (Fig. 2.7). These fusion pro-
teins possess a unique cleavage site for Prescission Protease™ between the
GST- and the FLAG- or myc-tags, respectively [Busch et al., 2003]. There-
fore, the addition of Prescission Protease™ leads to well-defined cleavage
products whose aggregation can be monitored over time.
First, the aggregation kinetics of the proteins were assessed by incubat-
ing 100-300 ng/µl GST-FLAG-HDQ53 with Prescission Protease™ at 30 ℃.
At different time points, aliquots were analyzed by SDS-PAGE and Western
blotting with the HD1 and GST antibodies, respectively (Fig. 2.8 A). After
1 h of incubation, cleavage of the 55 kDa GST-FLAG-HDQ53 protein was
observed, which resulted in two major fragments: The FLAG-HDQ53 pro-
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Figure 2.7: Schematic representation of the GST-FLAG- and GST-myc-HDQ53
proteins used for AFM, gel filtration and seeding experiments.
tein, which was detected with the HD1 antibody at 35 kDa, and the GST-tag
with a size of 26 kDa that was detected with the GST antibody. After 5 h,
the cleavage was complete for all protein concentrations tested, and at 6 h
a reduction of the FLAG-HDQ53 band was observed, which was due to the
formation of SDS-insoluble aggregates that did not enter the gel (Fig. 2.8
A). Both, the uncleaved GST-FLAG-HDQ53 protein and the FLAG-HDQ53
fragment migrated in the gel at positions higher than their calculated molec-
ular weights, which are 43 and 17 kDa, respectively. This phenomenon has
been observed before for proteins containing large polyQ stretches [Scher/-
zin/ ger et al., 1997].
In parallel, aliquots of the aggregation reactions were subjected to the
filter retardation assay to monitor the formation of SDS-insoluble aggregates
(Fig. 2.8 B). Consistent with the disappearance of monomeric FLAG-HDQ53
on the Western blot, SDS-resistant aggregates were observed on the filter af-
ter 5-6 h of incubation at 30 ℃. The amount of aggregates formed depended
on the incubation time and protein concentration, in agreement with pub-
lished data [Busch et al., 2003].
EM analyses further confirmed the fibrillar nature of the aggregates. This
is shown exemplarily for 100 ng/µl GST-FLAG-HDQ53 incubated for 3 h at
30 ℃ with Prescission Protease™ (Fig. 2.8 C).
Similar results were obtained for GST-myc-HDQ53 protein (data not
shown).
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Figure 2.8: Analysis of the aggregation kinetics of the GST-FLAG-HDQ53 protein.
(A): Different amounts of protein were incubated with Prescission Pro-
tease™ at 30 ℃ and at different time points samples were analyzed
by SDS-PAGE on a 12% acrylamide gel with subsequent Western blot-
ting and immunodetection with the HD1 or GST antibody. The arrows
indicate uncleaved Htt protein at 55 kDa and cleaved Htt protein at
35 kDa. The additional bands on the blot are due to degradation
products. The cleaved GST-tag can be detected at 26 kDa with a
GST-antibody. (B): Aliquots of the incubations were also subjected to
the filter retardation assay and immunodetected with the CAG53b an-
tibody to monitor the time- and concentration-dependent formation of
SDS-insoluble aggregates. (C): EM analysis of 100 ng/µl GST-FLAG-
HDQ53 incubated for 3 h with Prescission protease™ confirmed the
fibrillar nature of the aggregates.
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Figure 2.9: Aggregation kinetics of elastase-cleaved GST-HDQ51 and Prescission
protease™-cleaved GST-FLAG-HDQ53. 100 ng/µl GST-HDQ51 pro-
tein was incubated at 30 ℃ with elastase, 100 ng/µl GST-FLAG-
HDQ53 protein was incubated at 30℃ with Prescission protease™. At
different time points, aliquots were subjected to the filter retardation
assay and immunodetected with the CAG53b antibody. The aggrega-
tion of the elastase-cleaved protein reaches its steady-state after 6 h,
the Prescission protease™-cleaved protein needs 16 h to form compa-
rable amounts of aggregates. This is most probably due to the much
faster cleavage of elastase, leading to a larger pool of aggregation-prone
Htt fragments at early time points. (A): Representative filters. (B):
Quantification of the results shown in (A).
The fibrils seen in GST-FLAG-HDQ53 samples after cleavage with Prescis-
sion protease™ morphologically resembled the ones observed in GST-HDQ51
samples cleaved with elastase (Fig. 2.4). However, a pronounced difference
in the aggregation kinetics of Prescission protease™-cleaved GST-FLAG-
HDQ53 and elastase-cleaved GST-HDQ51 protein was observed, when the
same amounts of proteins (100 ng/µl) were incubated at 30 ℃ with the re-
spective proteases and analyzed in parallel with the filter retardation assay
(Fig. 2.9). The elastase-cleaved protein forms aggregates much faster than
the Prescission protease™ -cleaved protein. This is most probably due to the
faster cleavage with elastase that leads to a larger amount of aggregation-
prone Htt fragments at earlier time points (data not shown). Furthermore, it
is possible that the different sizes of the Htt fragments after cleavage influence
the aggregation kinetics. Smaller Htt fragments, such as those obtained by
elastase cleavage, are known to form aggregates faster than the larger frag-
ments generated by Prescission protease™ cleavage [Cooper et al., 1998].
52
2.2.1 EGCG accelerates the formation of amorphous
high molecular weight Htt aggregates
Next, the effect of EGCG on GST-FLAG-HDQ53 aggregation triggered by
Prescission protease™ was monitored with the filter retardation assay. 100
ng/µl GST-FLAG-HDQ53 protein was incubated with Prescission protease™ and
a tenfold molar excess of EGCG at 30 ℃. At different time points, aliquots
were taken, heat-denatured and subjected to the filter retardation assay. In-
soluble aggregates retained on the membrane were subsequently immunode-
tected with the CAG53b antibody. In this assay, EGCG slightly stimulated
the formation of SDS-resistant Htt aggregates captured on the filter (Fig.
2.10).
This finding is in contrast to the results obtained with the elastase-cleaved
GST-HDQ51 protein, where increasing EGCG concentrations led to a marked
decrease in SDS-resistant material monitored with the filter retardation assay
(Fig. 2.3). Therefore, further studies were performed to characterize the SDS-
insoluble structures formed upon EGCG treatment of the FLAG-HDQ53
protein.
Figure 2.10: Aggregation analysis of Prescission protease™ cleaved GST-HDQ53
in the presence of EGCG. 100 ng/µl GST-FLAG-HDQ53 protein was
incubated with Prescission protease™ at 30 ℃ in the presence of a
tenfold molar excess of EGCG. At different time points, samples were
taken, subjected to the filter retardation assay and immunodetected
with the CAG53b antibody. Between 2 and 6 h, EGCG-treated sam-
ples contain more SDS-insoluble aggregates than the solvent-treated
controls. (A): Representative filters. (B): Quantification of the results
shown in (A).
Atomic force microscopy (AFM) is a powerful tool for visualizing macro-
molecules, and in contrast to EM no fixation or staining is necessary, thus
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the risk of producing artefacts is minimized. In collaboration with Dr. Paul
Muchowski from the University of San Francisco, AFM experiments were
performed. 6 µM GST-myc-HDQ53 protein was incubated with Prescission
protease™ and a twofold molar excess of EGCG for 5 h at 30 ℃. Proteins
were then spotted onto freshly cleaved mica and imaged with a digital mul-
timode Nanoscope III scanning probe microscope operated in tapping mode.
Figure 2.11: EGCG stabilizes large Htt oligomers visualized by AFM. (A): 6
µM GST-myc-HDQ53 was cleaved with Prescission protease™ in the
presence of DMSO and incubated for 5 h at 30 ℃, resulting in the
formation of small oligomers with diameters of 20-40 nm. (B): 6 µM
GST-myc-HDQ53 protein was cleaved with Prescission protease™ in
the presence of a twofold molar excess of EGCG and incubated for 5
h at 30 ℃. EGCG treatment led to the formation of larger protein
assemblies with diameters of 160-220 nm. (A) and (B): Proteins were
spotted onto freshly cleaved mica and imaged with a digital multi-
mode Nanoscope III scanning probe microscope operated in tapping
mode. (C): Particle diameters were measured using custom written
software [Legleiter et al., 2004] and grouped in intervals of 20 nm.
Figure 2.11 A shows that in the solvent control, myc-HDQ53 protein
was present as small oligomeric structures with diameters of 20-40 nm after
incubation for 5 h, similar to data published before [Wacker et al., 2004].
In contrast, samples that have been incubated with EGCG (Fig. 2.11 B)
showed a marked reduction of small oligomers, and instead larger spherical
structures with diameters of 160-220 nm were detected. The particle size
was determined with custom written software [Legleiter et al., 2004], and the
particles were grouped with respect to their diameters in intervals of 20 nm
resulting in a size distribution diagram (Fig. 2.11 C).
The large Htt oligomers of 160-220 nm seen after incubation with EGCG
could possibly represent the species retained on the filter in Figure 2.10.
To determine how many Htt molecules were present in the large EGCG-
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stabilized oligomers, the volumes of spheres with the diameters measured
by AFM were calculated. Then, the value of 0.728 cm3/g for the average
density of protein particles published by Voss and Gerstein [2005] was used
to calculate the masses of these spheres. The amount of particles per spher-
ical oligomer was determined using the molecular weight of the cleaved Htt
fragment (17 kDa) and Avogadro’s number (1 x 1023 particles/mol).
This calculation showed that the large oligomers with diameters of 160-
200 nm contained 15,000-45,000 myc-HDQ53 molecules, whereas the small
oligomers with diameters of 20-40 nm in the controls contained 35-250 molecules.
The formation of large Htt oligomers upon incubation with EGCG was
confirmed with size exclusion chromatography. 100 ng/µl uncleaved GST-
FLAG-HDQ53 was incubated for 1 h at 4 ℃ with a tenfold molar excess
of EGCG or with the solvent alone. Samples were then loaded onto a Su-
perose 6 PC3.2/30 column fitted to a SMART FPLC system and run at 40
µl/min. Fractions containing 80 µl each were collected and aliquots thereof
were analysed by SDS-PAGE and Western blotting using the HD1 antibody.
Figure 2.12 (A) shows that GST-FLAG-HDQ53 treated with DMSO alone
eluted as a small oligomer (SO) at 1.62-1.46 ml, corresponding to oligomers
with a molecular weight of 110-470 kDa composed of 2-8 GST-FLAG-HDQ53
molecules. After incubation with EGCG, the elution curve of the GST-
FLAG-HDQ53 protein showed a marked decrease in the SO peak, with a
shoulder appearing at 550-900 kDa, representing larger protein oligomers
(LO). These large oligomers contained 10-16 GST-FLAG-HDQ53 molecules.
This finding was also represented by the Western blot of the corresponding
fractions (Fig. 2.12 B), showing an additional Htt band in the EGCG treated
sample at 1.3 ml which was not present in the DMSO control.
The results obtained from size-exclusion chromatography experiments are
in agreement with the AFM data. In both cases, small oligomers were ob-
served in solvent-treated samples, whereas incubation with EGCG led to the
formation of large Htt oligomers. The differences in size between the oligo-
mers observed by chromatography and AFM can be explained by the different
incubation times, different incubation temperatures and also by the presence
of the GST-tag in the chromatography experiment, which was cleaved with
Prescission protease™ for AFM.
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Figure 2.12: Detection of EGCG-stabilized Htt oligomers by size-exclusion chro-
matography. (A): 100 ng/µl uncleaved GST-FLAG-HDQ53 was in-
cubated for 1 h at 4 ℃ with either a tenfold molar excess of EGCG
or DMSO alone. Samples were then loaded onto a Superose 6 column
fitted to a SMART FPLC system and run at 40 µl/min. (B): Aliquots
of fractions eluted from the size-exclusion column were denatured and
separated on a 12% acrylamide SDS gel. Subsequent Western blot-
ting and immunodetection with the HD1 antibody revealed fractions
containing small (SO: 1.46-1.62 ml) and large (LO: 1.30 ml) GST-
FLAG-HDQ53 oligomers, the latter only appearing after treatment
with EGCG.
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2.2.2 EGCG crosslinks preformed fibrillar Htt parti-
cles and leads to the formation of large, SDS-
stable aggregates
In chapter 2.2.1 it was shown that EGCG induces the formation of large,
oligomeric Htt structures. The next question that arose was whether EGCG
is also able to crosslink preformed fibrillar Htt particles. To investigate this,
0.62 µM GST-HDQ51 protein was incubated with elastase at 37 ℃ for 16 h,
resulting in the formation of large, fibrillar aggregates that could be visualized
by EM. These aggregates were SDS-resistant and could therefore also be
detected with the filter retardation assay (Fig. 2.13 A).
The mature fibrils were then broken into smaller fibrillar aggregates by
sonification [Busch et al., 2003]. The largest particles that were found after
this treatment had a length of about 100-500 nm, and they were not detected
with the filter retardation assay (Fig. 2.13 B).
The particles derived from sonification were then incubated with a ten-
fold molar excess of EGCG or the solvent DMSO at 37 ℃. At different time
points aliquots were taken and subjected to the filter retardation assay using
the CAG53b antibody. In DMSO-treated samples, SDS-resistant aggregates
were detected after 6-8 h (Fig. 2.13 C), whereas the addition of EGCG to
the particles immediately, already at the time point of 0 h, led to the forma-
tion of aggregates. EM analyses showed that these aggregates had a mixed
morphology, and consisted of amorphous structures as well as fibrillar parti-
cles of about 200-400 nm in length (Fig. 2.13 D). This indicates that EGCG
crosslinks small Htt aggregates, which leads to large, SDS-resistant structures
with an amorphous and fibrillar morphology.
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Figure 2.13: EGCG crosslinks small Htt aggregates and promotes the formation
of larger SDS-stable structures. (A): 0.62 µM GST-HDQ51 was incu-
bated with elastase for 16 h at 37 ℃, resulting in fibrillar aggregates
(arrow) that could be visualized by EM and were also detected by the
filter retardation assay. (B): Sonification was used to break the fibrils
into small particles of 100-500 nm in length (arrows) as seen by EM.
These aggregates could not be detected with the filter retardation
assay. (C): Addition of EGCG to small Htt particles immediately re-
sulted in larger, SDS-resistant aggregates, whereas the appearance of
aggregates on the filter took about 8 h in the DMSO control. Shown
are representative filters and their quantification. (D): The SDS-
resistant aggregates resulting from EGCG-treated Htt particles were
amorphous (arrowhead) and fibrillar (arrow) as observed by EM.
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2.2.3 Oligomers generated by EGCG treatment are
unable to stimulate Htt fibrillogenesis
The aggregation of Htt is a nucleation-dependent process. The kinetics shows
an initial lag-phase during which small protein assemblies are formed that
act as nuclei for the formation of fibrils (see also Chapter 1.1.1) [Scherzinger
et al., 1999]. The lag-phase can be reduced, if oligomers or small fibrillar
particles obtained by sonification of mature fibrils are added to Htt aggre-
gation reactions in vitro [Scherzinger et al., 1999; Busch et al., 2003]. This
phenomenon has been termed ’seeding’, since the pre-aggregated particles
added accelerate the spontaneous aggregation of the soluble protein like seeds
added to a crystallization reaction.
Figure 2.14: EGCG-generated oligomers do not seed Htt fibrillogenesis. 100
ng/µl GST-myc-HDQ53 protein was incubated with Prescission pro-
tease™ at 30 ℃ for 16 h in the presence of a tenfold molar excess of
EGCG or the solvent DMSO. Samples were washed with buffer and 1
% (v/v) of the material was added to new aggregation reactions con-
taining 100 ng/µl GST-FLAG-HDQ53 and Prescission Protease™.
At different time points, aliquots were analyzed with the filter retar-
dation assay using the CAG53b antibody. Without the addition of
myc-HDQ53 seeds, the FLAG-HDQ53 aggregation kinetics shows a
lag-phase of 2 h. When myc-HDQ53 seeds generated in the presence
of DMSO were added, the lag-phase was shorter than 1 h, whereas
the addition of seeds generated in the presence of EGCG did not
influence the aggregation kinetics.
Since EGCG leads to the formation of oligomeric Htt assemblies in vitro,
I have investigated next whether these structures can seed Htt aggregation
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reactions. 100 ng/µl GST-myc-HDQ53 protein was incubated with Prescis-
sion protease™ and a tenfold molar excess of EGCG or the solvent DMSO
at 30 ℃ for 16 h. Then, the samples were washed with buffer in order to
remove excess EGCG. Small aliquots (1% of the total reaction volume) of
these preformed myc-HDQ53 fibrils were then added to new aggregation reac-
tions containing 100 ng/µl GST-FLAG-HDQ53 and Prescission protease™.
Samples were incubated at 30 ℃, and at different time points aliquots were
removed and subjected to the filter retardation assay using the CAG53b anti-
body. As expected, the myc-HDQ53 seeds derived from incubations contain-
ing the solvent DMSO reduced the lag phase and stimulated the formation
of FLAG-HDQ53 aggregates.
In contrast, the seeds generated after EGCG treatment did not acceler-
ate FLAG-HDQ53 aggregation (Fig. 2.14). This indicates that the EGCG-
stabilized oligomers do not enhance the fibrillogenesis of Htt and suggests
that they are ’off-pathway’ aggregation products.
2.2.4 EGCG interferes with a conformational change
in the Htt protein
Schaffar et al. [2004] demonstrated that proteolytic cleavage of GST-Htt
exon 1 fusion protein induces a rapid conformational change in the polyQ-
containing Htt fragment, which can be monitored by a FRET1 assay. Another
possibility to follow these early misfolding events is the usage of monoclonal
antibodies recognizing either the expanded polyQ tract or the polyproline
regions in the HDQ51 protein (Fig. 2.15, [Ko et al., 2001]).
Figure 2.15: Monoclonal antibodies recognizing the polyQ or polyproline regions in
HDQ51 protein. The antibodies MW1 and MW7 were raised against
the expanded polyQ tract or the polyproline regions in the Htt exon
1 protein and were described by Ko et al. [2001].
To test whether GST-HDQ51 protein undergoes a conformational change
after proteolytic cleavage with elastase, a dot-blot assay was performed. The
MW1 antibody efficiently recognized uncleaved GST-HDQ51 fusion protein,
when samples containing 0.6 µM GST-HDQ51 were spotted onto nitrocellu-
lose and immmunodetected (Fig. 2.16). However, when elastase was added
1fluorescence resonance energy transfer
60
Figure 2.16: GST-HDQ51 protein undergoes a rapid conformational change af-
ter cleavage with elastase. 0.6 µM GST-HDQ51 was incubated with
elastase for the indicated times and samples were spotted onto nitro-
cellulose for immunodetection with the antibodies MW1, MW7 and
CAG53b. MW1 immunoreactivity disappeared rapidly after cleavage,
indicating a fast conformational change in the polyQ tract, while the
signals obtained with the MW7 and CAG53b antibody stayed con-
stant. (A): Representative spotting results. (B): Evaluation of the
signal intensities obtained with the MW1 and CAG53b antibody.
to the GST-HDQ51 protein and the samples were spotted immediately after
mixing (corresponding to an incubation time of 0 s), app. 90% of MW1 im-
munoreactivity was lost. An incubation time of 2 min between the addition
of elastase and the spotting of the samples led to a complete disappearance
of the MW1 signal. These findings support previous results that point to
a very rapid structural rearrangement in the expanded polyQ region upon
cleavage from the GST tag [Schaffar et al., 2004; Wacker et al., 2004]. Such a
dramatic effect was neither seen with the antibody MW7, which specifically
recognizes the poly-proline region, nor with the polyclonal CAG53b anti-
body, which detects both the intact GST fusion protein and its fragments
after proteolytic cleavage and therefore served as a control.
Next, 0.3, 0.6 or 3 µMEGCG or the solvent DMSO was added to reactions
containing 0.6 µM GST-HDQ51 and elastase. Aliquots of the samples were
spotted onto nitrocellulose membranes at different time points and were im-
munodetected with the MW1 or the CAG53b antibody. When EGCG was
present, the loss of MW1-immunoreactivity was slowed down significantly
(but not prevented) in a concentration-dependent manner (Fig. 2.17). When
a 5-fold molar excess of EGCG was added, MW1 immunoreactivity was still
clearly detectable after an incubation time of 30 min, in contrast to solvent-
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Figure 2.17: EGCG interferes with the conformational change in GST-HDQ51 af-
ter cleavage with elastase. 0.6 µM GST-HttQ51 was incubated with
elastase and 0.3, 0.6 or 3 µM EGCG or the solvent at 37 ℃ for the
indicated times. Samples were spotted onto nitrocellulose for im-
munodetection with the MW1 (left) or CAG53b (right) antibody.
In the solvent-treated control, the MW1 signal disappeared rapidly
after the addition of elastase. EGCG-treated samples, however, dose-
dependently retained the MW1 signal for up to 30 min. No differences
in signal intensities were observed with the CAG53b antibody.
treated controls. This suggests that the compound binds to the unstructured
polyQ sequence and interferes with the conformational change in the polyQ
region assumed to occur immediately after cleavage [Schaffar et al., 2004].
2.2.5 EGCG inhibits Htt aggregate formation by ac-
celerating the Htt turnover in COS-1 cells
In order to evaluate the effect of EGCG on Htt aggregation in mammalian
cells, COS-1 cells were transiently transfected with pTL-HDQ90 or the empty
vector as a control. Different concentrations of EGCG or the solvent DMSO
were added to the culture medium, and 2 days after transfection the amount
of aggregates was determined. For the quantification of HDQ90 aggregates,
cells were lysed and the cell extracts were analyzed with the filter assay after
denaturation with SDS/DTT. The membranes were then immunodetected
with the CAG53b antibody. Fig. 2.18 A and B show that EGCG treat-
ment dose-dependently diminished the amount of HDQ90 aggregates. 50
µM EGCG in the medium thereby led to a reduction of Htt aggregation by
90 %.
In order to evaluate whether the inhibition of Htt aggregation by EGCG
in living cells facilitates the clearance of the mutant protein, pulse-chase ex-
periments were performed. COS-1 cells were transiently transfected with
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Figure 2.18: EGCG inhibits HDQ90 aggregation in COS-1 cells. COS-1 cells were
transiently transfected with the pTL-HDQ90 plasmid and treated
with different amounts of EGCG or the solvent DMSO. After two
days of expression, cell lysates were prepared and subjected to the
filter retardation assay. Aggregates were detected using the CAG53b
antibody. (A): Representative filters of cells grown in the presence of
the solvent or 0.1, 1, 10, 20 or 50 µM EGCG. (B): Quantification of
filters shown in (A). EGCG dose-dependently decreased the amount
of insoluble HDQ90 protein aggregates formed in COS-1 cells.
pCMV-FLAG-HDQ68 and treated with either 50 µM EGCG or the solvent
DMSO. One day after transfection, the cells were exposed to radioactively
labelled methionine ([35S]-methionine), which was added to the medium for 1
h. All proteins that were synthesized within this time therefore incorporated
the labelled amino acid. After a chase time of 0-4 h with non-radioactive me-
thionine, cells were lysed and FLAG-HDQ68 protein was immunoprecipitated
with anti-FLAG affinity beads. The affinity purified protein was separated
by SDS-PAGE and the radioactivity was quantified by autoradiography. Fig.
2.19 shows that the amount of radioactively labeled FLAG-HDQ68 gradually
decreased during the chase time. In the presence of DMSO, only app. 30% of
the radioactive FLAG-HDQ68 was degraded during the chase time, whereas
the treatment with 50 µM EGCG led to a significant increase in turnover,
with 70% of the labelled protein degraded after 2 h. This indicates that
the treatment with EGCG accelerated the turnover of mutant Htt in COS-1
cells, probably by preventing aggregation and thus keeping the protein in a
more soluble, better degradable state.
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Figure 2.19: EGCG accelerates the FLAG-HDQ68 turnover in COS-1 cells. COS-
1 cells were transiently transfected with pCMV-FLAG-HDQ68 and
treated with 50 µM EGCG or the solvent DMSO. One day after
transfection, cells were labelled with [35S]-methionine and lysed after
different chase times. FLAG-HDQ68 protein was precipitated with
anti-FLAG affinity beads, separated by SDS-PAGE and detected by
autoradiography. The band intensity obtained for DMSO treated
samples at a chase time of 0 h was set 100%. EGCG treatment of
transfected COS-1 cells significantly promoted the turnover of FLAG-
HDQ68 in this assay.
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2.3 EGCG inhibits Syn aggregation
2.3.1 Cloning and expression of His-tagged wt and A53T
mutant Syn
As already mentioned in Chapter 1.2, protein aggregation is a process linked
to several neurodegenerative disorders and the fibrillar structures as well as
the oligomeric aggregation intermediates of different amyloidogenic proteins
have strikingly similar morphologies and biochemical features. Therefore, a
compound that is able to inhibit the formation of Htt aggregates might also
be able to prevent the formation of fibrils derived from other proteins linked
to neurodegenerative disease such as Syn. Fibrillar Syn aggregates are the
main component of Lewy bodies found in PD brain tissue, and mutations
such as the A→ T exchange at amino acid 53 have been linked to familiar
forms of PD (see also Chapter 1.1.3).
Therefore, DNA constructs allowing the large-scale expression and purifi-
cation of Syn protein were generated. Wt and A53T mutant Syn cDNAs,
which were a kind gift of S. Engelender from Johns Hopkins Medical Institu-
tions, Baltimore, were excised from their originating vector pPC97 [Engelen-
der et al., 1999] and cloned into the pQE32N expression vector (Fig. 2.20) by
restriction digest with SalI and NotI as described in Materials and Methods.
Figure 2.20: Schematic representation of the pQE expression vector family (Qi-
agen). The multiple cloning site (MCS) of the pQE32N variant is
shown on the right [Wanker et al., 1997].
The correctness of the insertion was confirmed by sequencing, and the
plasmid was transformed into the E. coli strain SCS1-pSE111 for expres-
sion of the recombinant proteins. Wt and A53T mutant Syn expression
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Figure 2.21: Analysis of purified wt and A53T His-Syn by SDS-PAGE. (A): Se-
quence of the His-Syn proteins. Green square: 6x His-tag. Red
square: Site of the A → T exchange in the A53T mutant. (B):
Silver-stained SDS-PAGE of wt and A53T His-Syn. The major band
at app. 17 kDa represents the full length proteins, smaller bands:
degradation products.
was induced by addition of 1 mM IPTG (final concentration) to the growth
medium of liquid cultures, cells were harvested after 4 h and the pellet was
stored at -80 ℃. Then, bacteria were lysed under denaturing conditions with
buffer containing 8 M urea, and the recombinant proteins were purified using
Ni-NTA beads from Qiagen according to manufacturer’s instructions. Wt
and A53T His-Syn were eluted from the beads with a low pH buffer (pH
4.5) containing 8 M urea, and subsequently exchanged to TBS buffer via
PD10 desalting columns (Amersham). The purified proteins were analysed
by SDS-PAGE and silver staining of the gel (Fig. 2.21).
2.3.2 EGCG inhibits the formation of Syn aggregates
In order to monitor Syn aggregation, a Thioflavin T (ThT) fluorescence
method was applied. In this assay, the fluorescent dye ThT is added to
aggregation reactions. It binds to amyloid fibrils and thereby changes its flu-
orescence intensity [LeVine, 1993], which can be monitored by fluorescence
spectroscopy.
100 µM His-Syn wt protein was incubated in TBS buffer at 37 ℃ with
shaking (180 rpm). At various time points, aliquots were taken, diluted ten-
fold with a 80 ng/µl ThT solution in TBS and the fluorescence at an excita-
tion wavelength of 420 nm and emission wavelength of 485 nm was measured
with a plate fluorometer. Fig. 2.22 shows that the aggregation kinetics of
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wt His-Syn had a lag-time with fibril formation starting after app. 5 h. The
reaction entered its stationary phase after 20 h. When EGCG was present
during aggregation, however, fibrillization of wt His-Syn was inhibited in a
concentration-dependent manner. I found that already 10 µM EGCG signif-
icantly prolonged the lag-phase and that 100 µM EGCG, corresponding to a
protein:drug ratio of 1:1, completely prevented Syn aggregation in this assay.
Similar results were obtained for A53T His-Syn, indicating that the aggre-
gation of both wt and A53T mutant Syn can be prevented by the addition
of EGCG.
Figure 2.22: EGCG inhibits Syn aggregation. 100 µM wt His-Syn was incubated
in TBS at 37 ℃ and 180 rpm in the presence of the solvent or 10, 50
or 100 µM EGCG. At different time points, aliquots were mixed with
80 ng/µl ThT in TBS and fluorescence was measured with excitation
at 420 nm and emission at 485 nm. Solvent-treated wt His-Syn starts
to aggregate after a lag-time of app. 5 h. EGCG was found to inhibit
the formation of wt His-Syn fibrils in a dose-dependent manner. An
IC50 value of 30 µM was calculated. Similar results were obtained for
A53T His-Syn (IC50: 30 µM).
67
2.4 The mechanism of EGCG-mediated inhi-
bition of Syn aggregation
2.4.1 EGCG stabilizes large Syn oligomers
In order to further analyze the inhibition of Syn aggregation by EGCG, EM
analyses were performed. 150 µM His-Syn wt or A53T was incubated in
TBS at 37 ℃ for 16 h and the formation of fibrils was monitored with EM.
In solvent-treated control reactions, fibrils were obtained that possessed a
similar morphology as Syn fibrils described in the literature [Conway et al.,
2000a] (Fig. 2.23). In the presence of a 10-fold molar excess of EGCG, how-
ever, fibrils did not appear. Instead, a homogenous population of spherical
structures with a diameter of 25-30 nm was observed. The number of Syn
molecules per oligomer was determined as described before for Htt (Chapter
2.2.1), using the formula for the average density of protein particles (0.728
cm3/g) published by Voss and Gerstein [2005]. The large EGCG-stabilized
oligomers were calculated to contain 70-120 Syn molecules. EGCG-stabilized
Syn oligomers were therefore smaller than the large Htt oligomers that were
observed by AFM after EGCG treatment (Chapter 2.2.1).
Figure 2.23: EGCG induces the formation of spherical Syn oligomers. 150 µM
wt or A53T His-Syn was incubated for 16 h at 37 ℃ in the pres-
ence of a tenfold molar excess of EGCG or the solvent. Aliquots
were negatively stained with uranyl acetate and visualized with a
Philips CM100 EM. Fibrils were abundant in solvent-treated samples,
whereas EGCG-treated samples showed a homogenous population of
spherical particles with a diameter of 25-30 nm.
To further characterize the Syn oligomers visualized by EM, size-exclusion
chromatography was performed. 25 µM His-Syn wt in TBS was incubated
at 37 ℃ for 16 h with a tenfold molar excess of EGCG or the solvent alone.
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Aliquots were loaded onto a Superose 6 size-exclusion column fitted to a
SMART FPLC system and run at 40 µl/min.
The chromatogram of samples incubated in the presence of the solvent
alone exhibited one major peak corresponding to a molecular weight of 30-90
kDa (Fig. 2.24 A). This represented oligomers containing 2-5 Syn molecules,
since monomeric wt His-Syn has a molecular weight of 17 kDa. EGCG-
treated samples exhibited additional, earlier eluting peaks corresponding to
a molecular weight of 240-1600 kDa. These peaks represented large Syn
oligomers consisting of 15-100 Syn molecules. Similar results were obtained
for A53T His-Syn (data not shown).
The result obtained from size-exclusion chromatography is in very good
agreement with the EM data (Fig. 2.23). In both experiments, large, EGCG-
stabilized Syn oligomers were detected, which contained 70-120 and 15-95 Syn
molecules, respectively.
2.4.2 EGCG-induced Syn oligomers are resistant to
SDS
Next, fractions eluted from the size-exclusion column were collected, concen-
trated with Microcon™ centrifugal filter units and anaylzed by SDS-PAGE
and Western blotting. Immunodetection of the blots with an anti-Syn anti-
body revealed that in DMSO treated samples Syn was present in the fractions
that eluted between 1.79 and 1.63 ml, corresponding to the major peak seen
in the chromatogram (Fig. 2.24 A+B). In the SDS-PAGE, the Syn protein
had a size of 17 kDa, representing a monomer, whereas it eluted at the size
of small oligomers from the chromatography column. This indicates that the
oligomers seen in the chromatogram are not resistant to boiling in SDS/DTT
and are broken down into monomers during the denaturation step preceding
SDS-PAGE.
The blot obtained from EGCG-treated samples, however, showed Syn
bands in all fractions from 0.98 to 1.87 ml. The fractions from 1.63 to 1.87
ml thereby contained predominantly low molecular weight oligomers that
entered the separating gel and were separated into mono-, di-, and trimers.
The fractions from 0.98 to 1.55 ml showed larger Syn assemblies that were
stuck at the interface between the stacking and the separating gel (Fig. 2.24
C). These large oligomers (LO) corresponded to the high-molecular weight
peak that was only observed in the chromatogram of EGCG-treated samples
(Fig. 2.24 A). Interestingly, EGCG-induced oligomers could be separated
by SDS-PAGE, indicating that they were resistant to boiling in SDS/DTT.
This is in contrast to oligomers seen in the DMSO control. Similar data were
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Figure 2.24: Size exclusion chromatography of EGCG-induced Syn oligomers. 25
µM His-Syn wt was incubated in TBS at 37℃ for 16 h with a tenfold
molar excess of EGCG or the solvent DMSO. Aliquots were then sepa-
rated on a Superose 6 FPLC column fitted to a SMART FPLC system
and run at 40 µl/min. (A): Chromatogram showing a small peak of
app. 1 kDa which was due to DMSO and a large peak of 30-90 kDa
corresponding to small oligomers (SO) containing 2-5 Syn molecules.
In the EGCG treated sample, additional peaks were observed corre-
sponding to 240-1600 kDa, which represented EGCG-stabilized large
oligomers (LO). (B): Western blot of the DMSO treated column frac-
tions. The Syn protein eluting with the size of small oligomers (SO)
from the column ran as a monomer on the gel, suggesting that these
oligomers were disassembled by SDS. (C): Western blot of EGCG
treated fractions. Syn protein eluting as EGCG-stabilized large oli-
gomers (LO) from the column did not enter the separating gel. Oligo-
mers from the small oligomer (SO) fractions showed partial resistance
to SDS and were detected as mono-, di-, and trimers (1x, 2x, 3x).
(B)+(C): Fractions were concentrated with Microcon™ centrifugal
filter units (MWCO: 10 kDa) before denaturation. Both blots were
developed with an anti-Syn antibody, similar results were obtained
for the A53T mutant protein (data not shown).
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obtained for A53T Syn (data not shown). These results are in agreement with
data obtained for the Htt protein, where it was shown that EGCG is able to
crosslink small Htt particles, leading to the formation of large, SDS-resistant
structures (Chapter 2.2.2).
2.4.3 EGCG-stabilized Syn oligomers form in a time-
and concentration-dependent manner
The formation of SDS-stable Syn oligomers was further analyzed by SDS-
PAGE and silver staining, using time-course experiments as well as different
concentrations of EGCG. First, 20 µM His-Syn wt or A53T was incubated
with 2, 20, 100 or 200 µM EGCG for 16 h at 37 ℃. The samples were then
denatured by boiling in SDS/DTT, subjected to SDS-PAGE and the proteins
were visualized by silver staining. Fig. 2.25 shows that increasing amounts of
EGCG also increased the formation of SDS-stable oligomers. Small amounts
of Syn dimers were already detected at stoichiometric and substoichiometric
EGCG concentrations. A 5-fold molar excess of compound over protein led
to the additional formation of trimers and larger oligomers, a part of which
did not enter the separating gel.
Figure 2.25: The formation of SDS-stable Syn oligomers depends on the EGCG
concentration. 20 µM wt or A53T His-Syn was incubated for 16
h at 37 ℃ in the presence of 2, 20, 100 or 200 µM EGCG or the
corresponding amounts of DMSO. Samples were denatured by boil-
ing in SDS/DTT and analyzed by SDS-PAGE and silver staining.
Higher amounts of SDS-stable oligomers were detected with increas-
ing EGCG concentrations. (A): wt His-Syn. (B): A53T mutant His-
Syn. Arrows on the right indicate the location of mono-, di-, and
trimers and the stacking gel.
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Figure 2.26: EGCG-stabilized Syn oligomers form in a time-dependent manner.
20 µM wt or A53T His-Syn were incubated with 200 µM EGCG or
L-dopamine (DOPA) at 37 ℃. After different times, samples were
denatured by boiling in SDS/DTT and analyzed by SDS-PAGE and
silver staining. Small amounts of SDS-resistant oligomers were de-
tected in all A53T Syn samples due to impurities in the protein stock.
EGCG-stabilized oligomers formed in a time-dependent manner, with
a smear on top of the monomer band as well as dimers appearing
immediately (at 0 h), trimers were detected after 0.5 h and large oli-
gomers in the stacking gel after 20 h. Oligomerization induced by
DOPA was slower than with EGCG, SDS-stable oligomers appeared
only after 20 h of incubation. (A): Wt His-Syn. (B): A53T His-Syn.
Arrows on the right indicate the location of mono-, di-, and trimers
and the stacking gel.
Subsequently, the time dependence of oligomerization was analyzed. 20
µM wt or A53T His-Syn was incubated in the presence of 200 µM EGCG
for different times at 37 ℃. Samples were denatured by boiling in SDS/DTT
and subjected to SDS-PAGE and silver staining. Figure 2.26 shows that
the formation of SDS-stable Syn oligomers by EGCG is a time-dependent
process. A smear on top of the monomer band as well as dimers appeared
immediately (at 0 h), trimers were detected after 1 h and larger oligomers,
partly in the stacking gel, after 20 h of incubation. In this experiment, small
amounts of SDS-stable oligomers were present in all A53T Syn samples at
all time points, due to impurities in the initial protein preparation.
In parallel, 20 µM wt and A53T His-Syn were incubated with 200 µM
L-dopamine (DOPA) at 37 ℃, since it is reported in the literature that
dopamine also leads to the formation of SDS-stable Syn oligomers [Conway
et al., 2001]. Compared to EGCG, however, oligomer formation with DOPA
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was significantly slower, since SDS-stable oligomers were only detected after
an incubation of 20 h (Fig. 2.26).
No difference between wt and A53T Syn was observed in these experi-
ments concerning the EGCG concentration- and time-dependence of oligomer-
ization.
2.4.4 Ascorbic acid or alpha-tocopherol cannot induce
Syn oligomerization
Next, it was tested whether other antioxidants stimulate the formation of
SDS-resistant Syn oligomers in a similar manner as EGCG. 10 µM His-Syn
wt or A53T were incubated in the presence of 10 µM, 50 µM or 100 µM
EGCG, ascorbic acid, α-tocopherol or the solvent at 37 ℃ for 20 h. Samples
were denatured and analyzed by SDS-PAGE with subsequent silver staining.
Fig. 2.27 shows that only EGCG was able to induce the formation of SDS-
stable oligomers.
This suggests that the stabilization of Syn oligomers is not a general prop-
erty of antioxidant substances. It is more likely that the chemical structure
of EGCG, which differs significantly from ascorbic acid and α-tocopherol
(compare Figs. 2.2, 2.5 C), is responsible for the formation of SDS-stable
Syn oligomers.
2.4.5 EGCG-induced Syn oligomerization is abolished
by reducing agents
Next, it was determined whether the formation of EGCG-stabilized Syn oli-
gomers can be influenced by reducing or oxidizing conditions. 10 µM wt
or A53T His-Syn was incubated with the solvent or a tenfold molar excess
of EGCG in the presence of 100 µM, 500 µM or 1 mM DTT or H2O2 for
20 h at 37 ℃. Subsequently, the samples were denatured and separated by
SDS-PAGE. Protein bands were visualized with silver staining. Fig. 2.28
shows that a 1:1 molar ratio of DTT:EGCG already prevented the forma-
tion of Syn trimers and large oligomers in the stacking gel. A fivefold molar
excess of DTT over EGCG completely inhibited the compound-induced Syn
oligomerization. The addition of H2O2, however, only marginally reduced
Syn oligomerization at high concentrations. This indicates that reducing
conditions effectively prevent the formation of EGCG-stabilized Syn oligo-
mers.
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Figure 2.27: The compounds ascorbic acid and alpha-tocopherol do not induce
Syn oligomerization. 10 µM wt or A53T His-Syn was incubated at 37
℃ for 20 h in the presence of 10 µM, 50 µM or 100 µMDMSO, EGCG,
ascorbic acid or α-tocopherol. Samples were denatured, separated on
a 12.5% SDS polyacrylamide gel and visualized by silver staining.
Only EGCG stimulated the formation of SDS-stable Syn oligomers,
while the other antioxidant substances did not show such an effect.
(A): Wt His-Syn. (B): A53T His-Syn.
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Figure 2.28: EGCG-induced Syn oligomerization is abolished by DTT. 10 µM His-
Syn was incubated at 37℃ for 20 h in the presence of a tenfold molar
excess of DMSO or EGCG and 100 µM, 500 µM or 1 mM DTT or
H2O2. Samples were denatured, separated on a 12.5% SDS polyacry-
lamide gel and visualized by silver staining. H2O2 slightly inhibited
EGCG-induced Syn oligomerization at high concentrations, whereas
already a 1:1 molar ratio of DTT:EGCG prevented the formation of
SDS-stable Syn trimers and large oligomers in the stacking gel. A
fivefold molar excess of DTT over EGCG completely prevented the
formation of EGCG-stabilized Syn oligomers. (A): Wt His-Syn. (B):
A53T His-Syn.
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2.4.6 EGCG-stabilized Syn oligomers are not recog-
nized by an oligomer-specific antibody
Oligomers derived from different amyloidogenic proteins possess similar mor-
phologies and can be recognized by a conformation-specific antibody [Kayed
et al., 2003]. Therefore, it was determined, whether the epitope recognized
by this antibody is also present in EGCG-stabilized Syn oligomers. 100 µM
His-Syn wt or A53T was incubated at 37 ℃ in the presence of a tenfold
molar excess of EGCG or the solvent, and at different time points aliquots
were taken and spotted onto a nitrocellulose membrane. Next, the mem-
brane was immunodetected with the anti-oligomer or the anti-Syn antibody.
Fig. 2.29 shows that the signal obtained with the anti-oligomer antibody in-
creased over time in the solvent-treated samples. It reached its maximum at
4-6 h for the wt and at 2-4 h for the A53T protein and disappeared after 24
h. In strong contrast, the signal obtained with the anti-oligomer antibody
decreased rapidly after 1-2 h in samples incubated in the presence of EGCG.
This suggests that the oligomers formed through the action of the compound
do not possess the same epitope as oligomers in untreated reactions. The
polyclonal Syn antibody, which was raised against the denatured protein,
did not reveal major differences between EGCG and solvent treated samples.
This shows that equal amounts of Syn protein were present on the membranes
and that EGCG did not interfere with the immunodetection process.
2.5 Direct binding of EGCG to Syn
Next, it was investigated whether EGCG is able to directly bind to Syn. In
order to address this question experimentally, a staining method with the
dye nitroblue tetrazolium (NBT) was developed. This assay is similar to a
method described previously, which was used for the detection of protein-
bound quinones [Paz et al., 1991].
The NBT stain relies on the knowledge that EGCG is a redox-active sub-
stance, which is able to reduce the dye NBT to its formazan. The formazan
thereby forms a purple precipitate, which can be detected visually or by
measuring the absorbance at 530 nm photometrically.
In order to determine whether EGCG binds to wt and A53T Syn, 70 µM
protein was incubated at 37 ℃ for 20 h in the presence of 7, 70 or 700 µM
EGCG or the solvent. Samples were denatured and separated by SDS-PAGE.
Subsequently, the gels were either stained with silver nitrate to visualize the
proteins, or electroblotted onto nitrocellulose. The membranes were then in-
cubated with NBT, and the purple staining indicated the presence of EGCG
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Figure 2.29: EGCG-stabilized Syn oligomers are not recognized by an oligomer-
specific antibody. 100 µM wt or A53T His-Syn was incubated at 37
℃ in the presence of a tenfold molar excess of EGCG or the solvent
alone. At the indicated time points, aliquots were taken and spotted
onto nitrocellulose. The membranes were subsequently immunode-
tected with an anti-oligomer or a Syn antibody. In solvent-treated
samples, the signals obtained with the anti-oligomer antibody were
most intense between 2 and 4 h of incubation for A53T and between
4 and 6 h of incubation for wt His-Syn. In EGCG-treated samples,
the anti-oligomer signal decreased rapidly, indicating that EGCG-
stabilized oligomeric species were not detected. No difference in signal
intensity between EGCG- and solvent-treated samples were observed,
when the membranes were immunodetected with the Syn antibody.
that bound to Syn and migrated together with the protein in the gel. Fig.
2.30 shows that EGCG could be detected on the nitrocellulose membrane
as a smear localized directly on top of the Syn monomer bands as well as
colocalized with dimers, trimers and large oligomers that appear upon incu-
bation with the compound. No difference in binding intensity was observed
between the wt and the A53T mutant Syn proteins.
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Figure 2.30: EGCG directly binds to Syn. 70 µM His-Syn (wt or A53T mutant)
was incubated at 37 ℃ for 20 h in the presence of different amounts
of EGCG (7 µM, 70 µM, 700 µM). Samples were denatured, separated
on a 12% SDS gel and either electroblotted onto nitrocellulose (A) or
silver stained (B). Membranes in (A) were developed with the NBT
reagent, which specifically detects EGCG that bound to Syn and
migrated together with the protein on the SDS-PAGE. The silver
stained gel in (B) shows the localization of Syn on the gel.
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Figure 2.31: Quantification of EGCG binding to different proteins. 1, 3, 6 or 9
µM His-Syn wt, His-Syn A53T or GST protein was incubated in the
presence of 3 µM EGCG for 4 h at 37 ℃ and filtered through Mi-
crocon™ centrifugation filters (MWCO: 10 kDa). NBT solution was
added to the flowthrough, and unbound EGCG was detected due
to the formation of the formazan, which was quantified by measur-
ing the absorbance at 530 nm. Increasing amounts of protein (with
the exception of GST) decreased the amount of free EGCG in the
flowthrough, indicating that the Syn proteins tested, which are pre-
sumably natively unfolded, bound EGCG. GST, however, which was
included as a folded control protein, did not bind to the compound.
In order to quantify EGCG binding to different proteins, a membrane-free
NBT assay was performed. 1, 3, 6 or 9 µMHis-Syn wt, His-Syn A53T or GST
were incubated at different concentrations with 3 µM EGCG for 4 h at 37℃.
Then, the samples were filtered through 10 kDa cutoff centrifugal filter units
to separate the proteins, which stayed in the retenate together with bound
EGCG, from the unbound compound, which was able to pass through the
filter. The NBT reagent was added to the flowthrough, and the presence of
unbound EGCG led to the formation of the formazan. This colored product
was quantified by measuring the absorbance at 530 nm. As shown in Figure
2.31, increasing concentrations of His-Syn wt or A53T significantly reduced
the amount of unbound EGCG left in the flowthrough. The GST protein,
however, which was included as a control, did not retain any EGCG in the
bound fraction. Since Syn is a natively unfolded protein [Weinreb et al.,
1996], this results suggests that EGCG preferentially interacts with proteins
in a random coil conformation, while no binding was observed with the folded
protein GST.
Next, it was determined whether EGCG binding is different for native
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Figure 2.32: EGCG binds to denatured ovalbumin. Lyophilized ovalbumin was
dissolved at a concentration of 3 µM in either TBS buffer or TBS
containing 8 M urea. A tenfold molar excess of EGCG or the solvent
alone was added, samples were incubated for 1 h at 37 ℃, boiled in
SDS/DTT and run on a 12 % SDS-PAGE. The gel was either stained
with silver nitrate or electroblotted onto nitrocellulose and subjected
to the NBT staining method. With the NBT stain, EGCG was found
to bind to ovalbumin only in samples treated with 8 M urea, whereas
the silver stain confirms the presence of protein in all lanes.
and chemically denatured proteins. To this end, high urea concentrations
(8 M) were used. These conditions are known to lead to the unfolding of
proteins, since urea breaks the hydrogen bonds that hold the tertiary protein
structure together [Kohn et al., 2004]. The control protein ovalbumin was
dissolved either in TBS buffer or in TBS containing 8 M urea to obtain either
folded or unfolded protein samples. For both conditions, a tenfold molar
excess of EGCG or the solvent alone was added to the protein solution.
Then, samples were incubated for 1 h at 37 ℃, boiled in SDS/DTT and
separated by SDS-PAGE. The proteins were electroblotted onto nitrocellulose
and the membranes were subjected to the NBT stain to visualize bound
EGCG. In parallel, gels were stained with silver nitrate to detect the protein
bands. With this method, EGCG was found to bind to ovalbumin only in
the presence of 8 M urea, not in TBS buffer alone (Fig. 2.32). Similar results
were obtained with BSA, a second protein that is folded in aqueous buffers
(data not shown).
These results suggest, that EGCG binds to unfolded proteins with a
higher affinity than to their folded counterparts.
2.5.1 EGCG improves the survival of COS-1 cells tran-
siently expressing A53T mutant Syn
Next, the effect of EGCG on Syn-induced toxicity was evaluated in mam-
malian cells. COS-1 cells were transiently transfected with a pTL-HA-A53T
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expression vector and the cells were treated with different concentrations of
EGCG, which was added to the growth medium. After 4 days, cell survival
was evaluated with the MTT assay. This method exploits the ability of living
cells to metabolize a tetrazolium salt compound, resulting in a colored for-
mazan which can be quantified by measuring the absorbance at 570 nm. It
was found that solvent-treated cells expressing A53T Syn have a significantly
lower survival than cells transfected with the empty vector (Fig. 2.33). This
impairment could be reversed in a dose-dependent manner by the addition
of EGCG to the growth medium, with 50 µM EGCG restoring cell viability
almost completely.
Figure 2.33: EGCG-treated COS-1 cells expressing A53T Syn show increased vi-
ability. COS-1 cells were transiently transfected with pTL-HA-A53T
Syn or the empty vector. Different amounts of EGCG were added to
the growth medium and cell survival was evaluated with the MTT
assay after 4 days of expression. Solvent-treated cells expressing
A53T Syn exhibited app. 30 % reduced survival when compared to
empty vector transfected cells. The addition of EGCG to the growth
medium improved the survival dose-dependently, with 50 µM com-
pound restoring normal survival levels.
In a second experiment, it was evaluated whether EGCG prevents apop-
tosis caused by the expression of A53T Syn. Apoptotic cell death is accom-
panied by the activation of caspases, which can be detected experimentally
with substrates that are cleaved by the active enzyme, yielding fluorescent
products. Elevated levels of active caspases 3/7 were observed in COS-1 cells
transiently expressing A53T Syn (Fig. 2.34) after 3 days of expression. This
is in agreement with results from the MTT assay, where A53T Syn expres-
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sion led to a decrease in cell survival after 4 days. The addition of EGCG to
the growth medium prevented caspase activation, indicating that EGCG is
able to prevent apoptotic cell death in COS-1 cells caused by the expression
of A53T Syn.
Figure 2.34: EGCG treatment normalizes elevated active caspase 3/7 levels asso-
ciated with A53T Syn expression. COS-1 cells transiently expressing
A53T Syn exhibited elevated levels of active caspases 3/7, when com-
pared to vector transfected control cells. The addition of EGCG
to the growth medium reversed the caspase activation, A53T Syn
expressing cells treated with EGCG were not significantly different
from the vector transfected controls.
Chapter 3
Discussion
3.1 The need for new treatments for neu-
rodegenerative diseases
Neurodegenerative disorders such as HD and PD, which were discussed in
Chapters 1.1.2 and 1.1.3, are diseases that can be both of sporadic and inher-
ited origin and normally occur late in life. Protein aggregation and deposition
lead to neuronal death, for which there is no effective treatment available to
date. Impaired motor skills and memory functions as well as psychological
changes such as depression, anxiety and aggression that gradually worsen as
the disease progresses make everyday life increasingly difficult to handle for
patients as well as their relatives. Options for medication available today are
limited and mainly focus on symptomatic treatment. At the moment, it is
not possible to stop cell death in the affected brain areas, let alone prevent
the onset of disease.
There are also no reliable diagnostic markers for early disease stages and
most patients are diagnosed late in the disease process, when the first clinical
symptoms become evident and massive neuronal death has already occured.
A major focus of drug development therefore currently lies on molecules,
which are able to slow down or even stop the degenerative process and could
at least preserve the neuronal status at the time of diagnosis. Many studies
are conducted with the aim of elucidating the disease mechanisms and finding
a cure. In parallel, early diagnostic markers are being sought to prevent the
death of as many neurons as possible.
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3.2 Aggregation inhibitor screens
In HD, there is a known mutation in the Htt protein, namely the elongation
of the polyQ tract, which is responsible for the outbreak of the disease.
Intracellular fibrillar aggregates of the mutant Htt protein have been found
In the brains of patients. There is evidence that only small N-terminal Htt
protein fragments containing the polyQ tract are able to aggregate, whereas
the full-length Htt is soluble even with an elongated glutamine sequence
[DiFiglia et al., 1997]. In vitro aggregation studies support this conclusion,
showing that only a truncated Htt protein with an elongated polyQ stretch
consisting of the first exon is able to form SDS-stable, fibrillar aggregates
[Scher/-zin/ ger et al., 1997]. Since these aggregates formed in vitro have
similar morphological and biochemical properties as the ones from patient
brain tissue, they have been used extensively as a model system to study the
aggregation process [Busch et al., 2003] as well as for drug screening purposes
[Heiser et al., 2000, 2002].
In PD, the main component of Lewy bodies found in patient brain tissue
are fibrillar aggregates of the Syn protein [Arima et al., 1998]. Also for
this protein, aggregate formation has been successfully recapitulated in vitro
[Conway et al., 2000a].
Several studies have focused on the identification of molecules that are
able to interfere with protein aggregation linked to neurodegenerative disor-
ders. Antibodies have been described that efficiently inhibit Htt aggregation
in vitro or in cell culture models of HD [Heiser et al., 2000; Colby et al.,
2004] by binding to the elongated polyQ tract or the N-terminal region of
the protein. Similarly, immunization against the Aβ-peptide, the major com-
ponent of senile plaques in AD, has proven to lower aggregate load in mouse
models [Janus et al., 2000; McLaurin et al., 2002; Klyubin et al., 2005]. A
therapeutic trial of immunization with Aβ in humans, however, had to be
halted because some patients developed significant inflammatory reactions
[Check, 2002].
Another strategy to combat Htt aggregation uses bivalent polyQ-contai-
ning peptides, which were found to inhibit photoreceptor degeneration in fly
models of HD [Kazantsev et al., 2002; Nagai et al., 2003]. Also peptides
inhibiting Syn or Aβ aggregation have been described [Soto et al., 1998; El-
Agnaf et al., 2004]. However, peptides have a high probability of inducing
allergic reactions and are barely able to pass the blood-brain barrier.
These problems do not necessarily occur with chemical compounds. In
recent years, several research groups have been searching for small molecule
inhibitors of Htt, Syn and Aβ aggregation using cell-free and cell-based as-
says [Pollanen et al., 1992; Heiser et al., 2002; Gestwicki et al., 2004; Zhu
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et al., 2004; Zhang et al., 2005; Walsh et al., 2005; Ono and Yamada, 2006].
However, it is not known so far how or at which stage of the aggregation
process these compounds exert their inhibitory influence. Also, for most of
these substances it is unclear whether they have a therapeutic effect in animal
models of the respective diseases.
In this study, a library containing approximately 5000 natural compounds
was screened for protein aggregation inhibitors using a GST-Htt exon 1 fusion
protein with 51 glutamines and a filter retardation assay [Heiser et al., 2002].
With this method, EGCG was identified as a potent inhibitor of Htt exon 1
aggregation in vitro [Ehrnhoefer et al., 2006].
3.3 Properties of EGCG
EGCG belongs to the family of flavonoids, a group of polyphenols found in
vegetables and fruit such as pomegranates, raspberries and blueberries as well
as in plant beverages including tea and red wine. Flavonoids are secondary
plant metabolites with a number of functions in plant-microbe and plant-
pathogen interactions, UV protection and tissue pigmentation [Hutzler et al.,
1998]. The flavonoid subgroup particularly abundant in fresh tea (Camellia
sinensis) leaves are the catechins, known to account for 30-40% of the solid
green tea extract. Among the tea catechins, EGCG is the major compound
present, constituting more than 10% of the dry weight of green tea extract
[Yang and Wang, 1993].
EGCG is a molecule that has been tested extensively for its possible anti-
carcinogenic effects, and a lot of toxicological and pharmacological data are
already available. It has been shown that oral administration of EGCG at
a daily dose of 800 mg is safe and well tolerated in healthy human subjects
[Chow et al., 2003]. A study on the distribution of EGCG in mouse tissue
furthermore showed that 0.33 % of the orally administered compound can be
detected in the brain [Suganuma et al., 1998]. A recent study also provides
first evidence for the presence of plasma membrane binding sites for diverse
polyphenols, including EGCG, in the brain [Han et al., 2006]. This finding
could explain the neuroprotective properties of EGCG that have already been
demonstrated in numerous studies [Choi et al., 2001; Levites et al., 2001;
Choi et al., 2002]. The potential of EGCG to inhibit enzymes generating
the amyloidogenic Aβ peptide has also been investigated [Jeon et al., 2003;
Rezai-Zadeh et al., 2005]. Only recently, it has been suggested that EGCG
is also a modifier of amyloid protein aggregation [Bastianetto et al., 2006;
Masuda et al., 2006; Griffioen et al., 2006]. This study thereby provides the
first evidence for the inhibition of Htt aggregation by EGCG [Ehrnhoefer
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et al., 2006], and gives further insights into the mechanism by which EGCG
modulates amyloid protein fibrillization.
3.4 EGCG inhibits Htt exon 1 protein aggre-
gation in vitro
The potential of EGCG to inhibit Htt exon 1 protein aggregation was discov-
ered with the filter retardation method (Fig. 2.3). A GST-Htt exon 1 fusion
protein with 51 glutamines was used, which only starts to form aggregates
when the GST-tag is cleaved off with a protease.
These data demonstrate for the first time that green tea polyphenols
are able to modulate the aggregation process of an amyloidogenic polyQ-
containing protein. In addition to EGCG, three related compounds were
tested with the filter retardation assay: GCG, a stereoisomer of EGCG, and
GC and EGC, which both lack the gallate moiety. The two latter substances
were not able to inhibit HDQ51 aggregation in the filter retardation assay,
indicating that the gallate group is crucial for the interaction between EGCG
and the Htt exon 1 protein. Previous studies have shown that gallate esters
are important for the association of polyphenols with proteins, probably be-
cause they mediate weak hydrophobic interactions with proline-rich regions
in target proteins, which is a prerequisite for subsequent hydrogen bond for-
mation [Murray et al., 1994]. It could be furthermore hypothesized that the
gallate group enables the compound to bind more than one protein molecule,
thus linking them to form oligomeric structures.
EM analysis of the HDQ51 aggregation reactions exhibited a large amount
of fibrillar structures in solvent-treated controls (Fig. 2.4), similar to Htt ag-
gregates described in the literature [Scherzinger et al., 1999; Heiser et al.,
2002]. In EGCG treated samples, however, these fibrils were not observed.
Instead, small, amorphous microaggregates of less than 50 nm in diameter
appeared, which were not of fibrillar nature. This confirms the results from
the filter retardation assay, and indicates that EGCG stabilizes small assem-
blies of the HDQ51 protein. Other Htt aggregation inhibitors described in
the literature, such as the benzothiazoles PGL-001 and PGL-034, have also
been shown to reduce the number of fibrillar aggregates [Heiser et al., 2002].
However, it has not been assessed so far, which morphology of the Htt exon
1 protein is stabilized by these compounds.
Since EGCG is known for its antioxidant properties, it was next eval-
uated whether the inhibition of Htt aggregation is a general property of
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antioxidant substances. Two potent natural antioxidants, ascorbic acid and
α-tocopherol, were tested with the filter retardation assay. At the concen-
trations used (0.6-6 µM), these compounds had no effect on the formation
of SDS-insoluble aggregates (Fig. 2.5). Furthermore, EGC, which has the
same standard reduction potential as EGCG [Frei and Higdon, 2003], was
ineffective in the initial filter retardation assay (Fig. 2.3). This indicates that
the antioxidant properties of EGCG are not mainly responsible for inhibiting
aggregation. Rather the chemical structure of EGCG, which differs signifi-
cantly from ascorbic acid and tocopherol (Figs. 2.2, 2.5 C), seems to mediate
the effect of the catechin on Htt aggregation.
Next, it was evaluated whether the redox conditions in the buffer used
for HDQ51 aggregation influence the inhibitory potential of EGCG. H2O2 or
DTT were added to the reactions to either force or prevent the auto-oxidation
of the compound. As seen in Fig. 2.6, neither oxidizing nor reducing con-
ditions had an influence on EGCG’s ability to prevent aggregation. This
suggests that both, the reduced and the oxidized forms of the compound,
interfere with fibrillization of HDQ51 with the same efficiency. Interestingly,
Bors et al. [2001] and Valcic et al. [2000] report a number of oxidation prod-
ucts of EGCG. The gallate moiety, however, is not oxidized in any of these
structures. The interaction between the protein and the compound therefore
could involve a region such as the gallate group that is not changed during
oxidation.
3.5 EGCG stabilizes large Htt exon 1 oligo-
mers
In order to observe the impact of EGCG on Htt exon 1 oligomerization,
GST-FLAG-HDQ53 and GST-myc-HDQ53 fusion proteins were used. These
proteins contain a single cleavage site for Prescission Protease™, and cleav-
age separates the whole exon 1 fragment from the GST tag. Since Prescission
Protease™ cleaves much slower than the elastase used to initiate aggrega-
tion in the previous experiments (few hours for complete cleavage of GST-
FLAG-HDQ53 as compared to a few minutes for elastase, data not shown),
aggregation-prone polyQ containing fragments accumulate much slower in
this assay (Fig. 2.9). This makes the Prescission Protease™-system better
suitable to monitor aggregation intermediates, since oligomeric structures are
present for a longer time and do not immediately progress into fibrils.
In a collaboration with Dr. Paul Muchowski from the University of San
Francisco, the aggregation of Prescission Protease™-cleaved GST-myc-HD-
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Q53 was monitored with AFM. In solvent-treated samples, Htt assemblies
were observed that resembled spherical oligomers described before [Wacker
et al., 2004] (Fig. 2.11). With an average diameter of 20-40 nm, they have
been calculated to contain 35-250 HDQ53 molecules (calculated according to
Voss and Gerstein [2005]). The presence of EGCG in the aggregation reac-
tions, however, led to a dramatic increase in oligomer size. EGCG-treated
HDQ53 samples contained large, spherical structures with diameters of 160-
220 nm, which correspond to 15,000-45,000 HDQ53 molecules.
Interestingly, such large assemblies were never observed with elastase-
cleaved Htt exon 1 protein. This could be explained by the different cleavage
patterns of the two proteases: Prescission protease™ cleaves at a unique site
in the GST-FLAG-HDQ53 sequence, between the GST- and the FLAG-tag
(Fig. 3.1). This generates a Htt fragment of 35 kDa that consists of the whole
exon 1 sequence. Elastase, on the other hand, cleaves the GST-HDQ51 pro-
tein at amino acids with small side-chains, such as alanine. This leads to
the formation of smaller Htt fragments, among which only the polyQ con-
taining fragments will form fibrillar aggregates. It is therefore possible that
elastase-cleaved fragments are unable to form large spherical structures be-
cause a part of the Htt exon 1 protein sequence required for this process is
missing. Furthermore it is possible that elastase-cleaved fragments, due to
their smaller size, form smaller EGCG-stabilized oligomers than Prescission
protease™-cleaved fragments. Indeed, amorphous microaggregates were ob-
served by EM in elastase-cleaved GST-HDQ51 samples treated with EGCG
(Fig. 2.4), however, these structures were not further analyzed.
Figure 3.1: Schematic representation of the Prescission Protease™ and elastase
cleavage sites in the Htt fusion proteins used in this study. The GST-
FLAG-HDQ53 and GST-myc-HDQ53 proteins possess a unique cleav-
age site for Prescission Protease™, whereas the GST-HDQ51 fusion
protein is cleaved at different positions by elastase.
Also, the filter retardation assay yielded different results, depending on
which protease was used for cleavage of the GST-Htt exon 1 fusion proteins.
88
Increasing amounts of EGCG incubated with elastase-cleaved GST-HDQ51
led to a decrease in SDS-stable aggregates retained on the filter membrane
(Fig. 2.3). For Prescission protease™-cleaved GST-FLAG-HDQ53, however,
SDS-stable structures on the filter appeared faster in the presence of EGCG
than in solvent-treated controls (Fig. 2.10). As was the case for elastase-
cleaved GST-HDQ51, no fibrils were seen in EGCG-treated samples by AFM.
Instead, large spherical oligomers observed for the Prescission protease™-
cleaved protein (Fig. 2.11). Provided that these oligomers were resistant to
SDS, they could be caught on the filter membrane in a similar manner as
SDS-stable fibrils.
Since no large oligomers were observed in elastase-cleaved GST-HDQ51
samples treated with EGCG, the signal on the corresponding filter mem-
branes decreased upon treatment with the compound.
The formation of large oligomers upon incubation of Htt exon 1 protein
with EGCG was further confirmed with size-exclusion chromatography using
uncleaved GST-FLAG-HDQ53. A Superose-6 column with an exclusion limit
of 40,000 kDa was used in these experiments. The solvent-treated, uncleaved
GST-FLAG-HDQ53 samples thereby eluted from the column at a size of
110-470 kDa, which represents small oligomers composed of 2-8 GST-FLAG-
HDQ53 molecules (Fig. 2.12). These oligomers were not stable in SDS, since
fractions analyzed by SDS-PAGE and Western blotting exhibited a single
Htt band at 55 kDa.
Interestingly, upon incubation with EGCG the intensity of the small
oligomer peak decreased significantly, and a shoulder appeared between 550
and 900 kDa, indicating the presence of larger oligomers containing 10-16
GST-FLAG-HDQ53 molecules. These larger oligomers were also not stable
to boiling in SDS, as can be observed on the corresponding Western blot
in Fig. 2.12. EGCG therefore seems to be able to crosslink cleaved as well
as uncleaved GST-HDQ53 proteins, although the resulting high-molecular
weight oligomers differ in size as well as resistance to SDS. Oligomers formed
from uncleaved GST-FLAG-HDQ53 protein are most likely smaller and SDS-
soluble because EGCG crosslinking is less efficient due to steric hindrance by
the large (26 kDa) GST-tag.
Another experiment supported the idea that EGCG leads to the for-
mation of large Htt assemblies in the absence of the GST-tag, which are
resistant to SDS. Mature Htt fibrils  1.5 µm in length and detectable with
the filter retardation assay (Fig. 2.13 A) were obtained through incubation
of GST-HDQ51 with elastase. Sonification was used to break this start-
ing material into small fibrillar aggregates, which were not retained on the
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filter membrane any more (Fig. 2.13 B). When EGCG was added, these ag-
gregates immediately became insoluble in SDS and could be detected with
the filter assay (Fig. 2.13 C,D). These results indicate that EGCG is able
to transform small Htt fibrils into larger aggregates with a mixed, fibrillar
and amorphous nature. The compound therefore leads to the formation of
large, SDS-resistant protein assemblies, regardless of which starting material,
fibrillar or monomeric, is used.
3.6 EGCG-stabilized Htt oligomers represent
an alternative folding pathway
In order to investigate whether EGCG-stabilized Htt oligomers are able to
self-assemble into fibrils or whether they are ’off-pathway’ for fibril forma-
tion, seeding experiments were performed. Small amounts of on-pathway
Htt oligomers or sonified fibrils accelerate aggregation reactions, since they
obviate the otherwise slow formation of nuclei during the lag-phase of the
reaction [Scherzinger et al., 1999; Busch et al., 2003]. This effect was termed
’seeding’, because it is reminiscent of crystallization reactions that can be
accelerated by adding small amounts of preformed crystals. Successful seed-
ing can only take place if the seeds added can act as nuclei and possess a
structure that allows the addition of further protein monomers, resulting in
the fast formation of fibrillar aggregates [Jarrett et al., 1993].
Fig. 2.14 shows that small fibrils consisting of Prescission Protease™-
cleaved GST-myc-HDQ53 are able to seed FLAG-HDQ53 aggregation reac-
tions. Myc-HDQ53 aggregates formed in the presence of EGCG, however, do
not possess seeding potential. This result indicates that the surface structure
of EGCG-stabilized aggregates does not allow Htt fibril formation through
the addition of protein monomers.
Krebs et al. [2004] showed that efficient seeding can only be performed, if
the small fibrils used as seeds are derived from a protein that is closely related
to the one whose aggregation should be accelerated. Larger differences in
the sequence of the respective proteins abolish the seeding effect, especially if
these differences are located in the part of the protein that assumes a β-sheet
conformation and stabilizes the fibrillar assembly via hydrogen bonds [Biere
et al., 2000; Krebs et al., 2004]. The myc- and FLAG-HDQ53 proteins used
in this study have identical sequences, with the exception of the small tags
at the N-termini (Fig. 2.7). To abolish the seeding effect, EGCG therefore
needs to block the assembly of aggregation nuclei by the myc-HDQ53 protein
by preventing the formation of β-sheets or, once the conformational change
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has occured, through blocking the binding sites for monomer addition.
Spotting experiments using the MW1 antibody, which specifically detects
the elongated polyQ stretch, were used to monitor the conformational change
that occurs in this region of the Htt protein during the aggregation process.
In solvent-treated samples, the epitope recognized by the MW1 antibody dis-
appears rapidly after starting the aggregation reaction through the addition
of elastase (Fig. 2.16). This extremely fast conformational switch has been
described before [Schaffar et al., 2004] and can be delayed by the addition of
EGCG in a concentration-dependent manner (Fig. 2.17).
The most plausible explanation for these findings is that EGCG binds to
the monomeric Htt fragments generated by protease cleavage. The data ob-
tained for the Syn protein, showing EGCG binding to the monomer as well as
to oligomers (Fig. 2.30), support this hypothesis. By binding to the protein
monomer, the compound could modulate the intramolecular rearrangement
of mutant Htt exon 1 prior to aggregate formation, influencing the initial
misfolding step in the aggregation cascade. I propose that in untreated re-
actions protease cleavage of the GST fusion protein triggers a very rapid
intramolecular change in the polyQ-containing Htt exon 1 fragment that
leads to a compact β-sheet-rich structure. This compaction is most likely
caused by the formation of hydrogen bonds between the main chain and side
chain amides in the polyQ tract. The conformational switch could further-
more constitute the first step towards the formation of a seeding-competent
aggregation nucleus. In EGCG treated samples, however, either the for-
mation of stable hydrogen bonds is slowed down, or the binding of EGCG
molecules to Htt might induce the formation of a stable protein-drug adduct
that has a novel structure and cannot be recognized by the polyQ-specific
MW1 antibody.
Taken together, the Htt in vitro-data show that incubation of Htt exon
1 protein with EGCG leads to the formation of oligomeric structures, which
are morphologically different from intermediates normally occuring during
the aggregation process. These oligomers furthermore exhibit stability to
boiling in SDS/DTT, a property, which has so far only been described for
mature Htt fibrils [Scher/-zin/ ger et al., 1997]. Finally, the results from
spotting and seeding experiments suggest that EGCG-stabilized oligomers
expose different epitopes on their surface than normal aggregation interme-
diates and therefore cannot mediate seeding. Hence, the structures stabilized
by EGCG are different from normal aggregation intermediates and could rep-
resent a novel conformation of the Htt exon 1 protein, which has not been
described so far and does not lie on the pathway to fibril formation.
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3.7 EGCG reduces Htt exon 1 aggregation in
mammalian cells
In order to monitor the effect of EGCG on Htt aggregation in a cellular
environment, mammalian cells transiently expressing Htt exon 1 protein with
90 glutamines (HDQ90) were treated with the compound, which was added
to the growth medium. In solvent-treated control cells, HDQ90 formed SDS-
resistant aggregates that could be detected with the filter retardation assay
(Fig. 2.18). Cells treated with EGCG, however, showed a dose-dependent
decrease in Htt aggregate formation. This indicates that the compound is
able to exert its effect on protein aggregation also in a cellular environment.
Furthermore, pulse-chase experiments were performed to investigate the
turnover of HDQ68 protein in mammalian cells in the presence and ab-
sence of EGCG. The amount of labeled protein detected on the Western
blot gradually decreased during the chase time, most probably due to in-
tracellular degradation by the ubiquitin-proteasome system. Fig. 2.19 shows
that HDQ68 was degraded faster in EGCG-treated cells than in untreated
cells. Since EGCG also prevented intracellular Htt aggregation, it is possible
that the compound keeps the protein in a soluble, more easily degradable
state.
It is reported in the literature, that the formation of Htt aggregates is
paralleled by an impairment of the ubiquitin-proteasome system. Waelter
et al. [2001] report that the amount of Htt inclusion bodies accumulating
in mammalian cells depends highly on the activity of the proteasome. On
the other hand, it has been proposed that protein aggregation itself directly
impairs the function of the ubiquitin-proteasome system [Bence et al., 2001].
This leads to the conclusion that failure of the proteasome to keep up with
the degradation of mutant Htt would lead to the accumulation and aggrega-
tion of the protein. This process could then start a positive-feedback loop,
since the aggregates themselves block the ubiquitin-proteasome system and
even less protein is degraded. In our cell culture system, high amounts of
HDQ68 are overexpressed, making it difficult for the cells to keep protein
levels low enough to prevent aggregation. The presence of EGCG could keep
the Htt molecules in a more soluble state, thereby preventing impairment of
the ubiquitin-proteasome system by aggregates and securing the continuous
degradation of the overexpressed protein. Additional experiments quantify-
ing the proteasome activity in EGCG- and solvent-treated cells expressing
mutant Htt are needed to further clarify this point.
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3.8 EGCG reduces Htt aggregation and tox-
icity in yeast and Drosophila models of
HD
Further experiments performed by Dr. Martin Duennwald at the Whitehead
Institute for Biomedical Research in Cambridge and Dr. Leslie Thompson at
the University of California in Irvine support the protective role of EGCG
in HD model systems. A correlation between reduced Htt aggregation and
lowered toxicity upon EGCG treatment was observed in a yeast model sys-
tem, and a neuroprotective effect of the compound was found in Drosophila
expressing Htt exon 1 with an elongated polyQ tract [Ehrnhoefer et al., 2006].
Taken together, these in vivo findings support the hypothesis that com-
pounds modulating early steps in the aggregation pathway likely by inducing
off-pathway aggregation have a high potential for therapy development [Sac-
chettini and Kelly, 2002]. Currently, the molecular mechanisms by which
Htt fragments with pathogenic polyQ sequences exert their toxic effects in
a cellular environment are unclear. Misfolded β-sheet-rich Htt monomers
or small soluble oligomers form abnormal protein-protein interactions with
other polyQ proteins such as the transcription factors TBP and CBP in
vitro, suggesting that such interactions might also occur in vivo in neuronal
cells and contribute to HD pathogenesis [Schaffar et al., 2004]. EGCG might
reduce the polyQ-mediated Htt toxicity in vivo by changing the conforma-
tion of the disease protein and by preventing the formation of destructive
protein-protein interactions.
3.9 A model for EGCG-mediated modulation
of Htt exon 1 aggregation
Based on the results of this study, the following model for the impact of
EGCG on Htt exon 1 aggregation emerged (Fig. 3.2). The GST-tagged Htt
exon 1 fusion protein, which does not aggregate by itself, is the starting ma-
terial for the in vitro aggregation assay. It possesses an epitope (red) that
is recognized by the MW1 antibody. When the Htt fragment is released by
proteolytic cleavage without the presence of an aggregation inhibitor, Htt
monomers quickly undergo a conformational change, by which the MW1
epitope becomes occluded (Fig. 3.2 A). The β-sheet rich monomers then
oligomerize and finally form fibrils, which are SDS-resistant and can be ob-
served by EM.
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The results obtained in this study suggest that EGCG interferes with this
aggregation process at a very early step, since it delays the occlusion of the
MW1 epitope significantly. This could be achieved by binding of the com-
pound to the cleaved Htt monomer (Fig. 3.2 B). Then, EGCG might directly
cluster the Htt monomers without any conformational change, yielding large,
off-pathway oligomers. The MW1 epitope could hereby become hidden in-
side these structures, or EGCG and the MW1 antibody could compete for
the same binding site. It is also possible that the conformational change is
delayed by the EGCG, but β-sheet rich monomers are still formed. The com-
pound then further clusters these monomers into oligomers. In both cases,
the EGCG-stabilized oligomers are resistant to SDS and cannot progress
into fibrils, possibly because the compound stays bound to the protein and
interferes with the formation of regular amyloid fibres.
The spotting experiments using the MW1 antibody, which were per-
formed in this study, give a first hint towards important folding and misfold-
ing events that either lead to the formation of Htt fibrils or EGCG-stabilized
off-pathway oligomers. To further analyze the conformational changes that
occur during the aggregation process, NMR or CD spectroscopy could be per-
formed. Such studies could elucidate the mechanism of the EGCG-mediated
modulation of Htt exon 1 aggregation in more detail.
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Figure 3.2: A model for the modulation of Htt exon 1 aggregation by EGCG.
(A) GST-tagged Htt exon 1 protein represents the starting point for
the aggregation reaction. This protein possesses an epitope (red) that
is recognized by the MW1 antibody. When the GST-tag (circle) is
cleaved off in the absence of EGCG, the Htt fragment changes its
conformation rapidly, possibly adopting a β-sheet structure, and the
MW1-epitope disappears. The misfolded monomers then form on-
pathway oligomers and finally fibrils. (B): In EGCG-treated reactions,
the compound (green) keeps the MW1 epitope accessible for a longer
time, possibly by binding to the cleaved Htt monomer. Then, the
MW1 epitope slowly disappears also in EGCG-treated samples. This
might happen by clustering the monomers into off-pathway oligomers,
in which the epitope is hidden, without any conformational change.
Another possibility is that EGCG simply delays the conformational
switch leading to β-sheet rich monomers. The compound then links
these monomers and leads to the formation of the large oligomeric
structures seen by AFM. In both cases, the oligomers stabilized by
EGCG are SDS-stable and not able to assemble into fibrils.
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3.10 EGCG inhibits Syn aggregation in vitro
The process of amyloid formation is similar for different proteins associated
with neurodegenerative diseases. Also the fibrils and aggregation intermedi-
ates share morphological and biochemical characteristics (see Chapter 1.1.1).
Therefore, after having studied the effects of EGCG on the Htt exon 1 pro-
tein, I included another amyloidogenic protein in the study and investigated
whether EGCG can also inhibit the fibrillization of Syn, the major com-
ponent of Lewy bodies in PD (described in Chapter 1.1.3). The wild-type
protein, which forms aggregates in patients with sporadic PD, as well as Syn
containing the A53T mutation were used in this study. The A53T mutation
has been discovered in families with inherited PD [Polymeropoulos et al.,
1997].
The incubation of His-Syn wt and A53T proteins at 37 ℃ led to the for-
mation of fibrillar aggregates, which were detected with the ThT method.
ThT is a dye that is known to bind amyloid fibrils [LeVine, 1993], and
changes its fluorescence upon binding. In this assay, a pronounced inhibition
of Syn fibrillization was already achieved with subequimolar concentrations
of EGCG (Fig. 2.22). This inhibitory potential is similar to published sub-
stances inhibiting Syn aggregation such as baicalein and rifampicin, which
are both effective at substoichiometric concentrations, like EGCG [Zhu et al.,
2004; Li et al., 2004].
3.11 EGCG stabilizes large Syn oligomers
The morphology of Syn aggregates was determined by EM (Fig. 2.23). With
diameters of 4-5 nm, the fibrils observed in solvent-treated controls resem-
bled Syn fibrils described in the literature [Conway et al., 2000a]. However,
when Syn was aggregated in the presence of a tenfold molar excess of EGCG,
no fibrils were observed. Instead, a homogenous population of large spher-
ical oligomers with diameters of 25-30 nm was found. These particles were
estimated to contain 70-120 Syn molecules. The structures were about five
times larger than on-pathway oligomeric aggregation intermediates described
previously, which had diameters ranging from 2-5 nm [Conway et al., 2000b].
These findings are in agreement with data obtained for the Htt exon 1 protein,
where AFM analyses also pointed towards the formation of large spherical
structures after EGCG treatment. The sizes of these oligomers, however,
differ between the two proteins (160-220 nm diameter for Htt and 25-30 nm
diameter for Syn).
EGCG-stabilized Syn oligomers could also be separated with size-exclusion
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chromatography (Fig. 2.24). They eluted in a high-molecular weight peak
of 240-1600 kDa. This corresponds to 15-100 Syn monomers, and is in very
good agreement with data obtained from EM analyses.
The peak at 30-90 kDa, which was found in solvent-treated control re-
actions, represents small oligomers containing 2-5 Syn molecules. However,
size-exclusion chromatography measures the hydrodynamic radius of a pro-
tein, and since Syn is reported to be natively unfolded, it is possible that
it shows an abnormal migration behavior when compared to globular pro-
tein standards. Interestingly, there have been reports in the literature that
Syn monomers elute from size-exclusion columns at a size corresponding to
trimers [Weinreb et al., 1996]. Therefore, the small oligomers observed in
this experiment could also represent a monomer in an unfolded conforma-
tion. Further experiments such as analytical ultracentrifugation would be
necessary to determine the oligomerization grade of the Syn proteins eluting
in this peak.
Further analyses by SDS-PAGE revealed that EGCG-stabilized Syn oli-
gomers are resistant to boiling in SDS and form in a time- and EGCG-
concentration-dependent manner (Figs. 2.24 C, 2.25 and 2.26). SDS-stable
oligomers were not observed in control samples even after prolonged incu-
bation. It has been reported in the literature that the cytosolic catechol
dopamine inhibits Syn aggregation by stabilizing SDS-resistant protein oli-
gomers [Conway et al., 2001; Cappai et al., 2005]. However, in contrast to
the first assumption of the authors that these oligomers could be respon-
sible for the specific death of dopaminergic neurons in PD, a recent study
demonstrated that the formation of dopamine-stabilized Syn oligomers does
not lead to toxicity [Mazzulli et al., 2006]. Fig. 2.26 shows that the incuba-
tion of Syn with EGCG or dopamine led to a similar pattern of SDS-stable
oligomers, and only the speed of oligomerization was different for the two
compounds. It is therefore possible that EGCG and dopamine both stabilize
similar, non-toxic oligomers of the Syn protein.
Fig. 2.27 furthermore shows that the formation of SDS-stable Syn oligo-
mers is a specific property of EGCG, which is not shared by other antioxidant
substances such as ascorbic acid or α-tocopherol. It can be concluded that,
for Syn as well as for Htt, it is most probably the chemical structure of
EGCG, which is responsible for the inhibition of protein fibrillization.
Next, it was analyzed whether the redox conditions in the buffer influence
the ability of EGCG to stabilize Syn oligomers. Fig. 2.28 shows, that oxidiz-
ing conditions do not have a major influence on the formation of SDS-stable
Syn oligomers. The reducing agent DTT, however, inhibited the formation of
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EGCG-stabilized Syn oligomers in a dose-dependent manner. This indicates
that only the oxidized form of EGCG is able to induce Syn oligomerization.
It has been reported, that EGCG in its oxidized form can oligomerize by
itself [Bors et al., 2001]. The large, SDS-stable oligomers could therefore be
formed under oxidative conditions by linking single Syn molecules via EGCG
bridges (see also the model presented in Fig. 3.3). These bridges cannot form
under reducing conditions and no SDS-stable oligomers are observed in the
gel. However, recent data for Syn indicate that both, the reduced and the
oxidized form of the compound, inhibit fibril formation (data not shown), as
it was observed for the Htt protein (Fig. 2.6). It is possible that the reduced
form of EGCG keeps the aggregating proteins in a monomeric state, without
the formation of large oligomers.
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Figure 3.3: Model for the stabilization of Syn oligomers by EGCG. (A): Syn
molecules (circles) are able to bind one or more EGCG molecules
(squares). EGCG itself can oligomerize under oxidizing conditions,
leading to EGCG-chains bound to Syn. This assumption could ex-
plain the smear seen on top of the Syn monomer bands in all SDS-gels
of EGCG-treated samples, since an undefined amount of n EGCG
molecules would be bound by each Syn monomer, increasing the ap-
parent size of the monomer on the gel. Over time, Syn monomers could
form oligomers, which are stabilized by the EGCG-chains. (B): Un-
der reducing conditions, EGCG cannot oligomerize, and therefore no
stable Syn oligomers can be formed. However, reduced EGCG might
still be able to bind to Syn and prevent fibrillogenesis by keeping the
protein in the monomeric state.
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3.12 EGCG preferentially binds to unfolded
proteins
Binding experiments under non-reducing conditions revealed that EGCG
binds directly to Syn (Fig. 2.30). EGCG-Syn complexes were detected with
monomeric Syn, but also with EGCG-stabilized dimers, trimers and large
oligomers after separation by SDS-PAGE. A smear that was larger than the
Syn monomer, but smaller than the dimer, showed the strongest NBT signal.
This smear of ill-defined size could be due to the binding of varying numbers
of EGCG molecules to the Syn monomer, as suggested in the model in Fig.
3.3. The compound was also still present in the Syn oligomers, indicating
that it stays bound to the protein during oligomerization.
Even though EGCG forms stable adducts with the Syn protein, the com-
pound did not bind to the control protein GST (Fig. 2.31). Also ovalbumin,
another protein used as a control, did not bind to EGCG in a non-denaturing
buffer (Fig. 2.32). One major structural feature that distinguishes Syn from
these two control proteins is the fact that Syn is natively unfolded in aque-
ous buffer systems [Weinreb et al., 1996]. In order to elucidate whether this
lack of tertiary structure is responsible for the binding of EGCG to Syn, the
control protein ovalbumin was treated with 8 M urea. This agent destroys
intramolecular hydrogen bonds in proteins and thus leads to their unfold-
ing. Under these conditions, binding of EGCG to ovalbumin was observed
(Fig. 2.32). This indicates that EGCG preferentially interacts with unfolded
proteins, which expose hydrophobic patches to the solvent that are normally
hidden within the folded structure.
Intracellularly, chaperones trigger the degradation and detoxification of
misfolded proteins by interacting with hydrophobic surfaces [Muchowski and
Wacker, 2005]. Since EGCG seems to bind to unfolded proteins in a simi-
lar manner, it could assist the chaperone machinery and contribute to the
clearance of aggregation-prone proteins associated with neurodegenerative
disorders.
3.13 EGCG-stabilized Syn oligomers do not
expose an epitope found in normal ag-
gregation intermediates
A recent study reports the properties of a conformation-specific antibody,
which is able to recognize oligomeric structures formed during the aggrega-
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tion process of different amyloidogenic proteins [Kayed et al., 2003]. However,
the antibody does not react with monomers or mature fibrils of the respective
proteins. When aliquots of Syn incubations were spotted onto nitrocellulose
and probed with this antibody, maximum immunoreactivity could be seen
between 4 and 6 h of incubation at 37 ℃ (Fig. 2.29). After 24 h, the signal
intensity decreased to background levels. This is consistent with the results
of the ThT assay, where Syn aggregation was found to be complete after 20
h of incubation (Fig. 2.22). The immunoreactivity with the anti-oligomer
antibody obtained from non-incubated Syn spots (0 h) is most probably due
to oligomers, which are formed rapidly even in freshly prepared protein sam-
ples. In EGCG-treated samples the anti-oligomer signal decreased rapidly
(during the first 2 h of incubation), even though the time-course analysis in
Fig. 2.26 shows that during this time the first EGCG-stabilized oligomers are
formed. This indicates that EGCG-stabilized oligomers are not recognized
by the oligomer-specific antibody.
Since Kayed et al. [2003] have reported that their antibody recognizes a
toxic oligomeric form of amyloidogenic proteins, it can be speculated that in
EGCG-stabilized oligomers the toxic epitope is blocked through binding of
the drug or it is hidden inside the structures.
3.14 A model for the influence of EGCG on
Syn aggregation
Based on the results from this study, a model for the interaction of EGCG
with Syn was generated (Fig. 3.4). The aggregation process starts with the
native, presumably unfolded, Syn monomer. Incubation without the addi-
tion of inhibitory compounds leads to the formation of SDS-soluble oligomers
(Fig. 3.4 A). This process might involve a conformational change of the Syn
monomers, however, this has not been investigated in detail in the present
study. Oligomeric intermediates are formed during the lag phase of the ag-
gregation process, before the appearance of fibrils that bind the fluorescent
dye ThT. The intermediates are soluble in SDS and expose an epitope (red)
recognized by the anti-oligomer antibody, which is not present in monomers
or fibrillar Syn aggregates.
Similarly as for Htt, incubation of the Syn monomer in the presence of
EGCG leads to the rapid formation of SDS-insoluble oligomers, the size of
which slowly increases over time, until large spherical oligomers are formed
(Fig. 3.4 B). These oligomers do not progress into fibrils, and also do not
react with the anti-oligomer antibody. This suggests that they represent
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the endpoint of an alternative Syn aggregation pathway, which circumvents
the formation of potentially toxic protein assemblies, such as on-pathway
oligomers and fibrils.
Figure 3.4: A model for the modulation of Syn aggregation by EGCG. (A): In
solvent-treated aggregation reactions, the soluble Syn monomer starts
to form SDS-soluble oligomers over time, which expose an epitope (red)
recognized by the anti-oligomer antibody. Upon prolonged incubation,
this epitope slowly disappears, since the oligomers assemble into fibrils.
(B): Treatment with EGCG (green) modifies Syn oligomerization. The
compound binds to the soluble protein monomers and clusters them
into SDS-insoluble oligomers, possibly by an oxidative mechanism (see
Fig. 3.3). These EGCG-stabilized oligomers do not possess the epitope
recognized by the anti-oligomer antibody and cannot assemble into
fibrils.
3.15 EGCG lowers toxicity caused by A53T
Syn expression in mammalian cells
In this study, the aggregation properties of the A53T Syn protein was similar
to those of the wt in all experiments. In vitro studies have shown, that fibrils
formed of wt as well as of A53T Syn protein have the same features such
as morphology, dye binding properties and resistance to proteolysis [Conway
et al., 2000a]. There is evidence that A53T Syn forms aggregates faster than
the wt protein [Conway et al., 2000b], a finding which was not reproduced
in my study. However, this could be due to the presence of the His-tag or
the fact that the aggregation reactions were shaken vigorously to accelerate
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fibrillization.
In transiently transfected COS-1 cells, however, the expression of A53T
Syn was significantly more toxic than the wt protein (data not shown). In
fact, the survival of cells expressing wt Syn did not differ from cells trans-
fected with the vector control. Therefore, the effect of EGCG was investi-
gated only in A53T expressing cells. Fig. 2.33 shows that the expression of
A53T Syn leads to a decrease in cell survival of 30 % compared to the vector-
transfected control. The addition of EGCG to the cell culture medium caused
a dose-dependent improvement of the impaired survival, with the highest
EGCG concentration tested (50 µM) almost restoring survival to levels seen
in the control cells.
An additional experiment suggests that the toxicity caused by A53T Syn
expression leads to apoptotic cell death, since the levels of active caspases
in these cells were 80 % higher than in vector-transfected control cells (Fig.
2.34). This caspase activation was reduced to normal levels through the
addition of EGCG to the cells.
These results indicate that EGCG reduces the toxicity caused by A53T
Syn, probably by binding to the misfolded protein and thereby triggering a
different, non-toxic fold or promoting its degradation.
In the mammalian cell model system no Syn protein aggregates were
found at any time point, neither with the filter retardation assay nor with
immunofluorescence methods. Therefore, the influence of EGCG on Syn
aggregation in the cellular surrounding could not be studied with this system.
In the literature, there is no case reported in which transfected laboratory
cell lines show Syn aggregation without the addition of extracellular factors.
There are only a few examples for Syn protein aggregation in cultured cells:
Ostrerova-Golts et al. [2000] show that Syn aggregation in neuroblastoma
cells can be induced through the extracellular addition of iron. McLean et al.
[2001] observe Syn aggregation in transfected primary neurons. It might be
possible, that the Syn protein requires specific conditions for the formation of
aggregates, that are only present in the dopaminergic neurons of PD patients
and, to some extent, in primary neuronal cultures. Therefore, the inhibitory
potential of EGCG and other aggregation inhibitors can only be tested in
a cellular context with the help of transgenic animals exhibiting inclusion
bodies or primary neuronal cultures derived from such animal models.
In conclusion, this study shows that EGCG is one of the few chemical
substances described so far that are able to inhibit the aggregation of different
amyloidogenic proteins. The probably best described ’generic’ aggregation
inhibitor is the dye Congo red, which has been reported to block polyQ,
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prion, Aβ and Syn aggregation [Caughey and Lansbury, 2003; Lorenzo and
Yankner, 1994; Heiser et al., 2000; Masuda et al., 2006]. It has been shown
to prevent oligomerization and facilitates the proteasomal degradation of a
polyQ peptide [Sanchez et al., 2003]. Also EGCG inhibits polyQ and Syn
aggregation at a very early step. It leads to the formation of large off-pathway
oligomers and reduces the toxicity caused by the expression of amyloidogenic
proteins in mammalian cells. An important advantage of EGCG over other
substances such as Congo red is, that it has been reported to cross the blood-
brain barrier [Suganuma et al., 1998] and to be safe for humans when tested
in clinical studies [Chow et al., 2003]. It may therefore have considerable
potential as a drug candidate for the development of treatments for protein
misfolding and amyloid diseases in general.
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Appendix A
Materials and Methods
A.1 Materials
A.1.1 Bacterial strains
SURE e14- (McrA-) D (mcrCB-hsdSMR-mrr)171 endA1
supE44 thi-1 gyrA96 relA1 lac recB recJ sbcC
umuC::Tn5 (Kanr) uvrC [F’ proAB lacIqZDM15 Tn10
(Tetr)] Stratagene, for increased stability of unstable
DNA, for the cloning of huntingtin fragments with long
polyQ stretches
SCS1-
pSE111
RecA1 endA1 gyrA96 thi-1 hsdR17 (rkm+k ) supE44
relA1 (Stratagene), contains plasmid pSE111 with the
lacIq repressor gene and the argU gene for the rare
arginine-tRNA [Bussow et al., 1998]
A.1.2 Cell lines
COS-1 Fibroblast-like cells that grow in adherent monolayers;
kidney cells of the african green monkey; transfected
with a mutant of SV-40, that is defect in its origin of
replication; host cell for the propagation of
recombinant SV-viruses (DSMZ, Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH)
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A.1.3 Plasmid vectors
pGEX-5X-
1, 2,
3
Expression vectors with the synthetic tac-promoter for
the IPTG-inducible expression of glutathione
S-transferase (GST)-fusion proteins. The vectors
contain an internal lacIq repressor gene for the
repression of expression in every strain of E. coli.
Fusion proteins contain a restriction site for Factor Xa
directly after the GST-protein sequence, which allows
the cleavage of the GST-tag (Amersham Biotech
Europe GmbH).
pGEX-6P-
1, 2,
3
Expression vectors with the synthetic tac-promoter for
the IPTG-inducible expression of glutathione
S-transferase (GST)-fusion proteins. The vectors
contain an internal lacIq repressor gene for the
repression of expression in every strain of E. coli.
Fusion proteins contain a restriction site for
PreScission™ protease directly after the GST-protein
sequence, which allows the cleavage of the GST-tag
(Amersham Biotech Europe GmbH).
pQE30N,
31N, 32N
Expression vectors based on pBR322 with the strong
phage T5 promoter and two lac-operator sequences for
the IPTG-inducible expression of recombinant proteins
with a N-terminal 6xHis-epitope in all three reading
frames (Qiagen), further restriction sites have been
introduced into the multiple cloning site [Wanker
et al., 1997].
pTL (1, 2,
3)
Derivative of vector pSG5 with an early SV40
promoter for protein expression in vivo and a T7
promoter for expression in vitro (Stratagene). The
following restriction sites have been introduced into the
multiple cloning site: EcoRI, BamHI, HindIII, XhoI,
NotI, SmaI, PstI, SacI, KpnI and BglIII [Kastner
et al., 1992].
pTL-HA
(1, 2, 3)
Upstream of the multiple cloning site of pTL (1, 2, 3)
the coding sequence for the HA-epitope has been
introduced in all three reading frames (HA 1, 2, 3),
and a Kozak-sequence has been inserted [Sittler et al.,
1998].
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pFLAG-
CMV 5a,
b, c
Expression vector for C-terminal FLAG fusion proteins
in mammalian cells under the control of the CMV
promoter. Contains an ampicillin resistance for
propagation in E.coli (Sigma-Aldrich).
A.1.4 Microbiological media and buffers
1000x
Ampicillin
stock
100mg/ml dissolved in 50% ethanol, stored at -20℃
AttoPhos™ buffer50mM Tris-HCl pH 9.0,500mM NaCl, 1mM MgCl2
AttoPhos™ reagent10mM AttoPhos reagent dissolved in 100mM Tris
pH9.0
Dialysis
buffer
50mM NaCl, 10mM Tris-HCl pH 7.4, 0.1mM EDTA
10x DNA
sample
buffer
0.42% bromophenol blue, 0.42% xylene cyanol, 25%
ficoll type 400, dissolved in distilled water, stored at
4℃
GST-P1-
buffer
50mM NaH2PO4, 5mM Tris-HCl pH 8.0, 150mM NaCl,
1mM EDTA
GST wash
buffer
50mM NaH2PO4 pH 8.0, 150mM NaCl, 1mM EDTA
His elution
buffer
100mM NaH2PO4, 10mM Tris-HCl, 8M urea, pH 4.5,
adjust pH directly before use
His lysis
buffer
100mM NaH2PO4, 10mM Tris-HCl, 8M urea, pH 8.0,
adjust pH directly before use
His wash
buffer
100mM NaH2PO4, 10mM Tris-HCl, 8M urea, pH 6.3,
adjust pH directly before use
1000x Ka-
namycin
stock
25mg/ml dissolved in distilled water, stored at -20℃
Lysis
buffer for
mammali-
an
cells
50mM Tris-HCl pH 8.8, 100mM NaCl, 5mM MgCl2,
0.5% IGEPAL CA630, 1mM EDTA, stored at room
temperature, add protease inhibitors (Complete™,
final concentration: 1x) and 25U/ml benzonase
straight before use
NBT
staining
solution
0.24mM nitroblue-tetrazolium chloride dissolved in 1M
sodium glycinate, pH 10, prepared immediately before
use
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10x PBS 80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4, to
1l with distilled water
10x PCR
buffer
500mM KCl, 100mM Tris-HCl, 15mM MgCl2, pH 8.3,
filtered sterile, stored at -20℃
PMSF 100mM PMSF dissolved in isopropanol, stored at -20℃
10x
Prescission
pro-
tease™ buffer
500mM Tris-HCl, 1.5M NaCl, 10mM EDTA, 10mM
DTT (add immediately before use), pH 7, stored
(without DTT) at 4℃.
25x
Protease
inhibitors
One tablet of Complete™ protease inhibitor (Roche)
dissolved in 2ml distilled water, stored at -20℃
5x SDS
loading
buffer
250mM Tris-HCl pH 6.8, 500mM DTT, 10% SDS,
5mg/ml bromophenol blue, 50% glycerol, store at -20℃
5x SDS
running
buffer
120mM Trizma™ base, 1.25M glycine, 0.5% SDS, pH
8.5
Silver
stain de-
velopment
solution
0.7ml/l formaldehyde (from 37% stock), 30g/l
potassium carbonate (anhydrous), 10mg/l sodium
thiosulfate
Silver
stain fixing
reagent
30% ethanol, 0.5% acetic acid
Silver
stain sensi-
tization
reagent
0.2g/l sodium thiosulfate
Silver
stain
solution
2g/l silver nitrate
Silver
stain stop
solution
50g/l Tris, 2.5% acetic acid
3% skim
milk
skim milk powder was dissolved in TBS to a final
concentration of 3% (w/v)
SOB--
Medium
20g tryptone, 5g yeast extract, 0.584g NaCl, 0.186g
KCl, to 1l with distilled water
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Stripping
buffer
2% SDS, 60mM Tris-HCl pH 6.8, 50mM DTT (add
straight before use)
1x TAE 1mM EDTA, 40mM Tris-Acetate pH 8.0
1x TBE 1mM EDTA, 45mM Tris-Borate pH 8.0
TBS 20mM Tris-HCl pH 7.4, 150mM NaCl
TTBS 20mM Tris-HCl pH 7.4, 150mM NaCl, 0.01% Triton
X-100
Western
blot buffer
25mM Tris-HCl pH 8.0, 192mM Glycine, 20% methanol
A.1.5 Media and supplements for mammalian cell cul-
ture
Dulbecco’s modified Eagle medium (DMEM) with
sodium pyruvate, L-glutamine and 100mg/l glucose
Gibco
DMEM with 4.5g/l glucose, without
methionine/cystine, L-glutamine, sodium pyruvate
Gibco
Fetal calf serum from E.G. approved countries Gibco
Dulbecco’s phosphate buffered saline (D-PBS) without
calcium, magnesium
Gibco
10000 units/ml Penicillin G and 10000µg/ml
Streptomycin sulfate in 0,85% saline
Gibco
0,5% Trypsin and 0.53mM Na-EDTA in Hanks’ B.S.S. Gibco
L-glutamine, 200mM (100x) Gibco
Na-pyruvate, 100mM (100x) Gibco
L-Cystine, hydrochloride solution (10mM) Sigma-
Aldrich
Redivue L-[35S]methionine (cell labeling grade) Amersham
Bio-
sciences
A.1.6 PCR primers
Name 5’-Sequence -3’ Application
Syn-For GGA GGG AGT TGT
GGC TGC TGC T
Colony-PCR
Syn-Rev CCG CTT AGG CTT
CAG GTT CGT A
Colony-PCR
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Name 5’-Sequence -3’ Application
A53T Stop
For
ACT ACG AAC CTG
AAG CCT AAG CCG
CCC CGG GCT
QuikChange™ Kit
A53T Stop
Rev
AGC CCG GGG CGG
CTT AGG CTT CAG
GTT CGT AGT
QuikChange™ Kit
pSG5 For
-90
TCT GCT AAC CAT
GTT CAT GCC
sequencing primer for
pTL-vectors
pSG5 Rev
-90
GGA CAA ACC ACA
ACT AGA ATG
sequencing primer for
pTL-vectors
pQE For CGG ATA ACA ATT TCA
CAC AG
sequencing primer for
pQE-vectors
pQE Rev GTT CTG AGG TCA
TTA CTG G
sequencing primer for
pQE-vectors
The listed oligonucleotides were synthesized by Operon Biotechnologies, Inc.
A.1.7 Antibodies
Primary antibodies Species Dilution Supplier
Anti-CAG53b
(GST-HttEx1-CAG53)
rabbit 1:5000 own production by E.
Scherzinger
Anti-HD1 (Htt exon 1) rabbit 1:5000 own production by E.
Wanker
MW1 (elongated polyQ
stretch in Htt exon 1)
mouse 1:1000 Developmental Studies
Hybridoma Bank
(University of Iowa)
MW7 (poly-Proline
stretch in Htt exon 1)
mouse 1:1000 Developmental Studies
Hybridoma Bank
(University of Iowa)
Anti-GST goat 1:2000 Amersham Biosciences
Anti-Synuclein rabbit 1:5000 own production by E.
Scherzinger
Anti-oligomer
(oligomeric assemblies of
amyloidogenic proteins)
rabbit 1:1000 Biomol
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Secondary
antibodies
Conjugate Species Dilution Supplier
Anti-rabbit IgG Alkaline
Phosphatase
goat 1:5000 Promega
Anti-mouse IgG Alkaline
Phosphatase
goat 1:5000 Promega
Anti-goat IgG Alkaline
Phosphatase
mouse 1:50000 Sigma-
Aldrich
A.1.8 Enzymes and Markers
Benchmark pre-stained protein ladder Invitrogen
Benzonase purity grade II Merck
Elastase from porcine pancreas Roche Applied
Science
Lysozyme Sigma-Aldrich
Prescission protease ™ Amersham
Biosciencess
Ready-Load™ 1 Kb Plus DNA ladder Invitrogen
Restriction enzymes Roche Applied
Science
Shrimp alkaline phosphatase USB
Taq Polymerase MPI für molekulare
Genetik, Berlin
T4 DNA Ligase New England Biolabs
A.1.9 Chemicals, membranes and chromatography ma-
terials
Agarose Invitrogen
Amicon™ Ultra-15 centrifugal filter units Millipore
Ammoniumpersulfate BioRad
Ampicillin-trihydrate Sigma-Aldrich
Ascorbic acid Sigma-Aldrich
Bromophenol blue Merck Eurolab GmbH
Cellulose acetate membrane 0.2µm Schleicher and Schuell
Complete™ protease inhibitor cocktail Roche
Dialysis discs 0.025µm pore size Millipore
Dialysis tubes, 5.000kDa cutoff SpectraPor
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Dithiothreitol (DTT) Serva
Dimethylsulfoxide (DMSO) Sigma-Aldrich
L-Dopamine Sigma-Aldrich
(-)-Epicatechin gallate Sigma-Aldrich
(-)-Epigallocatechin gallate from green tea Sigma-Aldrich
Ethidium bromide solution 10mg/ml Sigma-Aldrich
Ethylenediamine tetraacetic acid Merck Eurolab GmbH
EZview™ Red ANTI-FLAG affinity gel Sigma-Aldrich
Filter paper GB005 Schleicher and Schuell
(-)-Gallocatechin from green tea Sigma-Aldrich
Glutathione-agarose Sigma-Aldrich
Glutathione, reduced Sigma-Aldrich
Glycerol Merck Eurolab GmbH
Hydrogen peroxide, 30% solution Sigma-Aldrich
IGEPAL CA 630 Sigma-Aldrich
Kanamycin A monosulfate Sigma-Aldrich
Microcon™ centrifugal filter units, cutoff
10.000Da
Millipore
Ni-NTA-Agarose Qiagen
Nitroblue tetrazolium chloride Calbiochem
Nitrocellulose membrane 0.2µm Schleicher and Schuell
p-t-Octylphenyl-polyoxyethylen (Triton
X-100)
Sigma-Aldrich
PD-10 desalting columns Amersham
Biosciences
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich
Polyoxyethylensorbitan-Monolaureat
(Tween 20)
Sigma-Aldrich
Ponceau S-solution, 0.1% Sigma-Aldrich
Sodium glycinate Sigma-Aldrich
TEMED Life Technologies
Thiamine Sigma-Aldrich
α-Tocopherol Sigma-Aldrich
Whatman chromatography paper 3MM Whatman
X-ray film: ECL Hyperfilm Amersham
Biosciencess
All other chemicals, salts, buffer substances, solvents, acids and bases were
from Carl Roth GmbH.
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A.1.10 Kits
Apo-ONE™ homogenous caspase-3/7 assay Promega
BCA Protein assay reagent Pierce
CellTiter-96™ non radioactive cell
proliferation assay
Promega
Lipofectamine Plus™ transfection reagent Invitrogen
Qiaprep spin miniprep kit Qiagen
Qiagen plasmid maxi kit Qiagen
Qiaquick gel extraction kit Qiagen
QuikChange™ site-directed mutagenesis kit Stratagene
A.1.11 Laboratory equipment and consumables
Cryo 1C freezing container Nalgene
Cell culture dishes TRP
Cell scrapers (COSTAR) Corning Inc.
Electroporator BioRad
Electroporation cuvettes BioRad
Film developer Agfa
Fluoronunc 96well plates for photometrical
measurements
Nunc
Gel dryer BioRad
Gene Genius Bio Imaging System Syngene
Image reader LAS-100 Fujifilm
Microtiter plates for filter assays Costar
Photometer Ultraspec 3000 Amersham
Biosciencess
ELISA Plate reader Synergy HT BIO-TEK
Polyacrylamide gel electrophoresis
apparatus
Criterion system,
BioRad
PTC-200 gradient cycler MJ Research
Quartz glass cuvettes Hellmer
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A.2 Methods
A.2.1 Molecular biology
Preparation of plasmid DNA
For plasmid amplification, LB medium containing the appropriate antibiotics
was inoculated with E. coli colonies carrying the respective plasmid, grown
over night at 37℃ in an incubator-shaker, and harvested the next day by
centrifugation. Plasmids were purified using the Qiaprep Spin Miniprep Kit
for small quantities or the Qiagen Plasmid Maxi Kit for larger quantities of
DNA according to manufacturer’s instructions.
Determination of DNA concentration
The concentration of DNA in aqueous solution was determined by measuring
the absorbance at 260 nm in a spectrophotometer. An absorption of 1.0 at
this wavelength corresponds to 50 µg/ml double stranded DNA.
Restriction digest of DNA
Restriction digests were performed in the restriction buffers and according
to the protocols supplied by the manufacturer. Reactions were incubated at
the appropriate temperature for the enzyme for 1-2 h, stopped by adding
10x DNA sample buffer and the products were separated electrophoretically.
In order to inhibit religation of a vector, Shrimp alkaline phosphatase was
added to some restriction digests.
DNA electrophoresis
DNA mixed with sample buffer was loaded to a 0.8-1.5% (w/v) agarose gel,
depending on the size of the DNA fragment. Gels contained 0.5 g/ml ethid-
ium bromide to visualize the DNA after separation under UV light, TBE was
used as a running buffer.
Cleanup of DNA fragments
The appropriate DNA bands from agarose gels were excised with a scalpel and
processed with the QIAquick gel extraction kit according to manufacturer’s
instructions.
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Ligation of DNA fragments
To ligate a DNA fragment with a vector possessing matching cohesive ends,
fragment and vector were mixed at a molar ratio of about 3:1. 400 units
T4-ligase and ligase buffer to a final concentration of 1x were added, and the
reaction was incubated at 16 ℃ overnight.
Ligations were then pipetted onto a filter disc (0.025 µm pore size) float-
ing on distilled water for dialysis, dialysed for 30 minutes and subsequently
transformed into electrocompetent E. coli cells by electroporation.
Preparation of electrocompetent E. coli
1 l of SOB--medium containing antibiotics, if necessary, was inoculated with
1 ml of an overnight-culture of the respective E. coli strain. The culture
was grown at 37 ℃ to an optical density of 0.6-0.8 at 600 nm. From now
on, all steps were performed on ice. Cells were then centrifuged at 4000xg
for 20 minutes, washed in an equal volume of ice cold 10% glycerol and
centrifuged again at 4000xg for 20 minutes. This washing step was repeated
three more times, with the glycerol volume decreasing to 500 ml, 100 ml and
10 ml, respectively. After another centrifugation step, the resulting pellet
was suspended in 1-2 ml of 10% glycerol, aliquots of 100 µl were snap frozen
in liquid nitrogen and stored at -80 ℃.
Electroporation of E.coli
Transformation of plasmid DNA into electrocompetent E. coli was performed
using the Genepulser equipment (Biorad), set to 200 W, 25 mF and 1.68 kV.
30 µl electrocompetent cells were mixed with 3 µl dialysed ligation mix in
a gene pulser cuvette (Biorad) on ice and electroporated. Cells were then
suspended in 1 ml LB medium without antibiotics and incubated at 37 ℃ in
an incubator-shaker for 45 minutes. Aliquots were then plated onto LB-agar
plates containing the appropriate antibiotics and grown at 37 ℃ over night.
Colony PCR
To verify, whether synuclein fragments were indeed inserted into the cho-
sen plasmid, colony PCR was performed. To this end, the PCR mix was
prepared, containing the following: 0.5% Taq polymerase, 1x PCR buffer,
0.25 mM of each dNTP and Syn-For and Syn-Rev primers (1 µM each), all
final concentrations. Then, single colonies of transformants were picked with
sterile toothpicks, the PCR mix briefly stirred with the toothpick in order
to transfer some bacteria into the mix, and the rest of the picked colony was
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striked out on a fresh LB agar plate with the appropriate antibiotics. As a
positive control, approximately 2 ng synuclein DNA was added to the mix.
PCR was performed using the following program:
min:sec 2:00 0:30 0:30 1:00 5:00 forever
Temperature 96℃ 96℃ 62℃ 72℃ 72℃ 4℃
Cycles 30
Reactions were subsequently run on agarose gels to visualize the amplified
synuclein DNA from positive colonies. The LB agar plates were grown over
night at 37 ℃, so the colonies containing the insert could be retrieved.
A.2.2 Plasmid constructions
Htt constructs
These plasmids were described and used before (see Table below), with the
exception of pFLAG-CMV-HDQ68, which was cloned by Dr. Annie Sittler.
pGEX-5X1-HDQ51 Heiser et al. [2002]
pGEX-6P-FLAG-HDQ53 Busch et al. [2003]
pGEX-6P-myc-HDQ53 Muchowski et al.
[2000]
pTL-HDQ90 Scherzinger et al.
[1999]
pQE-32N-Syn wt and A53T
The original wt and A53T α-Synuclein DNAs were a kind gift of Dr. Sabine
Engelender, from Johns Hopkins Medical Institutions, Baltimore.
Synuclein-DNA was excised from plasmids pGEX-6P-2 Syn wt and A53T,
constructed by Anne Busch, by restriction digest with SalI and NotI. The
pQE32N plasmid was opened with the same enzymes, including shrimp al-
kaline phosphatase in the reaction to prevent religation. Ligation was per-
formed at 16℃ over night and the ligated plasmids were transformed into E.
coli SCS1-pSE111 by electroporation. Correct insertion of the synuclein frag-
ments was checked by colony PCR with primers syn For/Rev and sequencing
of positive clones.
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pTL-HA-synuclein wt and A53T
Vector pTL-HA-synuclein wt and A53T were constructed by Dr. Anne Busch,
however, pTL-HA-synuclein A53T did not have an appropriate stop-codon,
so a new stop codon was inserted with the site-directed mutagenesis kit
QuikChange™ from Stratagene and primers A53T Stop For/Rev according
to manufacturer’s instructions.
The correctness of the sequence of the resulting vector was checked by
sequencing.
All sequencing reactions were performed by AGOWA, Gesellschaft für
molekularbiologische Technologie mbH, Glienicker Weg 185, D-12489 Berlin.
A.2.3 Protein biochemistry
Expression of GST-tagged fusion proteins in E.coli
For the expression of GST-fusion proteins 100 ml of LB medium with the
appropriate antibiotics were inoculated with a single colony of E. coli con-
taining the expression vector. The culture was allowed to grow over night in
an incubator-shaker at 37 ℃. The next day, this culture was used to inocu-
late 1.5 l of LB with antibiotics, also containing the following supplements:
20 mM MOPS/KOH pH 7.9, 0.2% glucose and 20 µg/ml thiamine (all final
concentrations). The main culture was grown until an optical density of 0.4-
0.6 at 600 nm was reached, then expression was induced by adding 1 mM
IPTG (final concentration) for 4 h at 37 ℃. The cells were then harvested by
centrifugation at 4000xg for 20 min, the resulting pellet suspended in wash
buffer and re-centrifuged. The final pellet was snap-frozen in liquid nitrogen
and stored at -80 ℃.
Purification of GST fusion proteins
For the purification of a GST fusion protein from a 1.5 l culture, 200 mg of
glutathione-agarose were allowed to swell in 30 ml 1 M NaCl at 4 ℃ over
night. The agarose was then briefly centrifuged at 2000xg and washed three
times in wash buffer. The bacterial cell pellet was thawed in 25 ml GST-P1-
buffer, resuspended, and Lysozyme and PMSF were added to final concentra-
tions of 0.5 mg/ml and 1 mM, respectively. Lysis was allowed to proceed for
45 min on ice, before the lysate was sonicated two times for 45 sec. Triton-
X100 was added to a final concentration of 0.1% (v/v) and the lysate was
cleared by centrifugation at 30000xg and 4 ℃ for 30 min. The supernatant
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was added to 200 mg of swollen and washed glutathione-agarose and incu-
bated for 1 h at 4 ℃ on a rotating wheel. The suspension was then poured
onto a 5 ml plastic column, washed two times with 30 ml of GST-P1-buffer
containing 0.1% Triton-X100 and 1 mM PMSF and once with 30 ml of GST-
P1-buffer alone. Elution was achieved by pouring 1 ml of GST-P1-buffer
containing 720 ng/ml reduced glutathione onto the column and letting it
rest for 5 min before adding further 2 ml of elution buffer and collecting the
eluate. This stepwise elution was continued until the protein concentration
of the eluate (as determined photometrically by measuring the absorption at
280 nm) was below 0.2 mg/ml. The main fractions were pooled and dialysed
over night against dialysis buffer. Protein concentration of the resulting solu-
tion was again determined and, if necessary, the solution was concentrated by
centrifugation through an Amicon concentrating device with an appropriate
molecular weight cutoff at 2000xg, until a final concentration of 0.8-1 mg/ml
was reached. The protein solution was then aliquoted, snap-frozen in liquid
nitrogen and stored at -80 ℃.
Expression of His-tagged fusion proteins
As for GST-fusion proteins, 100 ml of LB medium containing the appropriate
antibiotics were inoculated with a single colony of E. coli containing the
expression plasmid and grown over night at 37 ℃ in an incubator-shaker.
The following day, 1.5 l of LB medium with antibiotics were inoculated with
this culture and grown, until a optical density of 0.4-0.6 at 600 nm was
reached. Protein expression was then induced by addition of 1 mM (final
concentration) of IPTG and further incubation for 4 h at 37 ℃. The cells
were harvested by centrifugation at 4000xg for 20 min, the pellet was snap-
frozen in liquid nitrogen and stored at -80 ℃.
Purification of His-tagged fusion proteins
Protein purification was performed according to Qiagen’s instructions con-
cerning protein purification under denaturing conditions, using 8 M urea in
all buffers to keep the proteins in an unfolded state and to prevent an early
accumulation of aggregates. 5 ml of Ni-NTA agarose were used per 1.5 l
culture volume, all steps were performed at room temperature according to
Qiagen’s manual.
After elution, fractions with the highest protein content (according to ab-
sorption at 280 nm) were pooled. The urea-containing elution buffer was then
exchanged for TBS via a PD10 desalting column (Amersham Biosciences)
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according to manufacturer’s instructions, and the purified protein was short-
term stored on ice at 4 ℃ for immediate use.
Determination of the protein concentration in aqueous solution
The absorption at 280 nm was routinely used to determine protein concentra-
tions. In order to calculate the concentration from the measured absorbance,
the theoretical extinction coefficients were calculated for the respective amino
acid sequence (http://au.expasy.org/ tools/protparam.html).
Protein aggregation reactions
Htt with elastase cleavage: 25 ng/µl GST-HDQ51, 25 ng/µl elastase
(final concentrations) and the drug were incubated in Protease buffer at 37
℃ over night (app. 16 h). Aggregates were detected with the filter retarda-
tion assay.
Htt with Prescission protease™ cleavage: 100 ng/µl GST-FLAG- or
GST-myc-HDQ53, 1.3 units Prescission protease™ (final concentrations) and
the drug were incubated in Prescission protease™ buffer at 30 ℃ over night
(app. 16 h). Aggregates were detected with the filter retardation assay.
Syn: 100-150 µM His-Syn (wt or A53T) were incubated with the drug in
TBS buffer at 37 ℃ with vigorous shaking (180 rpm). Each well contained
a small glass bead (app. 2 mm diameter) to additionally stir the reactions.
Aggregates were detected with the Thioflavin T fluorescence method.
Detection of protein aggregates
In vitro- filter retardation assay: The filter test method for the detec-
tion of SDS-insoluble Htt aggregates has been described extensively in the
literature [Scher/-zin/ ger et al., 1997; Wanker et al., 1999]. Briefly, 2% SDS
and 50 mM DTT (final concentrations) were added to aggregation reactions
and heated to 95 ℃ for 5 min. Two Whatman 3MM filter papers and one
piece of cellulose acetate membrane were wetted in 0.2% SDS and mounted
in a filter unit. 100 µl 0.2% SDS were pipetted in each well of the unit,
10 µl of the denatured samples were added and the mix was filtered. The
membrane was washed twice with 100 µl 0.2% SDS per well, taken out of
the filter unit and processed with the same immunodetection methods as
Western blots (see below).
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Filter retardation assay from cell culture extracts: Mammalian cells
cultured in 96well-dishes were washed briefly with PBS, lysed in 60 µl of
lysis buffer for 30 min on ice and the total protein concentration of the lysate
was determined from 5 µl of lysate with the BCA assay (Pierce) according
to manufacturer’s instructions. 55 µl of 2%SDS and 50 mM DTT (final
concentrations) were added to the lysate, the mix was denatured at 98℃ for
5 min and 80 µl of lysate were filtered the same way as in vitro aggregation
reactions.
Thioflavin T fluorescence method: 10 µl aliquots were removed from
Syn aggregation reactions and mixed with 90 µl Thioflavin T solution (80
µg/µl in TBS). Fluorescence was measured with a plate fluorometer with an
excitation wavelength of 420 nm and an emission wavelength of 485 nm.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was performed according to the instructions by Sambrook and
Russell [2001], with gels containing 12% polyacrylamide. As a marker, Bench-
mark™ from Invitrogen was used.
Analysis of epitope accessibility with the dot-blot assay
Htt: Aggregation reactions with GST-HDQ51 with elastase cleavage were
set up as described above and incubated for different times at 37 ℃. After
incubation, aliquots corresponding to 2 µg fusion protein were spotted onto
Protran™ nitrocellulose membranes and immunodetected.
Syn: 25 µM Syn protein was incubated in TBS buffer for different times
at 37 ℃. Then, aliquots corresponding to 4 µg protein were spotted onto
Protran™ nitrocellulose membranes and immunodetected.
Silver staining of SDS-gels
The proteins were fixed in the gel by incubation with fixing buffer for 2x30
min or over night. Gels were then rinsed for 10 min each first with 20%
ethanol, then with distilled water, and the sensitization step was performed
by incubation for 1 min in sensitization solution. The gel was quickly rinsed
with water, and incubated with silver nitrate solution for 30 min. After
another short rinsing step with water, incubation with the development so-
lution was performed until the desired staining was achieved, and staining
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was stopped by immersing the gel in stop solution for 1 min. All steps were
performed at room temperature.
Western Blotting
The proteins separated on SDS-gels were blotted onto nitrocellulose mem-
branes by the following procedure: The gel was put onto a nitrocellulose
membrane soaked in blotting buffer, carefully avoiding air bubbles. On both
sides, two layers of Schleicher and Schuell GB005 filter paper (also soaked
in blotting buffer) were added, and the ’sandwich’ was placed on a semi-dry
blotting apparatus (Biorad) with the nitrocellulose versus the bottom and
the gel facing the upper side. Surplus buffer and possibly remaining air bub-
bles were removed with a rubber roll, the apparatus assembled completely
and blotting was performed at 20 V for 1 h.
Ponceau-S staining of nitrocellulose membranes
For the staining of all proteins present on a nitrocellulose membrane, the
membrane was incubated in Ponceau-S solution for a few seconds and sub-
sequently washed with distilled water to remove background staining.
NBT-staining of nitrocellulose membranes
Nitroblue tetrazolium chloride (NBT) was dissolved in 1 M sodium glycinate,
pH 10 to a final concentration of 0.24 mM. The nitrocellulose membrane was
incubated in this (freshly prepared) solution for 1-3 h at room temperature
in the dark, until the desired staining was achieved. The membrane was then
briefly washed in distilled water and dried.
Immunodetection of proteins on nitrocellulose or cellulose acetate
membranes
Membranes were incubated in 3% skim milk either for 30 min at room tem-
perature or over night at 4 ℃ to block any unspecific reaction of the an-
tibodies in the following steps. The first antibody was diluted in 3% skim
milk and incubated with the membrane for 45 min at room temperature.
The membrane was then washed once with TTBS and twice with TBS for
10 min each, before the second antibody, also diluted in 3% skim milk, was
added. Because of the easy quantifiable fluorescent signal secondary antibod-
ies conjugated to alkaline phosphatase (AP) were used at all times. After
45 min incubation at room temperature the washing steps with TTBS and
TBS were repeated, and detection was performed as follows:
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The membrane was incubated for 3-4 min in a 200fold dilution of Atto-
Phos reagent (Europa Bioproducts) in AttoPhos buffer. Protein bands (or
spots) were visualized by fluorescence under blue light in an Image reader
(Fuji) and quantified using the AIDA software.
If the same membrane was to be re-developed with another antibody,
the following stripping protocol was applied: The membrane was incubated
in stripping buffer for 30 min at 70 ℃, then washed two times with TTBS
and two times with TBS before the new immunodetection was started with
blocking in 3% skim milk.
NBT stain in solution
Different amounts of protein were incubated with 3 µM EGCG in TBS for 5 h
at 37 ℃. Incubations were filtered through 10 kDa cutoff Microcon™ centri-
fugal filters (Millipore) and the amount of unbound EGCG was determined
in the flowthrough with the following procedure: In a 96well FluoroNunc
plate (Nunc), 50 µl flowthrough were mixed with 50 µl NBT solution (0.24
mM NBT in 1 M sodium glycinate, pH 10) and incubated in the dark for 3
h at room temperature. The absorbance at 530 nm was read with an ELISA
plate reader.
A.2.4 Analytical methods
Electron microscopy
Aliquots of in vitro aggregation reactions were absorbed onto carbon-coated
copper grids, negatively stained with 1% uranyl acetate, blotted dry and
viewed on a Philips CM100 EM.
Atomic force microscopy
Aliquots of in vitro aggregation reactions were diluted into 50 mM Tris-HCl
pH 7, the protein was spotted on freshly cleaved mica, allowed to adhere
for 2 minutes and then washed with 200 ml distilled water. The samples
were partially dried with compressed air and then dried to completion at
room temperature. The samples were imaged in air with a digital multimode
NanoscopeIII scanning probe microscope operating in tapping mode, repre-
sentative 3 mm2 images obtained in three separate experiments were used for
size/density analysis. The analysis of particle diameter was performed using
custom written software described elsewhere [Legleiter et al., 2004].
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Size-exclusion chromatography
Protein samples were loaded to a Superose 6 PC3.2/30 column fitted to a
SMART FPLC system. The column was run at a flow rate of 40 µl/min at 4
℃, eluted peaks were detected by measuring the absorbance at 280 nm. The
eluate was collected in fractions of 80 µl for further analyses.
A.2.5 Methods in cell biology
Thawing of cryoconserved mammalian cells
Cells stored in a liquid nitrogen tank at -198 ℃ were quickly thawed in a
37 ℃ water-bath and seeded in pre-warmed culture medium in cell culture
flasks. Cells were grown over night at 37 ℃ and 5% CO2. The next day, the
culture medium was changed to eliminate the DMSO used for freezing.
Cultivation of mammalian cells
COS-1 cells: These cells were kept in D-MEM supplemented with 5% FCS,
100 iu/ml penicillin and 100 µg/ml streptomycin at 37℃ and 5% CO2. Cells
were grown up to 80% confluence and split down to 5% confluence. To this
end, the culture medium was removed, cells were washed with pre-warmed
PBS and detached from the flask by incubation with 0.5% (w/v) trypsin/1
mM EDTA at 37 ℃ for 5 min. Cells were then resuspended in 10 ml pre-
warmed culture medium and diluted into fresh culture flasks.
Long-term storage of mammalian cells
Cells were grown in a 75 cm2 culture flask to 80% confluence, detached with
trypsin and pelleted by centrifugation at 1000xg for 10 min. Cells were then
resuspended in 1 ml of culture medium with 20% FCS, and DMSO was slowly
added to a final concentration of 10%. Cells were then slowly cooled down to
-80 ℃ in a cryo-tube placed in a box filled with isopropanol. The following
day, the tubes were transferred to the liquid nitrogen tank.
Transient transfection of mammalian cells
In order to achieve transient transfection of COS-1 cells, the Lipofectamine
Plus™ reagent from Invitrogen was used according to manufacturer’s in-
structions, yielding a transfection efficiency of about 10-15%.
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Determination of cell survival
Cell survival was quantified using the CellTiter-96™ non radioactive cell
proliferation assay (Promega) according to manufacturer’s instructions. This
assay is based on living cells converting the MTT tetrazolium component of
the dye solution into a formazan product, that can be quantified photomet-
rically.
Determination of active caspases 3 and 7
For the detection of caspase activation in a 96well format, the Apo-ONE™
Homogenous Caspase-3/7 Assay (Promega) was used according to maufac-
turer’s instructions. The buffer of this assay rapidly lyses mammalian cells,
and the caspase substrate Z-DEVD-R110 present in the solution can be se-
quentially cleaved by caspases 3 and 7, revealing a fluorescent group, whose
emission at 521 nm can be detected after excitation at 499 nm.
Pulse Chase experiments
Cells were seeded in 6well dishes and transfected with the Lipofectamine™ -
as described above. The next day, cells were washed once with pre-warmed
PBS and incubated for 30-40 min in pulse medium, which was D-MEM with-
out methionine and cysteine, supplemented with 200 µM cysteine, 1x Na-
pyruvate, 1x glutamine, 1x penicillin/streptomycin (all final concentrations).
From now on all steps were performed in the radioactive laboratory. The
medium was replaced with fresh pulse medium supplemented with 20 µCi
[35S]-methionine (RediVue™ formulation from Amersham Biosciences), cells
were incubated for 1h and washed with PBS. Afterwards, cells were incubated
for 0-4 h in chase medium (D-MEM with 1x penicillin/streptomycin and 10%
FCS) and lysed by scraping in ice-cold cell lysis buffer. Afer a minimum of 30
min incubation on ice, lysates were spun briefly to remove cellular debris and
incubated with 20 µl FLAG-agarose slurry (EZview™ ANTI-FLAG affinity
gel from Sigma-Aldrich) at 4 ℃ on a wheel over night. Beads were then
pelleted by centrifugation and washed three times with ice-cold TBS. Subse-
quently, SDS-loading buffer was added, samples denatured and loaded onto
12% SDS-PAGE gels. After electrophoresis, gels were dried and exposed to
X-ray film at -80 ℃. Films were developed on an Agfa developing machine.
Appendix B
Abbreviations
AD Alzheimer’s disease
AFM atomic force microscopy
AP alkaline phosphatase
app approximately
APS ammonium persulfate
ATP adenosine triphosphate
BSA bovine serum albumine
CBP CREB-binding protein
CD spec-
troscopy
circular dichroism spectroscopy
DMEM Dulbecco’s modified Eagle medium
DMSO dimethylsulfoxide
DOPA L-dopamine
DTT dithiothreitole
DNA desoxyribonucleic acid
EDTA ethylenediamine tetraacetic acid
EGC (-)-epigallocatechin
EGCG (-)-epigallocatechin gallate
ELISA enzyme-linked immunosorbent assay
EM electron microscopy
FPLC fast protein liquid chromatograhy
FRET fluorescence resonance energy transfer
GC (-)-gallocatechin
GCG (-)-gallocatechin gallate
GST glutathione-S -transferase
GTP guanosine triphosphate
GuHCl guanidinium hydrochloride
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HA haemagglutinin
HD Huntington’s disease
His histidine
Htt Huntingtin
IC50 concentration at 50% inhibition
IPTG isopropyl-3-D-thiogalactopyranoside
LB Luria broth
MOPS 3-[N-morpholino]propanesulphonic acid
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium
bromide
MWCO molecular weight cutoff
NBT nitroblue tetrazolium
NMR nuclear magnetic resonance
OD optical density
PBS phospho-buffered saline
PCR polymerase chain reaction
PD Parkinson’s disease
PMSF phenylmethylsulfonyl fluoride
PolyQ polyglutamine
RNA ribonucleic acid
rpm rotations per minute
SDS sodium dodecyl sulphate
SDS-
PAGE
sodium dodecyl sulphate polyacrylamide gel
electrophoresis
SV simian virus
Syn Synuclein
TBS tris buffered saline
TBP TATA-binding protein
TEMED N,N,N’,N’-tetramethylethylenediamine,
1,2-bis(dimethylamino)-ethane
Tris tris(hydroxymethyl)aminomethane
UV ultraviolet
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